II 

Calendar No. 389 

112TH CONGRESS 

2D SESSION S. 2516 

To amend the Federal Food, Drug, and Cosmetic Act to revise and extend 

the user-fee programs for prescription drugs and medical devices, to 

establish user-fee programs for generic drugs and biosimilars, and for 

other purposes. 

IN THE SENATE OF THE UNITED STATES 

MAY 7, 2012 

Mr. HARKIN, from the Committee on Health, Education, Labor, and Pensions, 

reported the following original bill; which was read twice and placed on 

the calendar 

A BILL 

To amend the Federal Food, Drug, and Cosmetic Act to 

revise and extend the user-fee programs for prescription 

drugs and medical devices, to establish user-fee programs 

for generic drugs and biosimilars, and for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Food and Drug Ad5 ministration Safety and Innovation Act’’. 

mstockstill on DSK4VPTVN1PROD with BILLS

2 

•S 2516 PCS

1 SEC. 2. TABLE OF CONTENTS; REFERENCES IN ACT. 

2 (a) TABLE OF CONTENTS.—The table of contents of 

3 this Act is as follows: 

Sec. 1. Short title. 

Sec. 2. Table of contents; references in Act. 

TITLE I—FEES RELATING TO DRUGS 

Sec. 101. Short title; finding. 

Sec. 102. Definitions. 

Sec. 103. Authority to assess and use drug fees. 

Sec. 104. Reauthorization; reporting requirements. 

Sec. 105. Sunset dates. 

Sec. 106. Effective date. 

Sec. 107. Savings clause. 

TITLE II—FEES RELATING TO DEVICES 

Sec. 201. Short title; findings. 

Sec. 202. Definitions. 

Sec. 203. Authority to assess and use device fees. 

Sec. 204. Reauthorization; reporting requirements. 

Sec. 205. Savings clause. 

Sec. 206. Effective date. 

Sec. 207. Sunset dates. 

Sec. 208. Streamlined hiring authority to support activities related to the process for the review of device applications. 

TITLE III—FEES RELATING TO GENERIC DRUGS 

Sec. 301. Short title. 

Sec. 302. Authority to assess and use human generic drug fees. 

Sec. 303. Reauthorization; reporting requirements. 

Sec. 304. Sunset dates. 

Sec. 305. Effective date. 

Sec. 306. Amendment with respect to misbranding. 

Sec. 307. Streamlined hiring authority of the Food and Drug Administration 

to support activities related to human generic drugs. 

TITLE IV—FEES RELATING TO BIOSIMILAR BIOLOGICAL 

PRODUCTS 

Sec. 401. Short title; finding. 

Sec. 402. Fees relating to biosimilar biological products. 

Sec. 403. Reauthorization; reporting requirements. 

Sec. 404. Sunset dates. 

Sec. 405. Effective date. 

Sec. 406. Savings clause. 

Sec. 407. Conforming amendment. 

TITLE V—PEDIATRIC DRUGS AND DEVICES 

Sec. 501. Permanence. 

Sec. 502. Written requests. 

mstockstill on DSK4VPTVN1PROD with BILLS

3 

•S 2516 PCS

Sec. 503. Communication with Pediatric Review Committee. 

Sec. 504. Access to data. 

Sec. 505. Ensuring the completion of pediatric studies. 

Sec. 506. Pediatric study plans. 

Sec. 507. Reauthorizations. 

Sec. 508. Report. 

Sec. 509. Technical amendments. 

Sec. 510. Relationship Between Pediatric Labeling and New Clinical Investigation Exclusivity. 

TITLE VI—MEDICAL DEVICE REGULATORY IMPROVEMENTS 

Sec. 601. Reclassification procedures. 

Sec. 602. Condition of approval studies. 

Sec. 603. Postmarket surveillance. 

Sec. 604. Sentinel. 

Sec. 605. Recalls. 

Sec. 606. Clinical holds on investigational device exemptions. 

Sec. 607. Unique device identifier. 

Sec. 608. Clarification of least burdensome standard. 

Sec. 609. Custom devices. 

Sec. 610. Agency documentation and review of certain decisions regarding devices. 

Sec. 611. Good guidance practices relating to devices. 

Sec. 612. Modification of de novo application process. 

Sec. 613. Humanitarian device exemptions. 

Sec. 614. Reauthorization of third-party review and inspections. 

Sec. 615. 510(k) device modifications. 

TITLE VII—DRUG SUPPLY CHAIN 

Sec. 701. Registration of domestic drug establishments. 

Sec. 702. Registration of foreign establishments. 

Sec. 703. Identification of drug excipient information with product listing. 

Sec. 704. Electronic system for registration and listing. 

Sec. 705. Risk-based inspection frequency. 

Sec. 706. Records for inspection. 

Sec. 707. Failure to allow foreign inspection. 

Sec. 708. Exchange of information. 

Sec. 709. Enhancing the safety and quality of the drug supply. 

Sec. 710. Accreditation of third-party auditors for drug establishments. 

Sec. 711. Standards for admission of imported drugs. 

Sec. 712. Notification. 

Sec. 713. Protection against intentional adulteration. 

Sec. 714. Enhanced criminal penalty for counterfeiting drugs. 

Sec. 715. Extraterritorial jurisdiction. 

Sec. 716. Compliance with international agreements. 

TITLE VIII—GENERATING ANTIBIOTIC INCENTIVES NOW 

Sec. 801. Extension of exclusivity period for drugs. 

Sec. 802. Priority review. 

Sec. 803. Fast track product. 

Sec. 804. GAO study. 

Sec. 805. Clinical trials. 

Sec. 806. Regulatory certainty and predictability. 

mstockstill on DSK4VPTVN1PROD with BILLS

4 

•S 2516 PCS

TITLE IX—DRUG APPROVAL AND PATIENT ACCESS 

Sec. 901. Enhancement of accelerated patient access to new medical treatments. 

Sec. 902. Breakthrough therapies. 

Sec. 903. Consultation with external experts on rare diseases, targeted therapies, and genetic targeting of treatments. 

Sec. 904. Accessibility of information on prescription drug container labels by 

visually-impaired and blind consumers. 

Sec. 905. Risk-benefit framework. 

Sec. 906. Independent study on medical innovation inducement model. 

TITLE X—DRUG SHORTAGES 

Sec. 1001. Drug shortages. 

TITLE XI—OTHER PROVISIONS 

Subtitle A—Reauthorizations 

Sec. 1101. Reauthorization of provision relating to exclusivity of certain drugs 

containing single enantiomers. 

Sec. 1102. Reauthorization of the Critical Path Public-Private Partnerships. 

Subtitle B—Medical Gas Product Regulation 

Sec. 1111. Regulation of medical gas products. 

Sec. 1112. Regulations. 

Sec. 1113. Applicability. 

Subtitle C—Miscellaneous Provisions 

Sec. 1121. Advisory committee conflicts of interest. 

Sec. 1122. Guidance document regarding product promotion using the Internet. 

Sec. 1123. Electronic submission of applications. 

Sec. 1124. Combating prescription drug abuse. 

Sec. 1125. Tanning bed labeling. 

Sec. 1126. Optimizing global clinical trials. 

Sec. 1127. Advancing regulatory science to promote public health innovation. 

Sec. 1128. Information technology. 

Sec. 1129. Reporting requirements. 

Sec. 1130. Strategic integrated management plan. 

Sec. 1131. Drug development and bioequivalence testing. 

1 (b) REFERENCES IN ACT.—Except as otherwise spec2 ified, amendments made by this Act to a section or other 

3 provision of law are amendments to such section or other 

4 provision of the Federal Food, Drug, and Cosmetic Act 

5 (21 U.S.C. 301 et seq.). 

mstockstill on DSK4VPTVN1PROD with BILLS

5 

•S 2516 PCS

1 TITLE I—FEES RELATING TO 

2 DRUGS 

3 SEC. 101. SHORT TITLE; FINDING. 

4 (a) SHORT TITLE.—This title may be cited as the 

5 ‘‘Prescription Drug User Fee Amendments of 2012’’. 

6 (b) FINDING.—The Congress finds that the fees au7 thorized by the amendments made in this title will be dedi8 cated toward expediting the drug development process and 

9 the process for the review of human drug applications, in10 cluding postmarket drug safety activities, as set forth in 

11 the goals identified for purposes of part 2 of subchapter 

12 C of chapter VII of the Federal Food, Drug, and Cosmetic 

13 Act, in the letters from the Secretary of Health and 

14 Human Services to the Chairman of the Committee on 

15 Health, Education, Labor, and Pensions of the Senate and 

16 the Chairman of the Committee on Energy and Commerce 

17 of the House of Representatives, as set forth in the Con18 gressional Record. 

19 SEC. 102. DEFINITIONS. 

20 Paragraph (7) of section 735 (21 U.S.C. 379g) is 

21 amended, in the matter preceding subparagraph (A), by 

22 striking ‘‘incurred’’. 

23 SEC. 103. AUTHORITY TO ASSESS AND USE DRUG FEES. 

24 Section 736 (21 U.S.C. 379h) is amended— 

25 (1) in subsection (a)— 

mstockstill on DSK4VPTVN1PROD with BILLS

6 

•S 2516 PCS

1 (A) in the matter preceding paragraph (1), 

2 by striking ‘‘fiscal year 2008’’ and inserting 

3 ‘‘fiscal year 2013’’; 

4 (B) in paragraph (1), in clauses (i) and (ii) 

5 of subparagraph (A), by striking ‘‘subsection 

6 (c)(5)’’ each place such term appears and in7 serting ‘‘subsection (c)(4)’’; 

8 (C) in the matter following clause (ii) in 

9 paragraph (2)(A)— 

10 (i) by striking ‘‘subsection (c)(5)’’ and 

11 inserting ‘‘subsection (c)(4)’’; and 

12 (ii) by striking ‘‘payable on or before 

13 October 1 of each year’’ and inserting 

14 ‘‘due on the later of the first business day 

15 on or after October 1 of each fiscal year or 

16 the first business day after the enactment 

17 of an appropriations Act providing for the 

18 collection and obligation of fees for such 

19 fiscal year under this section’’; and 

20 (D) in paragraph (3)— 

21 (i) in subparagraph (A)— 

22 (I) by striking ‘‘subsection 

23 (c)(5)’’ and inserting ‘‘subsection 

24 (c)(4)’’; and 

mstockstill on DSK4VPTVN1PROD with BILLS

7 

•S 2516 PCS

1 (II) by striking ‘‘payable on or 

2 before October 1 of each year.’’ and 

3 inserting ‘‘due on the later of the first 

4 business day on or after October 1 of 

5 each fiscal year or the first business 

6 day after the enactment of an appro7 priations Act providing for the collec8 tion and obligation of fees for such 

9 fiscal year under this section.’’; and 

10 (ii) by amending subparagraph (B) to 

11 read as follows: 

12 ‘‘(B) EXCEPTION.—A prescription drug 

13 product shall not be assessed a fee under sub14 paragraph (A) if such product is— 

15 ‘‘(i) identified on the list compiled 

16 under section 505(j)(7) with a potency de17 scribed in terms of per 100 mL; 

18 ‘‘(ii) the same product as another 

19 product that— 

20 ‘‘(I) was approved under an ap21 plication filed under section 505(b) or 

22 505(j); and 

23 ‘‘(II) is not in the list of discon24 tinued products compiled under sec25 tion 505(j)(7); 

mstockstill on DSK4VPTVN1PROD with BILLS

8 

•S 2516 PCS

1 ‘‘(iii) the same product as another 

2 product that was approved under an abbre3 viated application filed under section 507 

4 (as in effect on the day before the date of 

5 enactment of the Food and Drug Adminis6 tration Modernization Act of 1997); or 

7 ‘‘(iv) the same product as another 

8 product that was approved under an abbre9 viated new drug application pursuant to 

10 regulations in effect prior to the implemen11 tation of the Drug Price Competition and 

12 Patent Term Restoration Act of 1984.’’; 

13 (2) in subsection (b)— 

14 (A) in paragraph (1)— 

15 (i) in the matter preceding subpara16 graph (A), by striking ‘‘fiscal years 2008 

17 through 2012’’ and inserting ‘‘fiscal years 

18 2013 through 2017’’; 

19 (ii) in subparagraph (A), by striking 

20 ‘‘$392,783,000; and’’ and inserting 

21 ‘‘$693,099,000;’’; and 

22 (iii) by striking subparagraph (B) and 

23 inserting the following: 

mstockstill on DSK4VPTVN1PROD with BILLS

9 

•S 2516 PCS

1 ‘‘(B) the dollar amount equal to the infla2 tion adjustment for fiscal year 2013 (as deter3 mined under paragraph (3)(A)); and 

4 ‘‘(C) the dollar amount equal to the work5 load adjustment for fiscal year 2013 (as deter6 mined under paragraph (3)(B)).’’; and 

7 (B) by striking paragraphs (3) and (4) and 

8 inserting the following: 

9 ‘‘(3) FISCAL YEAR 2013 INFLATION AND WORK10 LOAD ADJUSTMENTS.—For purposes of paragraph 

11 (1), the dollar amount of the inflation and workload 

12 adjustments for fiscal year 2013 shall be determined 

13 as follows: 

14 ‘‘(A) INFLATION ADJUSTMENT.—The infla15 tion adjustment for fiscal year 2013 shall be 

16 the sum of— 

17 ‘‘(i) $652,709,000 multiplied by the 

18 result of an inflation adjustment calcula19 tion determined using the methodology de20 scribed in subsection (c)(1)(B); and 

21 ‘‘(ii) $652,709,000 multiplied by the 

22 result of an inflation adjustment calcula23 tion determined using the methodology de24 scribed in subsection (c)(1)(C). 

mstockstill on DSK4VPTVN1PROD with BILLS

10 

•S 2516 PCS

1 ‘‘(B) WORKLOAD ADJUSTMENT.—Subject 

2 to subparagraph (C), the workload adjustment 

3 for fiscal 2013 shall be— 

4 ‘‘(i) $652,709,000 plus the amount of 

5 the inflation adjustment calculated under 

6 subparagraph (A); multiplied by 

7 ‘‘(ii) the amount (if any) by which a 

8 percentage workload adjustment for fiscal 

9 year 2013, as determined using the meth10 odology described in subsection (c)(2)(A), 

11 would exceed the percentage workload ad12 justment (as so determined) for fiscal year 

13 2012, if both such adjustment percentages 

14 were calculated using the 5-year base pe15 riod consisting of fiscal years 2003 

16 through 2007. 

17 ‘‘(C) LIMITATION.—Under no cir18 cumstances shall the adjustment under sub19 paragraph (B) result in fee revenues for fiscal 

20 year 2013 that are less than the sum of the 

21 amount under paragraph (1)(A) and the 

22 amount under paragraph (1)(B).’’; 

23 (3) by striking subsection (c) and inserting the 

24 following: 

25 ‘‘(c) ADJUSTMENTS.— 

mstockstill on DSK4VPTVN1PROD with BILLS

11 

•S 2516 PCS

1 ‘‘(1) INFLATION ADJUSTMENT.—For fiscal year 

2 2014 and subsequent fiscal years, the revenues es3 tablished in subsection (b) shall be adjusted by the 

4 Secretary by notice, published in the Federal Reg5 ister, for a fiscal year by the amount equal to the 

6 sum of— 

7 ‘‘(A) one; 

8 ‘‘(B) the average annual percent change in 

9 the cost, per full-time equivalent position of the 

10 Food and Drug Administration, of all personnel 

11 compensation and benefits paid with respect to 

12 such positions for the first 3 years of the pre13 ceding 4 fiscal years, multiplied by the propor14 tion of personnel compensation and benefits 

15 costs to total costs of the process for the review 

16 of human drug applications (as defined in sec17 tion 735(6)) for the first 3 years of the pre18 ceding 4 fiscal years; and 

19 ‘‘(C) the average annual percent change 

20 that occurred in the Consumer Price Index for 

21 urban consumers (Washington-Baltimore, DC– 

22 MD–VA–WV; Not Seasonally Adjusted; All 

23 items; Annual Index) for the first 3 years of the 

24 preceding 4 years of available data, multiplied 

25 by the proportion of all costs other than permstockstill on DSK4VPTVN1PROD with BILLS

12 

•S 2516 PCS

1 sonnel compensation and benefits costs to total 

2 costs of the process for the review of human 

3 drug applications (as defined in section 735(6)) 

4 for the first 3 years of the preceding 4 fiscal 

5 years. 

6 The adjustment made each fiscal year under this 

7 paragraph shall be added on a compounded basis to 

8 the sum of all adjustments made each fiscal year 

9 after fiscal year 2013 under this paragraph. 

10 ‘‘(2) WORKLOAD ADJUSTMENT.—For fiscal 

11 year 2014 and subsequent fiscal years, after the fee 

12 revenues established in subsection (b) are adjusted 

13 for a fiscal year for inflation in accordance with 

14 paragraph (1), the fee revenues shall be adjusted 

15 further for such fiscal year to reflect changes in the 

16 workload of the Secretary for the process for the re17 view of human drug applications. With respect to 

18 such adjustment: 

19 ‘‘(A) The adjustment shall be determined 

20 by the Secretary based on a weighted average 

21 of the change in the total number of human 

22 drug applications (adjusted for changes in re23 view activities, as described in the notice that 

24 the Secretary is required to publish in the Fed25 eral Register under this subparagraph), efficacy 

mstockstill on DSK4VPTVN1PROD with BILLS

13 

•S 2516 PCS

1 supplements, and manufacturing supplements 

2 submitted to the Secretary, and the change in 

3 the total number of active commercial investiga4 tional new drug applications (adjusted for 

5 changes in review activities, as so described) 

6 during the most recent 12-month period for 

7 which data on such submissions is available. 

8 The Secretary shall publish in the Federal Reg9 ister the fee revenues and fees resulting from 

10 the adjustment and the supporting methodolo11 gies. 

12 ‘‘(B) Under no circumstances shall the ad13 justment result in fee revenues for a fiscal year 

14 that are less than the sum of the amount under 

15 subsection (b)(1)(A) and the amount under 

16 subsection (b)(1)(B), as adjusted for inflation 

17 under paragraph (1). 

18 ‘‘(C) The Secretary shall contract with an 

19 independent accounting or consulting firm to 

20 periodically review the adequacy of the adjust21 ment and publish the results of those reviews. 

22 The first review shall be conducted and pub23 lished by the end of fiscal year 2013 (to exam24 ine the performance of the adjustment since fis25 cal year 2009), and the second review shall be 

mstockstill on DSK4VPTVN1PROD with BILLS

14 

•S 2516 PCS

1 conducted and published by the end of fiscal 

2 year 2015 (to examine the continued perform3 ance of the adjustment). The reports shall 

4 evaluate whether the adjustment reasonably 

5 represents actual changes in workload volume 

6 and complexity and present options to dis7 continue, retain, or modify any elements of the 

8 adjustment. The reports shall be published for 

9 public comment. After review of the reports and 

10 receipt of public comments, the Secretary shall, 

11 if warranted, adopt appropriate changes to the 

12 methodology. If the Secretary adopts changes to 

13 the methodology based on the first report, the 

14 changes shall be effective for the first fiscal 

15 year for which fees are set after the Secretary 

16 adopts such changes and each subsequent fiscal 

17 year. 

18 ‘‘(3) FINAL YEAR ADJUSTMENT.—For fiscal 

19 year 2017, the Secretary may, in addition to adjust20 ments under this paragraph and paragraphs (1) and 

21 (2), further increase the fee revenues and fees estab22 lished in subsection (b) if such an adjustment is nec23 essary to provide for not more than 3 months of op24 erating reserves of carryover user fees for the proc25 ess for the review of human drug applications for 

mstockstill on DSK4VPTVN1PROD with BILLS

15 

•S 2516 PCS

1 the first 3 months of fiscal year 2018. If such an 

2 adjustment is necessary, the rationale for the 

3 amount of the increase shall be contained in the an4 nual notice establishing fee revenues and fees for fis5 cal year 2017. If the Secretary has carryover bal6 ances for such process in excess of 3 months of such 

7 operating reserves, the adjustment under this para8 graph shall not be made. 

9 ‘‘(4) ANNUAL FEE SETTING.—The Secretary 

10 shall, not later than 60 days before the start of each 

11 fiscal year that begins after September 30, 2012, es12 tablish, for the next fiscal year, application, product, 

13 and establishment fees under subsection (a), based 

14 on the revenue amounts established under subsection 

15 (b) and the adjustments provided under this sub16 section. 

17 ‘‘(5) LIMIT.—The total amount of fees charged, 

18 as adjusted under this subsection, for a fiscal year 

19 may not exceed the total costs for such fiscal year 

20 for the resources allocated for the process for the re21 view of human drug applications.’’; and 

22 (4) in subsection (g)— 

23 (A) in paragraph (1), by striking ‘‘Fees 

24 authorized’’ and inserting ‘‘Subject to para25 graph (2)(C), fees authorized’’; 

mstockstill on DSK4VPTVN1PROD with BILLS

16 

•S 2516 PCS

1 (B) in paragraph (2)— 

2 (i) in subparagraph (A)— 

3 (I) in clause (i), by striking 

4 ‘‘shall be retained’’ and inserting 

5 ‘‘subject to subparagraph (C), shall be 

6 collected and available’’; and 

7 (II) in clause (ii), by striking 

8 ‘‘shall only be collected and available’’ 

9 and inserting ‘‘shall be available’’; and 

10 (ii) by adding at the end the following 

11 new subparagraph: 

12 ‘‘(C) PROVISION FOR EARLY PAYMENTS.— 

13 Payment of fees authorized under this section 

14 for a fiscal year, prior to the due date for such 

15 fees, may be accepted by the Secretary in ac16 cordance with authority provided in advance in 

17 a prior year appropriations Act.’’; 

18 (C) in paragraph (3), by striking ‘‘fiscal 

19 years 2008 through 2012’’ and inserting ‘‘fiscal 

20 years 2013 through 2017’’; and 

21 (D) in paragraph (4)— 

22 (i) by striking ‘‘fiscal years 2008 

23 through 2010’’ and inserting ‘‘fiscal years 

24 2013 through 2015’’; 

mstockstill on DSK4VPTVN1PROD with BILLS

17 

•S 2516 PCS

1 (ii) by striking ‘‘fiscal year 2011’’ and 

2 inserting ‘‘fiscal year 2016’’; 

3 (iii) by striking ‘‘fiscal years 2008 

4 though 2011’’ and inserting ‘‘fiscal years 

5 2013 through 2016’’; and 

6 (iv) by striking ‘‘fiscal year 2012’’ 

7 and inserting ‘‘fiscal year 2017’’. 

8 SEC. 104. REAUTHORIZATION; REPORTING REQUIREMENTS. 

9 Section 736B (21 U.S.C. 379h–2) is amended— 

10 (1) by amending subsection (a) to read as fol11 lows: 

12 ‘‘(a) PERFORMANCE REPORT.—Beginning with fiscal 

13 year 2013, not later than 120 days after the end of each 

14 fiscal year for which fees are collected under this part, 

15 the Secretary shall prepare and submit to the Committee 

16 on Energy and Commerce of the House of Representatives 

17 and the Committee on Health, Education, Labor, and 

18 Pensions of the Senate a report concerning the progress 

19 of the Food and Drug Administration in achieving the 

20 goals identified in the letters described in section 101(b) 

21 of the Prescription Drug User Fee Amendments of 2012 

22 during such fiscal year and the future plans of the Food 

23 and Drug Administration for meeting the goals. The re24 port under this subsection for a fiscal year shall include 

25 information on all previous cohorts for which the Secmstockstill on DSK4VPTVN1PROD with BILLS

18 

•S 2516 PCS

1 retary has not given a complete response on all human 

2 drug applications and supplements in the cohort.’’; 

3 (2) in subsection (b), by striking ‘‘2008’’ and 

4 inserting ‘‘2013’’; and 

5 (3) in subsection (d), by striking ‘‘2012’’ each 

6 place it appears and inserting ‘‘2017’’. 

7 SEC. 105. SUNSET DATES. 

8 (a) AUTHORIZATION.—Sections 735 and 736 of the 

9 Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379g; 

10 379h) shall cease to be effective October 1, 2017. 

11 (b) REPORTING REQUIREMENTS.—Section 736B of 

12 the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 

13 379h–2) shall cease to be effective January 31, 2018. 

14 (c) PREVIOUS SUNSET PROVISION.—The Prescrip15 tion Drug User Fee Amendments of 2007 is amended by 

16 striking section 106. 

17 SEC. 106. EFFECTIVE DATE. 

18 The amendments made by this title shall take effect 

19 on October 1, 2012, or the date of the enactment of this 

20 Act, whichever is later, except that fees under part 2 of 

21 subchapter C of chapter VII of the Federal Food, Drug, 

22 and Cosmetic Act shall be assessed for all human drug 

23 applications received on or after October 1, 2012, regard24 less of the date of the enactment of this Act. 

mstockstill on DSK4VPTVN1PROD with BILLS

19 

•S 2516 PCS

1 SEC. 107. SAVINGS CLAUSE. 

2 Notwithstanding the amendments made by this title, 

3 part 2 of subchapter C of chapter VII of the Federal Food, 

4 Drug, and Cosmetic Act, as in effect on the day before 

5 the date of the enactment of this title, shall continue to 

6 be in effect with respect to human drug applications and 

7 supplements (as defined in such part as of such day) that 

8 on or after October 1, 2007, but before October 1, 2012, 

9 were accepted by the Food and Drug Administration for 

10 filing with respect to assessing and collecting any fee re11 quired by such part for a fiscal year prior to fiscal year 

12 2012. 

13 TITLE II—FEES RELATING TO 

14 DEVICES 

15 SEC. 201. SHORT TITLE; FINDINGS. 

16 (a) SHORT TITLE.—This title may be cited as the 

17 ‘‘Medical Device User Fee Amendments of 2012’’. 

18 (b) FINDINGS.—The Congress finds that the fees au19 thorized under the amendments made by this title will be 

20 dedicated toward expediting the process for the review of 

21 device applications and for assuring the safety and effec22 tiveness of devices, as set forth in the goals identified for 

23 purposes of part 3 of subchapter C of chapter VII of the 

24 Federal Food, Drug, and Cosmetic Act in the letters from 

25 the Secretary of Health and Human Services to the Chair26 man of the Committee on Health, Education, Labor, and 

mstockstill on DSK4VPTVN1PROD with BILLS

20 

•S 2516 PCS

1 Pensions of the Senate and the Chairman of the Com2 mittee on Energy and Commerce of the House of Rep3 resentatives, as set forth in the Congressional Record. 

4 SEC. 202. DEFINITIONS. 

5 Section 737 (21 U.S.C. 379i) is amended— 

6 (1) in paragraph (9), by striking ‘‘incurred’’ 

7 after ‘‘expenses’’; 

8 (2) in paragraph (10), by striking ‘‘October 

9 2001’’ and inserting ‘‘October 2011’’; and 

10 (3) in paragraph (13), by striking ‘‘is required 

11 to register’’ and all that follows through the end of 

12 paragraph (13) and inserting the following: ‘‘is reg13 istered (or is required to register) with the Secretary 

14 under section 510 because such establishment is en15 gaged in the manufacture, preparation, propagation, 

16 compounding, or processing of a device.’’. 

17 SEC. 203. AUTHORITY TO ASSESS AND USE DEVICE FEES. 

18 (a) TYPES OF FEES.—Section 738(a) (21 U.S.C. 

19 379j(a)) is amended— 

20 (1) in paragraph (1), by striking ‘‘fiscal year 

21 2008’’ and inserting ‘‘fiscal year 2013’’; 

22 (2) in paragraph (2)(A)— 

23 (A) in the matter preceding clause (i)— 

mstockstill on DSK4VPTVN1PROD with BILLS

21 

•S 2516 PCS

1 (i) by striking ‘‘subsections (d) and 

2 (e)’’ and inserting ‘‘subsections (d), (e), 

3 and (f)’’; 

4 (ii) by striking ‘‘October 1, 2002’’ and 

5 inserting ‘‘October 1, 2012’’; and 

6 (iii) by striking ‘‘subsection (c)(1)’’ 

7 and inserting ‘‘subsection (c)’’; and 

8 (B) in clause (viii), by striking ‘‘1.84’’ and 

9 inserting ‘‘2’’; and 

10 (3) in paragraph (3)— 

11 (A) in subparagraph (A)— 

12 (i) by inserting ‘‘and subsection (f)’’ 

13 after ‘‘subparagraph (B)’’; and 

14 (ii) by striking ‘‘2008’’ and inserting 

15 ‘‘2013’’; and 

16 (B) in subparagraph (C), by striking ‘‘ini17 tial registration’’ and all that follows through 

18 ‘‘section 510.’’ and inserting ‘‘later of— 

19 ‘‘(i) the initial or annual registration 

20 (as applicable) of the establishment under 

21 section 510; or 

22 ‘‘(ii) the first business day after the 

23 date of enactment of an appropriations Act 

24 providing for the collection and obligation 

25 of fees for such year under this section.’’. 

mstockstill on DSK4VPTVN1PROD with BILLS

22 

•S 2516 PCS

1 (b) FEE AMOUNTS.—Section 738(b) (21 U.S.C. 

2 379j(b)) is amended to read as follows: 

3 ‘‘(b) FEE AMOUNTS.— 

4 ‘‘(1) IN GENERAL.—Subject to subsections (c), 

5 (d), (e), (f), and (i), for each of fiscal years 2013 

6 through 2017, fees under subsection (a) shall be de7 rived from the base fee amounts specified in para8 graph (2), to generate the total revenue amounts 

9 specified in paragraph (3). 

10 ‘‘(2) BASE FEE AMOUNTS.—For purposes of 

11 paragraph (1), the base fee amounts specified in this 

12 paragraph are as follows: 

‘‘Fee Type 

Fiscal 

Year 

2013 

Fiscal 

Year 

2014 

Fiscal 

Year 

2015 

Fiscal 

Year 

2016 

Fiscal 

Year 

2017 

Premarket Application ........................ $248,000 $252,960 $258,019 $263,180 $268,443 

Establishment Registration ................ $2,575 $3,200 $3,750 $3,872 $3,872 

13 ‘‘(3) TOTAL REVENUE AMOUNTS.—For pur14 poses of paragraph (1), the total revenue amounts 

15 specified in this paragraph are as follows: 

16 ‘‘(A) $97,722,301 for fiscal year 2013. 

17 ‘‘(B) $112,580,497 for fiscal year 2014. 

18 ‘‘(C) $125,767,107 for fiscal year 2015. 

19 ‘‘(D) $129,339,949 for fiscal year 2016. 

20 ‘‘(E) $130,184,348 for fiscal year 2017.’’. 

21 (c) ANNUAL FEE SETTING; ADJUSTMENTS.—Section 

22 738(c) (21 U.S.C. 379j(c)) is amended— 

mstockstill on DSK4VPTVN1PROD with BILLS

23 

•S 2516 PCS

1 (1) in the subsection heading, by inserting ‘‘; 

2 ADJUSTMENTS’’ after ‘‘SETTING’’; 

3 (2) by striking paragraphs (1) and (2); 

4 (3) by redesignating paragraphs (3) and (4) as 

5 paragraphs (4) and (5), respectively; and 

6 (4) by inserting before paragraph (4), as so re7 designated, the following: 

8 ‘‘(1) IN GENERAL.—The Secretary shall, 60 

9 days before the start of each fiscal year after Sep10 tember 30, 2012, establish fees under subsection (a), 

11 based on amounts specified under subsection (b) and 

12 the adjustments provided under this subsection, and 

13 publish such fees, and the rationale for any adjust14 ments to such fees, in the Federal Register. 

15 ‘‘(2) INFLATION ADJUSTMENTS.— 

16 ‘‘(A) ADJUSTMENT TO TOTAL REVENUE

17 AMOUNTS.—For fiscal year 2014 and each sub18 sequent fiscal year, the Secretary shall adjust 

19 the total revenue amount specified in subsection 

20 (b)(3) for such fiscal year by multiplying such 

21 amount by the applicable inflation adjustment 

22 under subparagraph (B) for such year. 

23 ‘‘(B) APPLICABLE INFLATION ADJUST24 MENT TO TOTAL REVENUE AMOUNTS.—The apmstockstill on DSK4VPTVN1PROD with BILLS

24 

•S 2516 PCS

1 plicable inflation adjustment for a fiscal year 

2 is— 

3 ‘‘(i) for fiscal year 2014, the base in4 flation adjustment under subparagraph (C) 

5 for such fiscal year; and 

6 ‘‘(ii) for fiscal year 2015 and each 

7 subsequent fiscal year, the product of— 

8 ‘‘(I) the base inflation adjust9 ment under subparagraph (C) for 

10 such fiscal year; and 

11 ‘‘(II) the product of the base in12 flation adjustment under subpara13 graph (C) for each of the fiscal years 

14 preceding such fiscal year, beginning 

15 with fiscal year 2014. 

16 ‘‘(C) BASE INFLATION ADJUSTMENT TO

17 TOTAL REVENUE AMOUNTS.— 

18 ‘‘(i) IN GENERAL.—Subject to further 

19 adjustment under clause (ii), the base in20 flation adjustment for a fiscal year is the 

21 sum of one plus— 

22 ‘‘(I) the average annual percent 

23 change in the cost, per full-time equiv24 alent position of the Food and Drug 

25 Administration, of all personnel commstockstill on DSK4VPTVN1PROD with BILLS

25 

•S 2516 PCS

1 pensation and benefits paid with re2 spect to such positions for the first 3 

3 years of the preceding 4 fiscal years, 

4 multiplied by 0.60; and 

5 ‘‘(II) the average annual percent 

6 change that occurred in the Consumer 

7 Price Index for urban consumers 

8 (Washington-Baltimore, DC–MD–VA– 

9 WV; Not Seasonally Adjusted; All 

10 items; Annual Index) for the first 3 

11 years of the preceding 4 years of 

12 available data multiplied by 0.40. 

13 ‘‘(ii) LIMITATIONS.—For purposes of 

14 subparagraph (B), if the base inflation ad15 justment for a fiscal year under clause 

16 (i)— 

17 ‘‘(I) is less than 1, such adjust18 ment shall be considered to be equal 

19 to 1; or 

20 ‘‘(II) is greater than 1.04, such 

21 adjustment shall be considered to be 

22 equal to 1.04. 

23 ‘‘(D) ADJUSTMENT TO BASE FEE

24 AMOUNTS.—For each of fiscal years 2014 

25 through 2017, the base fee amounts specified in 

mstockstill on DSK4VPTVN1PROD with BILLS

26 

•S 2516 PCS

1 subsection (b)(2) shall be adjusted as needed, 

2 on a uniform proportionate basis, to generate 

3 the total revenue amounts under subsection 

4 (b)(3), as adjusted for inflation under subpara5 graph (A). 

6 ‘‘(3) VOLUME-BASED ADJUSTMENTS TO ESTAB7 LISHMENT REGISTRATION BASE FEES.—For each of 

8 fiscal years 2014 through 2017, after the base fee 

9 amounts specified in subsection (b)(2) are adjusted 

10 under paragraph (2)(D), the base establishment reg11 istration fee amounts specified in such subsection 

12 shall be further adjusted, as the Secretary estimates 

13 is necessary in order for total fee collections for such 

14 fiscal year to generate the total revenue amounts, as 

15 adjusted under paragraph (2).’’. 

16 (d) FEE WAIVER OR REDUCTION.—Section 738 (21 

17 U.S.C. 379j) is amended by— 

18 (1) redesignating subsections (f) through (k) as 

19 subsections (g) through (l), respectively; and 

20 (2) by inserting after subsection (e) the fol21 lowing new subsection: 

22 ‘‘(f) FEE WAIVER OR REDUCTION.— 

23 ‘‘(1) IN GENERAL.—The Secretary may, at the 

24 Secretary’s sole discretion, grant a waiver or reduc25 tion of fees under subsection (a)(2) or (a)(3) if the 

mstockstill on DSK4VPTVN1PROD with BILLS

27 

•S 2516 PCS

1 Secretary finds that such waiver or reduction is in 

2 the interest of public health. 

3 ‘‘(2) LIMITATION.—The sum of all fee waivers 

4 or reductions granted by the Secretary in any fiscal 

5 year under paragraph (1) shall not exceed 2 percent 

6 of the total fee revenue amounts established for such 

7 year under subsection (c). 

8 ‘‘(3) DURATION.—The authority provided by 

9 this subsection terminates October 1, 2017.’’. 

10 (e) CONDITIONS.—Section 738(h)(1)(A) (21 U.S.C. 

11 379j(h)(1)(A)), as redesignated by subsection (d)(1), is 

12 amended by striking ‘‘$205,720,000’’ and inserting 

13 ‘‘$280,587,000’’. 

14 (f) CREDITING AND AVAILABILITY OF FEES.—Sec15 tion 738(i) (21 U.S.C. 379j(i)), as redesignated by sub16 section (d)(1), is amended— 

17 (1) in paragraph (1), by striking ‘‘Fees author18 ized’’ and inserting ‘‘Subject to paragraph (2)(C), 

19 fees authorized’’; 

20 (2) in paragraph (2)— 

21 (A) in subparagraph (A)— 

22 (i) in clause (i), by striking ‘‘shall be 

23 retained’’ and inserting ‘‘subject to sub24 paragraph (C), shall be collected and avail25 able’’; and 

mstockstill on DSK4VPTVN1PROD with BILLS

28 

•S 2516 PCS

1 (ii) in clause (ii)— 

2 (I) by striking ‘‘collected and’’ 

3 after ‘‘shall only be’’; and 

4 (II) by striking ‘‘fiscal year 

5 2002’’ and inserting ‘‘fiscal year 

6 2009’’; and 

7 (B) by adding at the end, the following: 

8 ‘‘(C) PROVISION FOR EARLY PAYMENTS.— 

9 Payment of fees authorized under this section 

10 for a fiscal year, prior to the due date for such 

11 fees, may be accepted by the Secretary in ac12 cordance with authority provided in advance in 

13 a prior year appropriations Act.’’; 

14 (3) by amending paragraph (3) to read as fol15 lows: 

16 ‘‘(3) AUTHORIZATIONS OF APPROPRIATIONS.— 

17 For each of the fiscal years 2013 through 2017, 

18 there is authorized to be appropriated for fees under 

19 this section an amount equal to the total revenue 

20 amount specified under subsection (b)(3) for the fis21 cal year, as adjusted under subsection (c) and, for 

22 fiscal year 2017 only, as further adjusted under 

23 paragraph (4).’’; and 

24 (4) in paragraph (4)— 

mstockstill on DSK4VPTVN1PROD with BILLS

29 

•S 2516 PCS

1 (A) by striking ‘‘fiscal years 2008, 2009, 

2 and 2010’’ and inserting ‘‘fiscal years 2013, 

3 2014, and 2015’’; 

4 (B) by striking ‘‘fiscal year 2011’’ and in5 serting ‘‘fiscal year 2016’’; 

6 (C) by striking ‘‘June 30, 2011’’ and in7 serting ‘‘June 30, 2016’’; 

8 (D) by striking ‘‘the amount of fees speci9 fied in aggregate in’’ and inserting ‘‘the cumu10 lative amount appropriated pursuant to’’; 

11 (E) by striking ‘‘aggregate amount in’’ be12 fore ‘‘excess shall be credited’’; and 

13 (F) by striking ‘‘fiscal year 2012’’ and in14 serting ‘‘fiscal year 2017’’. 

15 (g) CONFORMING AMENDMENT.—Section 

16 515(c)(4)(A) (21 U.S.C. 360e(c)(4)(A)) is amended by 

17 striking ‘‘738(g)’’ and inserting ‘‘738(h)’’. 

18 SEC. 204. REAUTHORIZATION; REPORTING REQUIREMENTS. 

19 (a) REAUTHORIZATION.—Section 738A(b) (21 

20 U.S.C. 379j–1(b)) is amended— 

21 (1) in paragraph (1), by striking ‘‘2012’’ and 

22 inserting ‘‘2017’’; and 

23 (2) in paragraph (5), by striking ‘‘2012’’ and 

24 inserting ‘‘2017’’. 

mstockstill on DSK4VPTVN1PROD with BILLS

30 

•S 2516 PCS

1 (b) REPORTS.—Section 738A(a) (21 U.S.C. 379j– 

2 1(a)) is amended— 

3 (1) by striking ‘‘2008 through 2012’’ each place 

4 it appears and inserting ‘‘2013 through 2017’’; and 

5 (2) by striking ‘‘section 201(c) of the Food and 

6 Drug Administration Amendments Act of 2007’’ and 

7 inserting ‘‘section 201(b) of the Medical Device User 

8 Fee Amendments of 2012’’. 

9 SEC. 205. SAVINGS CLAUSE. 

10 Notwithstanding the amendments made by this title, 

11 part 3 of subchapter C of chapter VII of the Federal Food, 

12 Drug, and Cosmetic Act (21 U.S.C. 379i et seq.), as in 

13 effect on the day before the date of the enactment of this 

14 title, shall continue to be in effect with respect to submis15 sions described in section 738(a)(2)(A) of the Federal 

16 Food, Drug, and Cosmetic Act (as in effect as of such 

17 day) that on or after October 1, 2007, but before October 

18 1, 2012, were accepted by the Food and Drug Administra19 tion for filing with respect to assessing and collecting any 

20 fee required by such part for a fiscal year prior to fiscal 

21 year 2013. 

22 SEC. 206. EFFECTIVE DATE. 

23 The amendments made by this title shall take effect 

24 on October 1, 2012, or the date of the enactment of this 

25 Act, whichever is later, except that fees under part 3 of 

mstockstill on DSK4VPTVN1PROD with BILLS

31 

•S 2516 PCS

1 subchapter C of chapter VII of the Federal Food, Drug, 

2 and Cosmetic Act shall be assessed for submissions de3 scribed in section 738(a)(2)(A) of the Federal Food, 

4 Drug, and Cosmetic Act received on or after October 1, 

5 2012, regardless of the date of the enactment of this Act. 

6 SEC. 207. SUNSET DATES. 

7 (a) AUTHORIZATIONS.—Sections 737 and 738 (21 

8 U.S.C. 739i; 739j) shall cease to be effective October 1, 

9 2017. 

10 (b) REPORTING REQUIREMENTS.—Section 738A (21 

11 U.S.C. 739j–1) shall cease to be effective January 31, 

12 2018. 

13 (c) PREVIOUS SUNSET PROVISION.—The Food and 

14 Drug Administration Amendments Act of 2007 is amend15 ed by striking section 217. 

16 SEC. 208. STREAMLINED HIRING AUTHORITY TO SUPPORT 

17 ACTIVITIES RELATED TO THE PROCESS FOR 

18 THE REVIEW OF DEVICE APPLICATIONS. 

19 Subchapter A of chapter VII (21 U.S.C. 371 et seq.) 

20 is amended by inserting after section 713 the following 

21 new section: 

22 ‘‘SEC. 714. STREAMLINED HIRING AUTHORITY. 

23 ‘‘(a) IN GENERAL.—In addition to any other per24 sonnel authorities under other provisions of law, the Sec25 retary may, without regard to the provisions of title 5, 

mstockstill on DSK4VPTVN1PROD with BILLS

32 

•S 2516 PCS

1 United States Code, governing appointments in the com2 petitive service, appoint employees to positions in the Food 

3 and Drug Administration to perform, administer, or sup4 port activities described in subsection (b), if the Secretary 

5 determines that such appointments are needed to achieve 

6 the objectives specified in subsection (c). 

7 ‘‘(b) ACTIVITIES DESCRIBED.—The activities de8 scribed in this subsection are activities under this Act re9 lated to the process for the review of device applications 

10 (as defined in section 737(8)). 

11 ‘‘(c) OBJECTIVES SPECIFIED.—The objectives speci12 fied in this subsection are with respect to the activities 

13 under subsection (b), the goals referred to in section 

14 738A(a)(1). 

15 ‘‘(d) INTERNAL CONTROLS.—The Secretary shall in16 stitute appropriate internal controls for appointments 

17 under this section. 

18 ‘‘(e) SUNSET.—The authority to appoint employees 

19 under this section shall terminate on the date that is three 

20 years after the date of enactment of this section.’’. 

21 TITLE III—FEES RELATING TO 

22 GENERIC DRUGS 

23 SEC. 301. SHORT TITLE. 

24 (a) SHORT TITLE.—This title may be cited as the 

25 ‘‘Generic Drug User Fee Amendments of 2012’’. 

mstockstill on DSK4VPTVN1PROD with BILLS

33 

•S 2516 PCS

1 (b) FINDING.—The Congress finds that the fees au2 thorized by the amendments made in this title will be dedi3 cated to human generic drug activities, as set forth in the 

4 goals identified for purposes of part 7 of subchapter C 

5 of chapter VII of the Federal Food, Drug, and Cosmetic 

6 Act, in the letters from the Secretary of Health and 

7 Human Services to the Chairman of the Committee on 

8 Health, Education, Labor, and Pensions of the Senate and 

9 the Chairman of the Committee on Energy and Commerce 

10 of the House of Representatives, as set forth in the Con11 gressional Record. 

12 SEC. 302. AUTHORITY TO ASSESS AND USE HUMAN GE13 NERIC DRUG FEES. 

14 Subchapter C of chapter VII (21 U.S.C. 379f et seq.) 

15 is amended by adding at the end the following: 

16 ‘‘PART 7—FEES RELATING TO GENERIC DRUGS 

17 ‘‘SEC. 744A. DEFINITIONS. 

18 ‘‘For purposes of this part: 

19 ‘‘(1) The term ‘abbreviated new drug applica20 tion’— 

21 ‘‘(A) means an application submitted 

22 under section 505(j), an abbreviated application 

23 submitted under section 507 (as in effect on the 

24 day before the date of enactment of the Food 

25 and Drug Administration Modernization Act of 

mstockstill on DSK4VPTVN1PROD with BILLS

34 

•S 2516 PCS

1 1997), or an abbreviated new drug application 

2 submitted pursuant to regulations in effect 

3 prior to the implementation of the Drug Price 

4 Competition and Patent Term Restoration Act 

5 of 1984; and 

6 ‘‘(B) does not include an application for a 

7 positron emission tomography drug. 

8 ‘‘(2) The term ‘active pharmaceutical ingre9 dient’ means— 

10 ‘‘(A) a substance, or a mixture when the 

11 substance is unstable or cannot be transported 

12 on its own, intended— 

13 ‘‘(i) to be used as a component of a 

14 drug; and 

15 ‘‘(ii) to furnish pharmacological activ16 ity or other direct effect in the diagnosis, 

17 cure, mitigation, treatment, or prevention 

18 of disease, or to affect the structure or any 

19 function of the human body; or 

20 ‘‘(B) a substance intended for final crys21 tallization, purification, or salt formation, or 

22 any combination of those activities, to become a 

23 substance or mixture described in subparagraph 

24 (A). 

mstockstill on DSK4VPTVN1PROD with BILLS

35 

•S 2516 PCS

1 ‘‘(3) The term ‘adjustment factor’ means a fac2 tor applicable to a fiscal year that is the Consumer 

3 Price Index for all urban consumers (all items; 

4 United States city average) for October of the pre5 ceding fiscal year divided by such Index for October 

6 2011. 

7 ‘‘(4) The term ‘affiliate’ means a business enti8 ty that has a relationship with a second business en9 tity if, directly or indirectly— 

10 ‘‘(A) one business entity controls, or has 

11 the power to control, the other business entity; 

12 or 

13 ‘‘(B) a third party controls, or has power 

14 to control, both of the business entities. 

15 ‘‘(5)(A) The term ‘facility’— 

16 ‘‘(i) means a business or other entity— 

17 ‘‘(I) under one management, either di18 rect or indirect; and 

19 ‘‘(II) at one geographic location or ad20 dress engaged in manufacturing or proc21 essing an active pharmaceutical ingredient 

22 or a finished dosage form; and 

23 ‘‘(ii) does not include a business or other 

24 entity whose only manufacturing or processing 

mstockstill on DSK4VPTVN1PROD with BILLS

36 

•S 2516 PCS

1 activities are one or more of the following: re2 packaging, relabeling, or testing. 

3 ‘‘(B) For purposes of subparagraph (A), sepa4 rate buildings within close proximity are considered 

5 to be at one geographic location or address if the ac6 tivities in them are— 

7 ‘‘(i) closely related to the same business 

8 enterprise; 

9 ‘‘(ii) under the supervision of the same 

10 local management; and 

11 ‘‘(iii) capable of being inspected by the 

12 Food and Drug Administration during a single 

13 inspection. 

14 ‘‘(C) If a business or other entity would meet 

15 the definition of a facility under this paragraph but 

16 for being under multiple management, the business 

17 or other entity is deemed to constitute multiple fa18 cilities, one per management entity, for purposes of 

19 this paragraph. 

20 ‘‘(6) The term ‘finished dosage form’ means— 

21 ‘‘(A) a drug product in the form in which 

22 it will be administered to a patient, such as a 

23 tablet, capsule, solution, or topical application; 

24 ‘‘(B) a drug product in a form in which re25 constitution is necessary prior to administration 

mstockstill on DSK4VPTVN1PROD with BILLS

37 

•S 2516 PCS

1 to a patient, such as oral suspensions or 

2 lyophilized powders; or 

3 ‘‘(C) any combination of an active pharma4 ceutical ingredient with another component of a 

5 drug product for purposes of production of a 

6 drug product described in subparagraph (A) or 

7 (B). 

8 ‘‘(7) The term ‘generic drug submission’ means 

9 an abbreviated new drug application, an amendment 

10 to an abbreviated new drug application, or a prior 

11 approval supplement to an abbreviated new drug ap12 plication. 

13 ‘‘(8) The term ‘human generic drug activities’ 

14 means the following activities of the Secretary asso15 ciated with generic drugs and inspection of facilities 

16 associated with generic drugs: 

17 ‘‘(A) The activities necessary for the re18 view of generic drug submissions, including re19 view of drug master files referenced in such 

20 submissions. 

21 ‘‘(B) The issuance of— 

22 ‘‘(i) approval letters which approve 

23 abbreviated new drug applications or sup24 plements to such applications; or 

mstockstill on DSK4VPTVN1PROD with BILLS

38 

•S 2516 PCS

1 ‘‘(ii) complete response letters which 

2 set forth in detail the specific deficiencies 

3 in such applications and, where appro4 priate, the actions necessary to place such 

5 applications in condition for approval. 

6 ‘‘(C) The issuance of letters related to 

7 Type II active pharmaceutical drug master files 

8 which— 

9 ‘‘(i) set forth in detail the specific de10 ficiencies in such submissions, and where 

11 appropriate, the actions necessary to re12 solve those deficiencies; or 

13 ‘‘(ii) document that no deficiencies 

14 need to be addressed. 

15 ‘‘(D) Inspections related to generic drugs. 

16 ‘‘(E) Monitoring of research conducted in 

17 connection with the review of generic drug sub18 missions and drug master files. 

19 ‘‘(F) Postmarket safety activities with re20 spect to drugs approved under abbreviated new 

21 drug applications or supplements, including the 

22 following activities: 

23 ‘‘(i) Collecting, developing, and re24 viewing safety information on approved 

25 drugs, including adverse event reports. 

mstockstill on DSK4VPTVN1PROD with BILLS

39 

•S 2516 PCS

1 ‘‘(ii) Developing and using improved 

2 adverse-event data-collection systems, in3 cluding information technology systems. 

4 ‘‘(iii) Developing and using improved 

5 analytical tools to assess potential safety 

6 problems, including access to external data 

7 bases. 

8 ‘‘(iv) Implementing and enforcing sec9 tion 505(o) (relating to postapproval stud10 ies and clinical trials and labeling changes) 

11 and section 505(p) (relating to risk evalua12 tion and mitigation strategies) insofar as 

13 those activities relate to abbreviated new 

14 drug applications. 

15 ‘‘(v) Carrying out section 505(k)(5) 

16 (relating to adverse-event reports and 

17 postmarket safety activities). 

18 ‘‘(G) Regulatory science activities related 

19 to generic drugs. 

20 ‘‘(9) The term ‘positron emission tomography 

21 drug’ has the meaning given to the term ‘com22 pounded positron emission tomography drug’ in sec23 tion 201(ii), except that paragraph (1)(B) of such 

24 section shall not apply. 

mstockstill on DSK4VPTVN1PROD with BILLS

40 

•S 2516 PCS

1 ‘‘(10) The term ‘prior approval supplement’ 

2 means a request to the Secretary to approve a 

3 change in the drug substance, drug product, produc4 tion process, quality controls, equipment, or facilities 

5 covered by an approved abbreviated new drug appli6 cation when that change has a substantial potential 

7 to have an adverse effect on the identity, strength, 

8 quality, purity, or potency of the drug product as 

9 these factors may relate to the safety or effective10 ness of the drug product. 

11 ‘‘(11) The term ‘resources allocated for human 

12 generic drug activities’ means the expenses for— 

13 ‘‘(A) officers and employees of the Food 

14 and Drug Administration, contractors of the 

15 Food and Drug Administration, advisory com16 mittees, and costs related to such officers and 

17 employees and to contracts with such contrac18 tors; 

19 ‘‘(B) management of information, and the 

20 acquisition, maintenance, and repair of com21 puter resources; 

22 ‘‘(C) leasing, maintenance, renovation, and 

23 repair of facilities and acquisition, maintenance, 

24 and repair of fixtures, furniture, scientific 

mstockstill on DSK4VPTVN1PROD with BILLS

41 

•S 2516 PCS

1 equipment, and other necessary materials and 

2 supplies; and 

3 ‘‘(D) collecting fees under subsection (a) 

4 and accounting for resources allocated for the 

5 review of abbreviated new drug applications and 

6 supplements and inspection related to generic 

7 drugs. 

8 ‘‘(12) The term ‘Type II active pharmaceutical 

9 ingredient drug master file’ means a submission of 

10 information to the Secretary by a person that in11 tends to authorize the Food and Drug Administra12 tion to reference the information to support approval 

13 of a generic drug submission without the submitter 

14 having to disclose the information to the generic 

15 drug submission applicant. 

16 ‘‘SEC. 744B. AUTHORITY TO ASSESS AND USE HUMAN GE17 NERIC DRUG FEES. 

18 ‘‘(a) TYPES OF FEES.—Beginning in fiscal year 

19 2013, the Secretary shall assess and collect fees in accord20 ance with this section as follows: 

21 ‘‘(1) ONE-TIME BACKLOG FEE FOR ABBRE22 VIATED NEW DRUG APPLICATIONS PENDING ON OC23 TOBER 1, 2012.— 

24 ‘‘(A) IN GENERAL.—Each person that 

25 owns an abbreviated new drug application that 

mstockstill on DSK4VPTVN1PROD with BILLS

42 

•S 2516 PCS

1 is pending on October 1, 2012, and that has 

2 not received a tentative approval prior to that 

3 date, shall be subject to a fee for each such ap4 plication, as calculated under subparagraph 

5 (B). 

6 ‘‘(B) METHOD OF FEE AMOUNT CALCULA7 TION.—The amount of each one-time backlog 

8 fee shall be calculated by dividing $50,000,000 

9 by the total number of abbreviated new drug 

10 applications pending on October 1, 2012, that 

11 have not received a tentative approval as of that 

12 date. 

13 ‘‘(C) NOTICE.—Not later than October 31, 

14 2012, the Secretary shall publish in the Federal 

15 Register a notice announcing the amount of the 

16 fee required by subparagraph (A). 

17 ‘‘(D) FEE DUE DATE.—The fee required 

18 by subparagraph (A) shall be due no later than 

19 30 calendar days after the date of the publica20 tion of the notice specified in subparagraph (C). 

21 ‘‘(2) DRUG MASTER FILE FEE.— 

22 ‘‘(A) IN GENERAL.—Each person that 

23 owns a Type II active pharmaceutical ingre24 dient drug master file that is referenced on or 

25 after October 1, 2012, in a generic drug submstockstill on DSK4VPTVN1PROD with BILLS

43 

•S 2516 PCS

1 mission by any initial letter of authorization 

2 shall be subject to a drug master file fee. 

3 ‘‘(B) ONE-TIME PAYMENT.—If a person 

4 has paid a drug master file fee for a Type II 

5 active pharmaceutical ingredient drug master 

6 file, the person shall not be required to pay a 

7 subsequent drug master file fee when that Type 

8 II active pharmaceutical ingredient drug master 

9 file is subsequently referenced in generic drug 

10 submissions. 

11 ‘‘(C) NOTICE.— 

12 ‘‘(i) FISCAL YEAR 2013.—Not later 

13 than October 31, 2012, the Secretary shall 

14 publish in the Federal Register a notice 

15 announcing the amount of the drug master 

16 file fee for fiscal year 2013. 

17 ‘‘(ii) FISCAL YEAR 2014 THROUGH

18 2017.—Not later than 60 days before the 

19 start of each of fiscal years 2014 through 

20 2017, the Secretary shall publish in the 

21 Federal Register the amount of the drug 

22 master file fee established by this para23 graph for such fiscal year. 

24 ‘‘(D) AVAILABILITY FOR REFERENCE.— 

mstockstill on DSK4VPTVN1PROD with BILLS

44 

•S 2516 PCS

1 ‘‘(i) IN GENERAL.—Subject to sub2 section (g)(2)(C), for a generic drug sub3 mission to reference a Type II active phar4 maceutical ingredient drug master file, the 

5 drug master file must be deemed available 

6 for reference by the Secretary. 

7 ‘‘(ii) CONDITIONS.—A drug master 

8 file shall be deemed available for reference 

9 by the Secretary if— 

10 ‘‘(I) the person that owns a Type 

11 II active pharmaceutical ingredient 

12 drug master file has paid the fee re13 quired under subparagraph (A) within 

14 20 calendar days after the applicable 

15 due date under subparagraph (E); 

16 and 

17 ‘‘(II) the drug master file has not 

18 failed an initial completeness assess19 ment by the Secretary, in accordance 

20 with criteria to be published by the 

21 Secretary. 

22 ‘‘(iii) LIST.—The Secretary shall 

23 make publicly available on the Internet 

24 Web site of the Food and Drug Adminis25 tration a list of the drug master file nummstockstill on DSK4VPTVN1PROD with BILLS

45 

•S 2516 PCS

1 bers that correspond to drug master files 

2 that have successfully undergone an initial 

3 completeness assessment, in accordance 

4 with criteria to be published by the Sec5 retary, and are available for reference. 

6 ‘‘(E) FEE DUE DATE.— 

7 ‘‘(i) IN GENERAL.—Subject to clause 

8 (ii), a drug master file fee shall be due no 

9 later than the date on which the first ge10 neric drug submission is submitted that 

11 references the associated Type II active 

12 pharmaceutical ingredient drug master file. 

13 ‘‘(ii) LIMITATION.—No fee shall be 

14 due under subparagraph (A) for a fiscal 

15 year until the later of— 

16 ‘‘(I) 30 calendar days after publi17 cation of the notice provided for in 

18 clause (i) or (ii) of subparagraph (C), 

19 as applicable; or 

20 ‘‘(II) 30 calendar days after the 

21 date of enactment of an appropria22 tions Act providing for the collection 

23 and obligation of fees under this sec24 tion. 

mstockstill on DSK4VPTVN1PROD with BILLS

46 

•S 2516 PCS

1 ‘‘(3) ABBREVIATED NEW DRUG APPLICATION

2 AND PRIOR APPROVAL SUPPLEMENT FILING FEE.— 

3 ‘‘(A) IN GENERAL.—Each applicant that 

4 submits, on or after October 1, 2012, an abbre5 viated new drug application or a prior approval 

6 supplement to an abbreviated new drug applica7 tion shall be subject to a fee for each such sub8 mission in the amount established under sub9 section (d). 

10 ‘‘(B) NOTICE.— 

11 ‘‘(i) FISCAL YEAR 2013.—Not later 

12 than October 31, 2012, the Secretary shall 

13 publish in the Federal Register a notice 

14 announcing the amount of the fees under 

15 subparagraph (A) for fiscal year 2013. 

16 ‘‘(ii) FISCAL YEARS 2014 THROUGH

17 2017.—Not later than 60 days before the 

18 start of each of fiscal years 2014 through 

19 2017, the Secretary shall publish in the 

20 Federal Register the amount of the fees 

21 under subparagraph (A) for such fiscal 

22 year. 

23 ‘‘(C) FEE DUE DATE.— 

24 ‘‘(i) IN GENERAL.—Except as pro25 vided in clause (ii), the fees required by 

mstockstill on DSK4VPTVN1PROD with BILLS

47 

•S 2516 PCS

1 subparagraphs (A) and (F) shall be due no 

2 later than the date of submission of the 

3 abbreviated new drug application or prior 

4 approval supplement for which such fee ap5 plies. 

6 ‘‘(ii) SPECIAL RULE FOR 2013.—For 

7 fiscal year 2013, such fees shall be due on 

8 the later of— 

9 ‘‘(I) the date on which the fee is 

10 due under clause (i); 

11 ‘‘(II) 30 calendar days after pub12 lication of the notice referred to in 

13 subparagraph (B)(i); or 

14 ‘‘(III) if an appropriations Act is 

15 not enacted providing for the collec16 tion and obligation of fees under this 

17 section by the date of submission of 

18 the application or prior approval sup19 plement for which the fees under sub20 paragraphs (A) and (F) apply, 30 cal21 endar days after the date that such an 

22 appropriations Act is enacted. 

23 ‘‘(D) REFUND OF FEE IF ABBREVIATED

24 NEW DRUG APPLICATION IS NOT CONSIDERED

25 TO HAVE BEEN RECEIVED.—The Secretary 

mstockstill on DSK4VPTVN1PROD with BILLS

48 

•S 2516 PCS

1 shall refund 75 percent of the fee paid under 

2 subparagraph (A) for any abbreviated new drug 

3 application or prior approval supplement to an 

4 abbreviated new drug application that the Sec5 retary considers not to have been received with6 in the meaning of section 505(j)(5)(A) for a 

7 cause other than failure to pay fees. 

8 ‘‘(E) FEE FOR AN APPLICATION THE SEC9 RETARY CONSIDERS NOT TO HAVE BEEN RE10 CEIVED, OR THAT HAS BEEN WITHDRAWN.—An 

11 abbreviated new drug application or prior ap12 proval supplement that was submitted on or 

13 after October 1, 2012, and that the Secretary 

14 considers not to have been received, or that has 

15 been withdrawn, shall, upon resubmission of the 

16 application or a subsequent new submission fol17 lowing the applicant’s withdrawal of the appli18 cation, be subject to a full fee under subpara19 graph (A). 

20 ‘‘(F) ADDITIONAL FEE FOR ACTIVE PHAR21 MACEUTICAL INGREDIENT INFORMATION NOT

22 INCLUDED BY REFERENCE TO TYPE II ACTIVE

23 PHARMACEUTICAL INGREDIENT DRUG MASTER

24 FILE.—An applicant that submits a generic 

25 drug submission on or after October 1, 2012, 

mstockstill on DSK4VPTVN1PROD with BILLS

49 

•S 2516 PCS

1 shall pay a fee, in the amount determined under 

2 subsection (d)(3), in addition to the fee re3 quired under subparagraph (A), if— 

4 ‘‘(i) such submission contains infor5 mation concerning the manufacture of an 

6 active pharmaceutical ingredient at a facil7 ity by means other than reference by a let8 ter of authorization to a Type II active 

9 pharmaceutical drug master file; and 

10 ‘‘(ii) a fee in the amount equal to the 

11 drug master file fee established in para12 graph (2) has not been previously paid 

13 with respect to such information. 

14 ‘‘(4) GENERIC DRUG FACILITY FEE AND ACTIVE

15 PHARMACEUTICAL INGREDIENT FACILITY FEE.— 

16 ‘‘(A) IN GENERAL.—Facilities identified, 

17 or intended to be identified, in at least one ge18 neric drug submission that is pending or ap19 proved to produce a finished dosage form of a 

20 human generic drug or an active pharma21 ceutical ingredient contained in a human ge22 neric drug shall be subject to fees as follows: 

23 ‘‘(i) GENERIC DRUG FACILITY.—Each 

24 person that owns a facility which is identi25 fied or intended to be identified in at least 

mstockstill on DSK4VPTVN1PROD with BILLS

50 

•S 2516 PCS

1 one generic drug submission that is pend2 ing or approved to produce one or more 

3 finished dosage forms of a human generic 

4 drug shall be assessed an annual fee for 

5 each such facility. 

6 ‘‘(ii) ACTIVE PHARMACEUTICAL IN7 GREDIENT FACILITY.—Each person that 

8 owns a facility which produces, or which is 

9 pending review to produce, one or more ac10 tive pharmaceutical ingredients identified, 

11 or intended to be identified, in at least one 

12 generic drug submission that is pending or 

13 approved or in a Type II active pharma14 ceutical ingredient drug master file ref15 erenced in such a generic drug submission, 

16 shall be assessed an annual fee for each 

17 such facility. 

18 ‘‘(iii) FACILITIES PRODUCING BOTH

19 ACTIVE PHARMACEUTICAL INGREDIENTS

20 AND FINISHED DOSAGE FORMS.—Each 

21 person that owns a facility identified, or 

22 intended to be identified, in at least one 

23 generic drug submission that is pending or 

24 approved to produce both one or more fin25 ished dosage forms subject to clause (i) 

mstockstill on DSK4VPTVN1PROD with BILLS

51 

•S 2516 PCS

1 and one or more active pharmaceutical in2 gredients subject to clause (ii) shall be 

3 subject to fees under both such clauses for 

4 that facility. 

5 ‘‘(B) AMOUNT.—The amount of fees estab6 lished under subparagraph (A) shall be estab7 lished under subsection (d). 

8 ‘‘(C) NOTICE.— 

9 ‘‘(i) FISCAL YEAR 2013.—For fiscal 

10 year 2013, the Secretary shall publish in 

11 the Federal Register a notice announcing 

12 the amount of the fees provided for in sub13 paragraph (A) within the timeframe speci14 fied in subsection (d)(1)(B). 

15 ‘‘(ii) FISCAL YEARS 2014 THROUGH

16 2017.—Within the timeframe specified in 

17 subsection (d)(2), the Secretary shall pub18 lish in the Federal Register the amount of 

19 the fees under subparagraph (A) for such 

20 fiscal year. 

21 ‘‘(D) FEE DUE DATE.— 

22 ‘‘(i) FISCAL YEAR 2013.—For fiscal 

23 year 2013, the fees under subparagraph 

24 (A) shall be due on the later of— 

mstockstill on DSK4VPTVN1PROD with BILLS

52 

•S 2516 PCS

1 ‘‘(I) not later than 45 days after 

2 the publication of the notice under 

3 subparagraph (B); or 

4 ‘‘(II) if an appropriations Act is 

5 not enacted providing for the collec6 tion and obligation of fees under this 

7 section by the date of the publication 

8 of such notice, 30 days after the date 

9 that such an appropriations Act is en10 acted. 

11 ‘‘(ii) FISCAL YEARS 2014 THROUGH

12 2017.—For each of fiscal years 2014 

13 through 2017, the fees under subpara14 graph (A) for such fiscal year shall be due 

15 on the later of— 

16 ‘‘(I) the first business day on or 

17 after October 1 of each such year; or 

18 ‘‘(II) the first business day after 

19 the enactment of an appropriations 

20 Act providing for the collection and 

21 obligation of fees under this section 

22 for such year. 

23 ‘‘(5) DATE OF SUBMISSION.—For purposes of 

24 this Act, a generic drug submission or Type II pharmstockstill on DSK4VPTVN1PROD with BILLS

53 

•S 2516 PCS

1 maceutical master file is deemed to be ‘submitted’ to 

2 the Food and Drug Administration— 

3 ‘‘(A) if it is submitted via a Food and 

4 Drug Administration electronic gateway, on the 

5 day when transmission to that electronic gate6 way is completed, except that a submission or 

7 master file that arrives on a weekend, Federal 

8 holiday, or day when the Food and Drug Ad9 ministration office that will review that submis10 sion is not otherwise open for business shall be 

11 deemed to be submitted on the next day when 

12 that office is open for business; or 

13 ‘‘(B) if it is submitted in physical media 

14 form, on the day it arrives at the appropriate 

15 designated document room of the Food and 

16 Drug Administration. 

17 ‘‘(b) FEE REVENUE AMOUNTS.— 

18 ‘‘(1) IN GENERAL.— 

19 ‘‘(A) FISCAL YEAR 2013.—For fiscal year 

20 2013, fees under subsection (a) except as pro21 vided in subsection (o) (relating to waivers) 

22 shall be established to generate a total esti23 mated revenue amount under such subsection of 

24 $299,000,000. Of that amount— 

mstockstill on DSK4VPTVN1PROD with BILLS

54 

•S 2516 PCS

1 ‘‘(i) $50,000,000 shall be generated 

2 by the one-time backlog fee for generic 

3 drug applications pending on October 1, 

4 2012, established in subsection (a)(1); and 

5 ‘‘(ii) $249,000,000 shall be generated 

6 by the fees under paragraphs (2) through 

7 (4) of subsection (a). 

8 ‘‘(B) FISCAL YEARS 2014 THROUGH 2017.— 

9 For each of the fiscal years 2014 through 2017, 

10 fees under paragraphs (2) through (4) of sub11 section (a) shall be established to generate a 

12 total estimated revenue amount under such sub13 section that is equal to $299,000,000, as ad14 justed pursuant to subsection (c). 

15 ‘‘(2) TYPES OF FEES.—In establishing fees 

16 under paragraph (1) to generate the revenue 

17 amounts specified in paragraph (1)(A)(ii) for fiscal 

18 year 2013 and paragraph (1)(B) for each of fiscal 

19 years 2014 through 2017, such fees shall be derived 

20 from the fees under paragraphs (2) through (4) of 

21 subsection (a) as follows: 

22 ‘‘(A) 6 percent shall be derived from fees 

23 under subsection (a)(2) (relating to drug mas24 ter files). 

mstockstill on DSK4VPTVN1PROD with BILLS

55 

•S 2516 PCS

1 ‘‘(B) 24 percent shall be derived from fees 

2 under subsection (a)(3) (relating to abbreviated 

3 new drug applications and supplements). The 

4 amount of a fee for a prior approval supplement 

5 shall be half the amount of the fee for an ab6 breviated new drug application. 

7 ‘‘(C) 56 percent shall be derived from fees 

8 under subsection (a)(4)(A)(i) (relating to ge9 neric drug facilities). The amount of the fee for 

10 a facility located outside the United States and 

11 its territories and possessions shall be not less 

12 than $15,000 and not more than $30,000 high13 er than the amount of the fee for a facility lo14 cated in the United States and its territories 

15 and possessions, as determined by the Secretary 

16 on the basis of data concerning the difference 

17 in cost between inspections of facilities located 

18 in the United States, including its territories 

19 and possessions, and those located outside of 

20 the United States and its territories and posses21 sions. 

22 ‘‘(D) 14 percent shall be derived from fees 

23 under subsection (a)(4)(A)(ii) (relating to active 

24 pharmaceutical ingredient facilities). The 

25 amount of the fee for a facility located outside 

mstockstill on DSK4VPTVN1PROD with BILLS

56 

•S 2516 PCS

1 the United States and its territories and posses2 sions shall be not less than $15,000 and not 

3 more than $30,000 higher than the amount of 

4 the fee for a facility located in the United 

5 States, including its territories and possessions, 

6 as determined by the Secretary on the basis of 

7 data concerning the difference in cost between 

8 inspections of facilities located in the United 

9 States and its territories and possessions and 

10 those located outside of the United States and 

11 its territories and possessions. 

12 ‘‘(c) ADJUSTMENTS.— 

13 ‘‘(1) INFLATION ADJUSTMENT.—For fiscal year 

14 2014 and subsequent fiscal years, the revenues es15 tablished in subsection (b) shall be adjusted by the 

16 Secretary by notice, published in the Federal Reg17 ister, for a fiscal year, by an amount equal to the 

18 sum of— 

19 ‘‘(A) one; 

20 ‘‘(B) the average annual percent change in 

21 the cost, per full-time equivalent position of the 

22 Food and Drug Administration, of all personnel 

23 compensation and benefits paid with respect to 

24 such positions for the first 3 years of the pre25 ceding 4 fiscal years multiplied by the propormstockstill on DSK4VPTVN1PROD with BILLS

57 

•S 2516 PCS

1 tion of personnel compensation and benefits 

2 costs to total costs of human generic drug ac3 tivities for the first 3 years of the preceding 4 

4 fiscal years; and 

5 ‘‘(C) the average annual percent change 

6 that occurred in the Consumer Price Index for 

7 urban consumers (Washington-Baltimore, DC– 

8 MD–VA–WV; Not Seasonally Adjusted; All 

9 items; Annual Index) for the first 3 years of the 

10 preceding 4 years of available data multiplied 

11 by the proportion of all costs other than per12 sonnel compensation and benefits costs to total 

13 costs of human generic drug activities for the 

14 first 3 years of the preceding 4 fiscal years. 

15 The adjustment made each fiscal year under this 

16 subsection shall be added on a compounded basis to 

17 the sum of all adjustments made each fiscal year 

18 after fiscal year 2013 under this subsection. 

19 ‘‘(2) FINAL YEAR ADJUSTMENT.—For fiscal 

20 year 2017, the Secretary may, in addition to adjust21 ments under paragraph (1), further increase the fee 

22 revenues and fees established in subsection (b) if 

23 such an adjustment is necessary to provide for not 

24 more than 3 months of operating reserves of carry25 over user fees for human generic drug activities for 

mstockstill on DSK4VPTVN1PROD with BILLS

58 

•S 2516 PCS

1 the first 3 months of fiscal year 2018. Such fees 

2 may only be used in fiscal year 2018. If such an ad3 justment is necessary, the rationale for the amount 

4 of the increase shall be contained in the annual no5 tice establishing fee revenues and fees for fiscal year 

6 2017. If the Secretary has carryover balances for 

7 such activities in excess of 3 months of such oper8 ating reserves, the adjustment under this subpara9 graph shall not be made. 

10 ‘‘(d) ANNUAL FEE SETTING.— 

11 ‘‘(1) FISCAL YEAR 2013.—For fiscal year 

12 2013— 

13 ‘‘(A) the Secretary shall establish, by Octo14 ber 31, 2012, the one-time generic drug backlog 

15 fee for generic drug applications pending on Oc16 tober 1, 2012, the drug master file fee, the ab17 breviated new drug application fee, and the 

18 prior approval supplement fee under subsection 

19 (a), based on the revenue amounts established 

20 under subsection (b); and 

21 ‘‘(B) the Secretary shall establish, not 

22 later than 45 days after the date to comply 

23 with the requirement for identification of facili24 ties in subsection (f)(2), the generic drug facil25 ity fee and active pharmaceutical ingredient famstockstill on DSK4VPTVN1PROD with BILLS

59 

•S 2516 PCS

1 cility fee under subsection (a) based on the rev2 enue amounts established under subsection (b). 

3 ‘‘(2) FISCAL YEARS 2014 THROUGH 2017.—Not 

4 more than 60 days before the first day of each of 

5 fiscal years 2014 through 2017, the Secretary shall 

6 establish the drug master file fee, the abbreviated 

7 new drug application fee, the prior approval supple8 ment fee, the generic drug facility fee, and the active 

9 pharmaceutical ingredient facility fee under sub10 section (a) for such fiscal year, based on the revenue 

11 amounts established under subsection (b) and the 

12 adjustments provided under subsection (c). 

13 ‘‘(3) FEE FOR ACTIVE PHARMACEUTICAL IN14 GREDIENT INFORMATION NOT INCLUDED BY REF15 ERENCE TO TYPE II ACTIVE PHARMACEUTICAL IN16 GREDIENT DRUG MASTER FILE.—In establishing the 

17 fees under paragraphs (1) and (2), the amount of 

18 the fee under subsection (a)(3)(F) shall be deter19 mined by multiplying— 

20 ‘‘(A) the sum of— 

21 ‘‘(i) the total number of such active 

22 pharmaceutical ingredients in such submis23 sion; and 

24 ‘‘(ii) for each such ingredient that is 

25 manufactured at more than one such facilmstockstill on DSK4VPTVN1PROD with BILLS

60 

•S 2516 PCS

1 ity, the total number of such additional fa2 cilities; and 

3 ‘‘(B) the amount equal to the drug master 

4 file fee established in subsection (a)(2) for such 

5 submission. 

6 ‘‘(e) LIMIT.—The total amount of fees charged, as 

7 adjusted under subsection (c), for a fiscal year may not 

8 exceed the total costs for such fiscal year for the resources 

9 allocated for human generic drug activities. 

10 ‘‘(f) IDENTIFICATION OF FACILITIES.— 

11 ‘‘(1) PUBLICATION OF NOTICE; DEADLINE FOR

12 COMPLIANCE.—Not later than October 1, 2012, the 

13 Secretary shall publish in the Federal Register a no14 tice requiring each person that owns a facility de15 scribed in subsection (a)(4)(A), or a site or organi16 zation required to be identified by paragraph (4), to 

17 submit to the Secretary information on the identity 

18 of each such facility, site, or organization. The no19 tice required by this paragraph shall specify the type 

20 of information to be submitted and the means and 

21 format for submission of such information. 

22 ‘‘(2) REQUIRED SUBMISSION OF FACILITY

23 IDENTIFICATION.—Each person that owns a facility 

24 described in subsection (a)(4)(A) or a site or organi25 zation required to be identified by paragraph (4) 

mstockstill on DSK4VPTVN1PROD with BILLS

61 

•S 2516 PCS

1 shall submit to the Secretary the information re2 quired under this subsection each year. Such infor3 mation shall— 

4 ‘‘(A) for fiscal year 2013, be submitted not 

5 later than 60 days after the publication of the 

6 notice under paragraph (1); and 

7 ‘‘(B) for each subsequent fiscal year, be 

8 submitted, updated, or reconfirmed on or before 

9 June 1 of the previous year. 

10 ‘‘(3) CONTENTS OF NOTICE.—At a minimum, 

11 the submission required by paragraph (2) shall in12 clude for each such facility— 

13 ‘‘(A) identification of a facility identified or 

14 intended to be identified in an approved or 

15 pending generic drug submission; 

16 ‘‘(B) whether the facility manufactures ac17 tive pharmaceutical ingredients or finished dos18 age forms, or both; 

19 ‘‘(C) whether or not the facility is located 

20 within the United States and its territories and 

21 possessions; 

22 ‘‘(D) whether the facility manufactures 

23 positron emission tomography drugs solely, or 

24 in addition to other drugs; and 

mstockstill on DSK4VPTVN1PROD with BILLS

62 

•S 2516 PCS

1 ‘‘(E) whether the facility manufactures 

2 drugs that are not generic drugs. 

3 ‘‘(4) CERTAIN SITES AND ORGANIZATIONS.— 

4 ‘‘(A) IN GENERAL.—Any person that owns 

5 or operates a site or organization described in 

6 subparagraph (B) shall submit to the Secretary 

7 information concerning the ownership, name, 

8 and address of the site or organization. 

9 ‘‘(B) SITES AND ORGANIZATIONS.—A site 

10 or organization is described in this subpara11 graph if it is identified in a generic drug sub12 mission and is— 

13 ‘‘(i) a site in which a bioanalytical 

14 study is conducted; 

15 ‘‘(ii) a clinical research organization; 

16 ‘‘(iii) a contract analytical testing site; 

17 or 

18 ‘‘(iv) a contract repackager site. 

19 ‘‘(C) NOTICE.—The Secretary may, by no20 tice published in the Federal Register, specify 

21 the means and format for submission of the in22 formation under subparagraph (A) and may 

23 specify, as necessary for purposes of this sec24 tion, any additional information to be sub25 mitted. 

mstockstill on DSK4VPTVN1PROD with BILLS

63 

•S 2516 PCS

1 ‘‘(D) INSPECTION AUTHORITY.—The Sec2 retary’s inspection authority under section 

3 704(a)(1) shall extend to all such sites and or4 ganizations. 

5 ‘‘(g) EFFECT OF FAILURE TO PAY FEES.— 

6 ‘‘(1) GENERIC DRUG BACKLOG FEE.—Failure 

7 to pay the fee under subsection (a)(1) shall result in 

8 the Secretary placing the person that owns the ab9 breviated new drug application subject to that fee on 

10 an arrears list, such that no new abbreviated new 

11 drug applications or supplement submitted on or 

12 after October 1, 2012, from that person, or any af13 filiate of that person, will be received within the 

14 meaning of section 505(j)(5)(A) until such out15 standing fee is paid. 

16 ‘‘(2) DRUG MASTER FILE FEE.— 

17 ‘‘(A) Failure to pay the fee under sub18 section (a)(2) within 20 calendar days after the 

19 applicable due date under subparagraph (E) of 

20 such subsection (as described in subsection 

21 (a)(2)(D)(ii)(I)) shall result in the Type II ac22 tive pharmaceutical ingredient drug master file 

23 not being deemed available for reference. 

24 ‘‘(B)(i) Any generic drug submission sub25 mitted on or after October 1, 2012, that refmstockstill on DSK4VPTVN1PROD with BILLS

64 

•S 2516 PCS

1 erences, by a letter of authorization, a Type II 

2 active pharmaceutical ingredient drug master 

3 file that has not been deemed available for ref4 erence shall not be received within the meaning 

5 of section 505(j)(5)(A) unless the condition 

6 specified in clause (ii) is met. 

7 ‘‘(ii) The condition specified in this clause 

8 is that the fee established under subsection 

9 (a)(2) has been paid within 20 calendar days of 

10 the Secretary providing the notification to the 

11 sponsor of the abbreviated new drug application 

12 or supplement of the failure of the owner of the 

13 Type II active pharmaceutical ingredient drug 

14 master file to pay the drug master file fee as 

15 specified in subparagraph (C). 

16 ‘‘(C)(i) If an abbreviated new drug applica17 tion or supplement to an abbreviated new drug 

18 application references a Type II active pharma19 ceutical ingredient drug master file for which a 

20 fee under subsection (a)(2)(A) has not been 

21 paid by the applicable date under subsection 

22 (a)(2)(E), the Secretary shall notify the sponsor 

23 of the abbreviated new drug application or sup24 plement of the failure of the owner of the Type 

mstockstill on DSK4VPTVN1PROD with BILLS

65 

•S 2516 PCS

1 II active pharmaceutical ingredient drug master 

2 file to pay the applicable fee. 

3 ‘‘(ii) If such fee is not paid within 20 cal4 endar days of the Secretary providing the noti5 fication, the abbreviated new drug application 

6 or supplement to an abbreviated new drug ap7 plication shall not be received within the mean8 ing of 505(j)(5)(A). 

9 ‘‘(3) ABBREVIATED NEW DRUG APPLICATION

10 FEE AND PRIOR APPROVAL SUPPLEMENT FEE.— 

11 Failure to pay a fee under subparagraph (A) or (F) 

12 of subsection (a)(3) within 20 calendar days of the 

13 applicable due date under subparagraph (C) of such 

14 subsection shall result in the abbreviated new drug 

15 application or the prior approval supplement to an 

16 abbreviated new drug application not being received 

17 within the meaning of section 505(j)(5)(A) until 

18 such outstanding fee is paid. 

19 ‘‘(4) GENERIC DRUG FACILITY FEE AND ACTIVE

20 PHARMACEUTICAL INGREDIENT FACILITY FEE.— 

21 ‘‘(A) IN GENERAL.—Failure to pay the fee 

22 under subsection (a)(4) within 20 calendar days 

23 of the due date as specified in subparagraph 

24 (D) of such subsection shall result in the fol25 lowing: 

mstockstill on DSK4VPTVN1PROD with BILLS

66 

•S 2516 PCS

1 ‘‘(i) The Secretary shall place the fa2 cility on a publicly available arrears list, 

3 such that no new abbreviated new drug ap4 plication or supplement submitted on or 

5 after October 1, 2012, from the person 

6 that is responsible for paying such fee, or 

7 any affiliate of that person, will be received 

8 within the meaning of section 505(j)(5)(A). 

9 ‘‘(ii) Any new generic drug submission 

10 submitted on or after October 1, 2012, 

11 that references such a facility shall not be 

12 received, within the meaning of section 

13 505(j)(5)(A) if the outstanding facility fee 

14 is not paid within 20 calendar days of the 

15 Secretary providing the notification to the 

16 sponsor of the failure of the owner of the 

17 facility to pay the facility fee under sub18 section (a)(4)(C). 

19 ‘‘(iii) All drugs or active pharma20 ceutical ingredients manufactured in such 

21 a facility or containing an ingredient man22 ufactured in such a facility shall be deemed 

23 misbranded under section 502(aa). 

24 ‘‘(B) APPLICATION OF PENALTIES.—The 

25 penalties under this paragraph shall apply until 

mstockstill on DSK4VPTVN1PROD with BILLS

67 

•S 2516 PCS

1 the fee established by subsection (a)(4) is paid 

2 or the facility is removed from all generic drug 

3 submissions that refer to the facility. 

4 ‘‘(C) NONRECEIVAL FOR NONPAYMENT.— 

5 ‘‘(i) NOTICE.—If an abbreviated new 

6 drug application or supplement to an ab7 breviated new drug application submitted 

8 on or after October 1, 2012, references a 

9 facility for which a facility fee has not been 

10 paid by the applicable date under sub11 section (a)(4)(C), the Secretary shall notify 

12 the sponsor of the generic drug submission 

13 of the failure of the owner of the facility 

14 to pay the facility fee. 

15 ‘‘(ii) NONRECEIVAL.—If the facility 

16 fee is not paid within 20 calendar days of 

17 the Secretary providing the notification 

18 under clause (i), the abbreviated new drug 

19 application or supplement to an abbre20 viated new drug application shall not be re21 ceived within the meaning of section 

22 505(j)(5)(A). 

23 ‘‘(h) LIMITATIONS.— 

24 ‘‘(1) IN GENERAL.—Fees under subsection (a) 

25 shall be refunded for a fiscal year beginning after 

mstockstill on DSK4VPTVN1PROD with BILLS

68 

•S 2516 PCS

1 fiscal year 2012, unless appropriations for salaries 

2 and expenses of the Food and Drug Administration 

3 for such fiscal year (excluding the amount of fees 

4 appropriated for such fiscal year) are equal to or 

5 greater than the amount of appropriations for the 

6 salaries and expenses of the Food and Drug Admin7 istration for the fiscal year 2009 (excluding the 

8 amount of fees appropriated for such fiscal year) 

9 multiplied by the adjustment factor (as defined in 

10 section 744A) applicable to the fiscal year involved. 

11 ‘‘(2) AUTHORITY.—If the Secretary does not 

12 assess fees under subsection (a) during any portion 

13 of a fiscal year and if at a later date in such fiscal 

14 year the Secretary may assess such fees, the Sec15 retary may assess and collect such fees, without any 

16 modification in the rate, for Type II active pharma17 ceutical ingredient drug master files, abbreviated 

18 new drug applications and prior approval supple19 ments, and generic drug facilities and active phar20 maceutical ingredient facilities at any time in such 

21 fiscal year notwithstanding the provisions of sub22 section (a) relating to the date fees are to be paid. 

23 ‘‘(i) CREDITING AND AVAILABILITY OF FEES.— 

24 ‘‘(1) IN GENERAL.—Fees authorized under sub25 section (a) shall be collected and available for obligamstockstill on DSK4VPTVN1PROD with BILLS

69 

•S 2516 PCS

1 tion only to the extent and in the amount provided 

2 in advance in appropriations Acts, subject to para3 graph (2). Such fees are authorized to remain avail4 able until expended. Such sums as may be necessary 

5 may be transferred from the Food and Drug Admin6 istration salaries and expenses appropriation account 

7 without fiscal year limitation to such appropriation 

8 account for salaries and expenses with such fiscal 

9 year limitation. The sums transferred shall be avail10 able solely for human generic drug activities. 

11 ‘‘(2) COLLECTIONS AND APPROPRIATION

12 ACTS.— 

13 ‘‘(A) IN GENERAL.—The fees authorized 

14 by this section— 

15 ‘‘(i) subject to subparagraphs (C) and 

16 (D), shall be collected and available in each 

17 fiscal year in an amount not to exceed the 

18 amount specified in appropriation Acts, or 

19 otherwise made available for obligation for 

20 such fiscal year; and 

21 ‘‘(ii) shall be available for a fiscal year 

22 beginning after fiscal year 2012 to defray 

23 the costs of human generic drug activities 

24 (including such costs for an additional 

25 number of full-time equivalent positions in 

mstockstill on DSK4VPTVN1PROD with BILLS

70 

•S 2516 PCS

1 the Department of Health and Human 

2 Services to be engaged in such activities), 

3 only if the Secretary allocates for such 

4 purpose an amount for such fiscal year 

5 (excluding amounts from fees collected 

6 under this section) no less than 

7 $97,000,000 multiplied by the adjustment 

8 factor, as defined in section 744A(3), ap9 plicable to the fiscal year involved. 

10 ‘‘(B) COMPLIANCE.—The Secretary shall 

11 be considered to have met the requirements of 

12 subparagraph (A)(ii) in any fiscal year if the 

13 costs funded by appropriations and allocated for 

14 human generic activities are not more than 10 

15 percent below the level specified in such sub16 paragraph. 

17 ‘‘(C) FEE COLLECTION DURING FIRST

18 PROGRAM YEAR.—Until the date of enactment 

19 of an Act making appropriations through Sep20 tember 30, 2013 for the salaries and expenses 

21 account of the Food and Drug Administration, 

22 fees authorized by this section for fiscal year 

23 2013, may be collected and shall be credited to 

24 such account and remain available until ex25 pended. 

mstockstill on DSK4VPTVN1PROD with BILLS

71 

•S 2516 PCS

1 ‘‘(D) PROVISION FOR EARLY PAYMENTS IN

2 SUBSEQUENT YEARS.—Payment of fees author3 ized under this section for a fiscal year (after 

4 fiscal year 2013), prior to the due date for such 

5 fees, may be accepted by the Secretary in ac6 cordance with authority provided in advance in 

7 a prior year appropriations Act. 

8 ‘‘(3) AUTHORIZATION OF APPROPRIATIONS.— 

9 For each of the fiscal years 2013 through 2017, 

10 there is authorized to be appropriated for fees under 

11 this section an amount equivalent to the total rev12 enue amount determined under subsection (b) for 

13 the fiscal year, as adjusted under subsection (c), if 

14 applicable, or as otherwise affected under paragraph 

15 (2) of this subsection. 

16 ‘‘(j) COLLECTION OF UNPAID FEES.—In any case 

17 where the Secretary does not receive payment of a fee as18 sessed under subsection (a) within 30 calendar days after 

19 it is due, such fee shall be treated as a claim of the United 

20 States Government subject to subchapter II of chapter 37 

21 of title 31, United States Code. 

22 ‘‘(k) CONSTRUCTION.—This section may not be con23 strued to require that the number of full-time equivalent 

24 positions in the Department of Health and Human Serv25 ices, for officers, employees, and advisory committees not 

mstockstill on DSK4VPTVN1PROD with BILLS

72 

•S 2516 PCS

1 engaged in human generic drug activities, be reduced to 

2 offset the number of officers, employees, and advisory 

3 committees so engaged. 

4 ‘‘(l) POSITRON EMISSION TOMOGRAPHY DRUGS.— 

5 ‘‘(1) EXEMPTION FROM FEES.—Submission of 

6 an application for a positron emission tomography 

7 drug or active pharmaceutical ingredient for a 

8 positron emission tomography drug shall not require 

9 the payment of any fee under this section. Facilities 

10 that solely produce positron emission tomography 

11 drugs shall not be required to pay a facility fee as 

12 established in subsection (a)(4). 

13 ‘‘(2) IDENTIFICATION REQUIREMENT.—Facili14 ties that produce positron emission tomography 

15 drugs or active pharmaceutical ingredients of such 

16 drugs are required to be identified pursuant to sub17 section (f). 

18 ‘‘(m) DISPUTES CONCERNING FEES.—To qualify for 

19 the return of a fee claimed to have been paid in error 

20 under this section, a person shall submit to the Secretary 

21 a written request justifying such return within 180 cal22 endar days after such fee was paid. 

23 ‘‘(n) SUBSTANTIALLY COMPLETE APPLICATIONS.— 

24 An abbreviated new drug application that is not consid25 ered to be received within the meaning of section 

mstockstill on DSK4VPTVN1PROD with BILLS

73 

•S 2516 PCS

1 505(j)(5)(A) because of failure to pay an applicable fee 

2 under this provision within the time period specified in 

3 subsection (g) shall be deemed not to have been ‘substan4 tially complete’ on the date of its submission within the 

5 meaning of section 505(j)(5)(B)(iv)(II)(cc). An abbre6 viated new drug application that is not substantially com7 plete on the date of its submission solely because of failure 

8 to pay an applicable fee under the preceding sentence shall 

9 be deemed substantially complete and received within the 

10 meaning of section 505(j)(5)(A) as of the date such appli11 cable fee is received.’’. 

12 SEC. 303. REAUTHORIZATION; REPORTING REQUIREMENTS. 

13 Part 7 of subchapter C of chapter VII, as added by 

14 section 302 of this Act, is amended by inserting after sec15 tion 744B the following: 

16 ‘‘SEC. 744C. REAUTHORIZATION; REPORTING REQUIRE17 MENTS. 

18 ‘‘(a) PERFORMANCE REPORT.—Beginning with fiscal 

19 year 2013, not later than 120 days after the end of each 

20 fiscal year for which fees are collected under this part, 

21 the Secretary shall prepare and submit to the Committee 

22 on Energy and Commerce of the House of Representatives 

23 and the Committee on Health, Education, Labor, and 

24 Pensions of the Senate a report concerning the progress 

25 of the Food and Drug Administration in achieving the 

mstockstill on DSK4VPTVN1PROD with BILLS

74 

•S 2516 PCS

1 goals identified in the letters described in section 301(b) 

2 of the Generic Drug User Fee Amendments of 2012 dur3 ing such fiscal year and the future plans of the Food and 

4 Drug Administration for meeting the goals. 

5 ‘‘(b) FISCAL REPORT.—Beginning with fiscal year 

6 2013, not later than 120 days after the end of each fiscal 

7 year for which fees are collected under this part, the Sec8 retary shall prepare and submit to the Committee on En9 ergy and Commerce of the House of Representatives and 

10 the Committee on Health, Education, Labor, and Pen11 sions of the Senate a report on the implementation of the 

12 authority for such fees during such fiscal year and the 

13 use, by the Food and Drug Administration, of the fees 

14 collected for such fiscal year. 

15 ‘‘(c) PUBLIC AVAILABILITY.—The Secretary shall 

16 make the reports required under subsections (a) and (b) 

17 available to the public on the Internet Web site of the 

18 Food and Drug Administration. 

19 ‘‘(d) REAUTHORIZATION.— 

20 ‘‘(1) CONSULTATION.—In developing rec21 ommendations to present to the Congress with re22 spect to the goals, and plans for meeting the goals, 

23 for human generic drug activities for the first 5 fis24 cal years after fiscal year 2017, and for the reaumstockstill on DSK4VPTVN1PROD with BILLS

75 

•S 2516 PCS

1 thorization of this part for such fiscal years, the Sec2 retary shall consult with— 

3 ‘‘(A) the Committee on Energy and Com4 merce of the House of Representatives; 

5 ‘‘(B) the Committee on Health, Education, 

6 Labor, and Pensions of the Senate; 

7 ‘‘(C) scientific and academic experts; 

8 ‘‘(D) health care professionals; 

9 ‘‘(E) representatives of patient and con10 sumer advocacy groups; and 

11 ‘‘(F) the generic drug industry. 

12 ‘‘(2) PRIOR PUBLIC INPUT.—Prior to beginning 

13 negotiations with the generic drug industry on the 

14 reauthorization of this part, the Secretary shall— 

15 ‘‘(A) publish a notice in the Federal Reg16 ister requesting public input on the reauthoriza17 tion; 

18 ‘‘(B) hold a public meeting at which the 

19 public may present its views on the reauthoriza20 tion, including specific suggestions for changes 

21 to the goals referred to in subsection (a); 

22 ‘‘(C) provide a period of 30 days after the 

23 public meeting to obtain written comments from 

24 the public suggesting changes to this part; and 

mstockstill on DSK4VPTVN1PROD with BILLS

76 

•S 2516 PCS

1 ‘‘(D) publish the comments on the Food 

2 and Drug Administration’s Internet Web site. 

3 ‘‘(3) PERIODIC CONSULTATION.—Not less fre4 quently than once every month during negotiations 

5 with the generic drug industry, the Secretary shall 

6 hold discussions with representatives of patient and 

7 consumer advocacy groups to continue discussions of 

8 their views on the reauthorization and their sugges9 tions for changes to this part as expressed under 

10 paragraph (2). 

11 ‘‘(4) PUBLIC REVIEW OF RECOMMENDA12 TIONS.—After negotiations with the generic drug in13 dustry, the Secretary shall— 

14 ‘‘(A) present the recommendations devel15 oped under paragraph (1) to the congressional 

16 committees specified in such paragraph; 

17 ‘‘(B) publish such recommendations in the 

18 Federal Register; 

19 ‘‘(C) provide for a period of 30 days for 

20 the public to provide written comments on such 

21 recommendations; 

22 ‘‘(D) hold a meeting at which the public 

23 may present its views on such recommenda24 tions; and 

mstockstill on DSK4VPTVN1PROD with BILLS

77 

•S 2516 PCS

1 ‘‘(E) after consideration of such public 

2 views and comments, revise such recommenda3 tions as necessary. 

4 ‘‘(5) TRANSMITTAL OF RECOMMENDATIONS.— 

5 Not later than January 15, 2017, the Secretary 

6 shall transmit to the Congress the revised rec7 ommendations under paragraph (4), a summary of 

8 the views and comments received under such para9 graph, and any changes made to the recommenda10 tions in response to such views and comments. 

11 ‘‘(6) MINUTES OF NEGOTIATION MEETINGS.— 

12 ‘‘(A) PUBLIC AVAILABILITY.—Before pre13 senting the recommendations developed under 

14 paragraphs (1) through (5) to the Congress, the 

15 Secretary shall make publicly available, on the 

16 Internet Web site of the Food and Drug Ad17 ministration, minutes of all negotiation meet18 ings conducted under this subsection between 

19 the Food and Drug Administration and the ge20 neric drug industry. 

21 ‘‘(B) CONTENT.—The minutes described 

22 under subparagraph (A) shall summarize any 

23 substantive proposal made by any party to the 

24 negotiations as well as significant controversies 

mstockstill on DSK4VPTVN1PROD with BILLS

78 

•S 2516 PCS

1 or differences of opinion during the negotiations 

2 and their resolution.’’. 

3 SEC. 304. SUNSET DATES. 

4 (a) AUTHORIZATION.—The amendments made by 

5 section 302 cease to be effective October 1, 2017. 

6 (b) REPORTING REQUIREMENTS.—The amendments 

7 made by section 303 cease to be effective January 31, 

8 2018. 

9 SEC. 305. EFFECTIVE DATE. 

10 The amendments made by this title shall take effect 

11 on October 1, 2012, or the date of the enactment of this 

12 title, whichever is later, except that fees under section 302 

13 shall be assessed for all human generic drug submissions 

14 and Type II active pharmaceutical drug master files re15 ceived on or after October 1, 2012, regardless of the date 

16 of enactment of this title. 

17 SEC. 306. AMENDMENT WITH RESPECT TO MISBRANDING. 

18 Section 502 (21 U.S.C. 352) is amended by adding 

19 at the end the following: 

20 ‘‘(aa) If it is a drug, or an active pharmaceutical in21 gredient, and it was manufactured, prepared, propagated, 

22 compounded, or processed in a facility for which fees have 

23 not been paid as required by section 744A(a)(4) or for 

24 which identifying information required by section 744B(f) 

25 has not been submitted, or it contains an active pharmamstockstill on DSK4VPTVN1PROD with BILLS

79 

•S 2516 PCS

1 ceutical ingredient that was manufactured, prepared, 

2 propagated, compounded, or processed in such a facility.’’. 

3 SEC. 307. STREAMLINED HIRING AUTHORITY OF THE FOOD 

4 AND DRUG ADMINISTRATION TO SUPPORT 

5 ACTIVITIES RELATED TO HUMAN GENERIC 

6 DRUGS. 

7 Section 714 of the Federal Food, Drug, and Cosmetic 

8 Act, as added by section 208, is amended— 

9 (1) in subsection (b)— 

10 (A) by striking ‘‘are activities’’ and insert11 ing ‘‘are— 

12 ‘‘(1) activities’’; 

13 (B) by striking the period at the end and 

14 inserting ‘‘; and’’; and 

15 (C) by adding at the end the following: 

16 ‘‘(2) activities under this Act related to human 

17 generic drug activities (as defined in section 

18 744A).’’; and 

19 (2) by amending subsection (c) to read as fol20 lows: 

21 ‘‘(c) OBJECTIVES SPECIFIED.—The objectives speci22 fied in this subsection are— 

23 ‘‘(1) with respect to the activities under sub24 section (b)(1), the goals referred to in section 

25 738A(a)(1); and 

mstockstill on DSK4VPTVN1PROD with BILLS

80 

•S 2516 PCS

1 ‘‘(2) with respect to the activities under sub2 section (b)(2), the performance goals with respect to 

3 section 744A (regarding assessment and use of 

4 human generic drug fees), as set forth in the letters 

5 described in section 301(b) of the Generic Drug 

6 User Fee Amendments of 2012.’’. 

7 TITLE IV—FEES RELATING TO 

8 BIOSIMILAR BIOLOGICAL 

9 PRODUCTS 

10 SEC. 401. SHORT TITLE; FINDING. 

11 (a) SHORT TITLE.—This title may be cited as the 

12 ‘‘Biosimilar User Fee Act of 2012’’. 

13 (b) FINDING.—The Congress finds that the fees au14 thorized by the amendments made in this title will be dedi15 cated to expediting the process for the review of biosimilar 

16 biological product applications, including postmarket safe17 ty activities, as set forth in the goals identified for pur18 poses of part 8 of subchapter C of chapter VII of the Fed19 eral Food, Drug, and Cosmetic Act, in the letters from 

20 the Secretary of Health and Human Services to the Chair21 man of the Committee on Health, Education, Labor, and 

22 Pensions of the Senate and the Chairman of the Com23 mittee on Energy and Commerce of the House of Rep24 resentatives, as set forth in the Congressional Record. 

mstockstill on DSK4VPTVN1PROD with BILLS

81 

•S 2516 PCS

1 SEC. 402. FEES RELATING TO BIOSIMILAR BIOLOGICAL 

2 PRODUCTS. 

3 Subchapter C of chapter VII (21 U.S.C. 379f et seq.) 

4 is amended by inserting after part 7, as added by title 

5 III of this Act, the following: 

6 ‘‘PART 8—FEES RELATING TO BIOSIMILAR 

7 BIOLOGICAL PRODUCTS 

8 ‘‘SEC. 744G. DEFINITIONS. 

9 ‘‘For purposes of this part: 

10 ‘‘(1) The term ‘adjustment factor’ applicable to 

11 a fiscal year that is the Consumer Price Index for 

12 all urban consumers (Washington-Baltimore, DC– 

13 MD–VA–WV; Not Seasonally Adjusted; All items) of 

14 the preceding fiscal year divided by such Index for 

15 September 2011. 

16 ‘‘(2) The term ‘affiliate’ means a business enti17 ty that has a relationship with a second business en18 tity if, directly or indirectly— 

19 ‘‘(A) one business entity controls, or has 

20 the power to control, the other business entity; 

21 or 

22 ‘‘(B) a third party controls, or has power 

23 to control, both of the business entities. 

24 ‘‘(3) The term ‘biosimilar biological product’ 

25 means a product for which a biosimilar biological 

26 product application has been approved. 

mstockstill on DSK4VPTVN1PROD with BILLS

82 

•S 2516 PCS

1 ‘‘(4)(A) Subject to subparagraph (B), the term 

2 ‘biosimilar biological product application’ means an 

3 application for licensure of a biological product 

4 under section 351(k) of the Public Health Service 

5 Act. 

6 ‘‘(B) Such term does not include— 

7 ‘‘(i) a supplement to such an application; 

8 ‘‘(ii) an application filed under section 

9 351(k) of the Public Health Service Act that 

10 cites as the reference product a bovine blood 

11 product for topical application licensed before 

12 September 1, 1992, or a large volume paren13 teral drug product approved before such date; 

14 ‘‘(iii) an application filed under section 

15 351(k) of the Public Health Service Act with 

16 respect to— 

17 ‘‘(I) whole blood or a blood component 

18 for transfusion; 

19 ‘‘(II) an allergenic extract product; 

20 ‘‘(III) an in vitro diagnostic biological 

21 product; or 

22 ‘‘(IV) a biological product for further 

23 manufacturing use only; or 

24 ‘‘(iv) an application for licensure under 

25 section 351(k) of the Public Health Service Act 

mstockstill on DSK4VPTVN1PROD with BILLS

83 

•S 2516 PCS

1 that is submitted by a State or Federal Govern2 ment entity for a product that is not distributed 

3 commercially. 

4 ‘‘(5) The term ‘biosimilar biological product de5 velopment meeting’ means any meeting, other than 

6 a biosimilar initial advisory meeting, regarding the 

7 content of a development program, including a pro8 posed design for, or data from, a study intended to 

9 support a biosimilar biological product application. 

10 ‘‘(6) The term ‘biosimilar biological product de11 velopment program’ means the program under this 

12 part for expediting the process for the review of sub13 missions in connection with biosimilar biological 

14 product development. 

15 ‘‘(7)(A) The term ‘biosimilar biological product 

16 establishment’ means a foreign or domestic place of 

17 business— 

18 ‘‘(i) that is at one general physical location 

19 consisting of one or more buildings, all of which 

20 are within five miles of each other; and 

21 ‘‘(ii) at which one or more biosimilar bio22 logical products are manufactured in final dos23 age form. 

24 ‘‘(B) For purposes of subparagraph (A)(ii), the 

25 term ‘manufactured’ does not include packaging. 

mstockstill on DSK4VPTVN1PROD with BILLS

84 

•S 2516 PCS

1 ‘‘(8) The term ‘biosimilar initial advisory meet2 ing’— 

3 ‘‘(A) means a meeting, if requested, that is 

4 limited to— 

5 ‘‘(i) a general discussion regarding 

6 whether licensure under section 351(k) of 

7 the Public Health Service Act may be fea8 sible for a particular product; and 

9 ‘‘(ii) if so, general advice on the ex10 pected content of the development pro11 gram; and 

12 ‘‘(B) does not include any meeting that in13 volves substantive review of summary data or 

14 full study reports. 

15 ‘‘(9) The term ‘costs of resources allocated for 

16 the process for the review of biosimilar biological 

17 product applications’ means the expenses in connec18 tion with the process for the review of biosimilar bio19 logical product applications for— 

20 ‘‘(A) officers and employees of the Food 

21 and Drug Administration, contractors of the 

22 Food and Drug Administration, advisory com23 mittees, and costs related to such officers em24 ployees and committees and to contracts with 

25 such contractors; 

mstockstill on DSK4VPTVN1PROD with BILLS

85 

•S 2516 PCS

1 ‘‘(B) management of information, and the 

2 acquisition, maintenance, and repair of com3 puter resources; 

4 ‘‘(C) leasing, maintenance, renovation, and 

5 repair of facilities and acquisition, maintenance, 

6 and repair of fixtures, furniture, scientific 

7 equipment, and other necessary materials and 

8 supplies; and 

9 ‘‘(D) collecting fees under section 744H 

10 and accounting for resources allocated for the 

11 review of submissions in connection with bio12 similar biological product development, bio13 similar biological product applications, and sup14 plements. 

15 ‘‘(10) The term ‘final dosage form’ means, with 

16 respect to a biosimilar biological product, a finished 

17 dosage form which is approved for administration to 

18 a patient without substantial further manufacturing 

19 (such as lyophilized products before reconstitution). 

20 ‘‘(11) The term ‘financial hold’— 

21 ‘‘(A) means an order issued by the Sec22 retary to prohibit the sponsor of a clinical in23 vestigation from continuing the investigation if 

24 the Secretary determines that the investigation 

25 is intended to support a biosimilar biological 

mstockstill on DSK4VPTVN1PROD with BILLS

86 

•S 2516 PCS

1 product application and the sponsor has failed 

2 to pay any fee for the product required under 

3 subparagraph (A), (B), or (D) of section 

4 744H(a)(1); and 

5 ‘‘(B) does not mean that any of the bases 

6 for a ‘clinical hold’ under section 505(i)(3) have 

7 been determined by the Secretary to exist con8 cerning the investigation. 

9 ‘‘(12) The term ‘person’ includes an affiliate of 

10 such person. 

11 ‘‘(13) The term ‘process for the review of bio12 similar biological product applications’ means the 

13 following activities of the Secretary with respect to 

14 the review of submissions in connection with bio15 similar biological product development, biosimilar bi16 ological product applications, and supplements: 

17 ‘‘(A) The activities necessary for the re18 view of submissions in connection with bio19 similar biological product development, bio20 similar biological product applications, and sup21 plements. 

22 ‘‘(B) Actions related to submissions in con23 nection with biosimilar biological product devel24 opment, the issuance of action letters which ap25 prove biosimilar biological product applications 

mstockstill on DSK4VPTVN1PROD with BILLS

87 

•S 2516 PCS

1 or which set forth in detail the specific defi2 ciencies in such applications, and where appro3 priate, the actions necessary to place such ap4 plications in condition for approval. 

5 ‘‘(C) The inspection of biosimilar biological 

6 product establishments and other facilities un7 dertaken as part of the Secretary’s review of 

8 pending biosimilar biological product applica9 tions and supplements. 

10 ‘‘(D) Activities necessary for the release of 

11 lots of biosimilar biological products under sec12 tion 351(k) of the Public Health Service Act. 

13 ‘‘(E) Monitoring of research conducted in 

14 connection with the review of biosimilar biologi15 cal product applications. 

16 ‘‘(F) Postmarket safety activities with re17 spect to biologics approved under biosimilar bio18 logical product applications or supplements, in19 cluding the following activities: 

20 ‘‘(i) Collecting, developing, and re21 viewing safety information on biosimilar bi22 ological products, including adverse-event 

23 reports. 

mstockstill on DSK4VPTVN1PROD with BILLS

88 

•S 2516 PCS

1 ‘‘(ii) Developing and using improved 

2 adverse-event data-collection systems, in3 cluding information technology systems. 

4 ‘‘(iii) Developing and using improved 

5 analytical tools to assess potential safety 

6 problems, including access to external data 

7 bases. 

8 ‘‘(iv) Implementing and enforcing sec9 tion 505(o) (relating to postapproval stud10 ies and clinical trials and labeling changes) 

11 and section 505(p) (relating to risk evalua12 tion and mitigation strategies). 

13 ‘‘(v) Carrying out section 505(k)(5) 

14 (relating to adverse-event reports and 

15 postmarket safety activities). 

16 ‘‘(14) The term ‘supplement’ means a request 

17 to the Secretary to approve a change in a biosimilar 

18 biological product application which has been ap19 proved, including a supplement requesting that the 

20 Secretary determine that the biosimilar biological 

21 product meets the standards for interchangeability 

22 described in section 351(k)(4) of the Public Health 

23 Service Act. 

mstockstill on DSK4VPTVN1PROD with BILLS

89 

•S 2516 PCS

1 ‘‘SEC. 744H. AUTHORITY TO ASSESS AND USE BIOSIMILAR 

2 BIOLOGICAL PRODUCT FEES. 

3 ‘‘(a) TYPES OF FEES.—Beginning in fiscal year 

4 2013, the Secretary shall assess and collect fees in accord5 ance with this section as follows: 

6 ‘‘(1) BIOSIMILAR DEVELOPMENT PROGRAM

7 FEES.— 

8 ‘‘(A) INITIAL BIOSIMILAR BIOLOGICAL

9 PRODUCT DEVELOPMENT FEE.— 

10 ‘‘(i) IN GENERAL.—Each person that 

11 submits to the Secretary a meeting request 

12 described under clause (ii) or a clinical 

13 protocol for an investigational new drug 

14 protocol described under clause (iii) shall 

15 pay for the product named in the meeting 

16 request or the investigational new drug ap17 plication the initial biosimilar biological 

18 product development fee established under 

19 subsection (b)(1)(A). 

20 ‘‘(ii) MEETING REQUEST.—The meet21 ing request described in this clause is a re22 quest for a biosimilar biological product 

23 development meeting for a product. 

24 ‘‘(iii) CLINICAL PROTOCOL FOR IND.— 

25 A clinical protocol for an investigational 

26 new drug protocol described in this clause 

mstockstill on DSK4VPTVN1PROD with BILLS

90 

•S 2516 PCS

1 is a clinical protocol consistent with the 

2 provisions of section 505(i), including any 

3 regulations promulgated under section 

4 505(i), (referred to in this section as ‘in5 vestigational new drug application’) de6 scribing an investigation that the Secretary 

7 determines is intended to support a bio8 similar biological product application for a 

9 product. 

10 ‘‘(iv) DUE DATE.—The initial bio11 similar biological product development fee 

12 shall be due by the earlier of the following: 

13 ‘‘(I) Not later than 5 days after 

14 the Secretary grants a request for a 

15 biosimilar biological product develop16 ment meeting. 

17 ‘‘(II) The date of submission of 

18 an investigational new drug applica19 tion describing an investigation that 

20 the Secretary determines is intended 

21 to support a biosimilar biological 

22 product application. 

23 ‘‘(v) TRANSITION RULE.—Each per24 son that has submitted an investigational 

25 new drug application prior to the date of 

mstockstill on DSK4VPTVN1PROD with BILLS

91 

•S 2516 PCS

1 enactment of the Biosimilars User Fee Act 

2 of 2012 shall pay the initial biosimilar bio3 logical product development fee by the ear4 lier of the following: 

5 ‘‘(I) Not later than 60 days after 

6 the date of the enactment of the 

7 Biosimilars User Fee Act of 2012, if 

8 the Secretary determines that the in9 vestigational new drug application de10 scribes an investigation that is in11 tended to support a biosimilar biologi12 cal product application. 

13 ‘‘(II) Not later than 5 days after 

14 the Secretary grants a request for a 

15 biosimilar biological product develop16 ment meeting. 

17 ‘‘(B) ANNUAL BIOSIMILAR BIOLOGICAL

18 PRODUCT DEVELOPMENT FEE.— 

19 ‘‘(i) IN GENERAL.—A person that 

20 pays an initial biosimilar biological product 

21 development fee for a product shall pay for 

22 such product, beginning in the fiscal year 

23 following the fiscal year in which the initial 

24 biosimilar biological product development 

25 fee was paid, an annual fee established 

mstockstill on DSK4VPTVN1PROD with BILLS

92 

•S 2516 PCS

1 under subsection (b)(1)(B) for biosimilar 

2 biological product development (referred to 

3 in this section as ‘annual biosimilar bio4 logical product development fee’). 

5 ‘‘(ii) DUE DATE.—The annual bio6 similar biological product development pro7 gram fee for each fiscal year will be due on 

8 the later of— 

9 ‘‘(I) the first business day on or 

10 after October 1 of each such year; or 

11 ‘‘(II) the first business day after 

12 the enactment of an appropriations 

13 Act providing for the collection and 

14 obligation of fees for such year under 

15 this section. 

16 ‘‘(iii) EXCEPTION.—The annual bio17 similar development program fee for each 

18 fiscal year will be due on the date specified 

19 in clause (ii), unless the person has— 

20 ‘‘(I) submitted a marketing appli21 cation for the biological product that 

22 was accepted for filing; or 

23 ‘‘(II) discontinued participation 

24 in the biosimilar biological product demstockstill on DSK4VPTVN1PROD with BILLS

93 

•S 2516 PCS

1 velopment program for the product 

2 under subparagraph (C). 

3 ‘‘(C) DISCONTINUATION OF FEE OBLIGA4 TION.—A person may discontinue participation 

5 in the biosimilar biological product development 

6 program for a product effective October 1 of a 

7 fiscal year by, not later than August 1 of the 

8 preceding fiscal year— 

9 ‘‘(i) if no investigational new drug ap10 plication concerning the product has been 

11 submitted, submitting to the Secretary a 

12 written declaration that the person has no 

13 present intention of further developing the 

14 product as a biosimilar biological product; 

15 or 

16 ‘‘(ii) if an investigational new drug 

17 application concerning the product has 

18 been submitted, by withdrawing the inves19 tigational new drug application in accord20 ance with part 312 of title 21, Code of 

21 Federal Regulations (or any successor reg22 ulations). 

23 ‘‘(D) REACTIVATION FEE.— 

24 ‘‘(i) IN GENERAL.—A person that has 

25 discontinued participation in the biosimilar 

mstockstill on DSK4VPTVN1PROD with BILLS

94 

•S 2516 PCS

1 biological product development program for 

2 a product under subparagraph (C) shall 

3 pay a fee (referred to in this section as ‘re4 activation fee’) by the earlier of the fol5 lowing: 

6 ‘‘(I) Not later than 5 days after 

7 the Secretary grants a request for a 

8 biosimilar biological product develop9 ment meeting for the product (after 

10 the date on which such participation 

11 was discontinued). 

12 ‘‘(II) Upon the date of submis13 sion (after the date on which such 

14 participation was discontinued) of an 

15 investigational new drug application 

16 describing an investigation that the 

17 Secretary determines is intended to 

18 support a biosimilar biological product 

19 application for that product. 

20 ‘‘(ii) APPLICATION OF ANNUAL

21 FEE.—A person that pays a reactivation 

22 fee for a product shall pay for such prod23 uct, beginning in the next fiscal year, the 

24 annual biosimilar biological product devel25 opment fee under subparagraph (B). 

mstockstill on DSK4VPTVN1PROD with BILLS

95 

•S 2516 PCS

1 ‘‘(E) EFFECT OF FAILURE TO PAY BIO2 SIMILAR DEVELOPMENT PROGRAM FEES.— 

3 ‘‘(i) NO BIOSIMILAR BIOLOGICAL

4 PRODUCT DEVELOPMENT MEETINGS.—If a 

5 person has failed to pay an initial or an6 nual biosimilar biological product develop7 ment fee as required under subparagraph 

8 (A) or (B), or a reactivation fee as re9 quired under subparagraph (D), the Sec10 retary shall not provide a biosimilar bio11 logical product development meeting relat12 ing to the product for which fees are owed. 

13 ‘‘(ii) NO RECEIPT OF INVESTIGA14 TIONAL NEW DRUG APPLICATIONS.—Ex15 cept in extraordinary circumstances, the 

16 Secretary shall not consider an investiga17 tional new drug application to have been 

18 received under section 505(i)(2) if— 

19 ‘‘(I) the Secretary determines 

20 that the investigation is intended to 

21 support a biosimilar biological product 

22 application; and 

23 ‘‘(II) the sponsor has failed to 

24 pay an initial or annual biosimilar bio25 logical product development fee for 

mstockstill on DSK4VPTVN1PROD with BILLS

96 

•S 2516 PCS

1 the product as required under sub2 paragraph (A) or (B), or a reactiva3 tion fee as required under subpara4 graph (D). 

5 ‘‘(iii) FINANCIAL HOLD.—Notwith6 standing section 505(i)(2), except in ex7 traordinary circumstances, the Secretary 

8 shall prohibit the sponsor of a clinical in9 vestigation from continuing the investiga10 tion if— 

11 ‘‘(I) the Secretary determines 

12 that the investigation is intended to 

13 support a biosimilar biological product 

14 application; and 

15 ‘‘(II) the sponsor has failed to 

16 pay an initial or annual biosimilar bio17 logical product development fee for 

18 the product as required under sub19 paragraph (A) or (B), or a reactiva20 tion fee for the product as required 

21 under subparagraph (D). 

22 ‘‘(iv) NO ACCEPTANCE OF BIOSIMILAR

23 BIOLOGICAL PRODUCT APPLICATIONS OR

24 SUPPLEMENTS.—If a person has failed to 

25 pay an initial or annual biosimilar biologimstockstill on DSK4VPTVN1PROD with BILLS

97 

•S 2516 PCS

1 cal product development fee as required 

2 under subparagraph (A) or (B), or a reac3 tivation fee as required under subpara4 graph (D), any biosimilar biological prod5 uct application or supplement submitted by 

6 that person shall be considered incomplete 

7 and shall not be accepted for filing by the 

8 Secretary until all such fees owed by such 

9 person have been paid. 

10 ‘‘(F) LIMITS REGARDING BIOSIMILAR DE11 VELOPMENT PROGRAM FEES.— 

12 ‘‘(i) NO REFUNDS.—The Secretary 

13 shall not refund any initial or annual bio14 similar biological product development fee 

15 paid under subparagraph (A) or (B), or 

16 any reactivation fee paid under subpara17 graph (D). 

18 ‘‘(ii) NO WAIVERS, EXEMPTIONS, OR

19 REDUCTIONS.—The Secretary shall not 

20 grant a waiver, exemption, or reduction of 

21 any initial or annual biosimilar biological 

22 product development fee due or payable 

23 under subparagraph (A) or (B), or any re24 activation fee due or payable under sub25 paragraph (D). 

mstockstill on DSK4VPTVN1PROD with BILLS

98 

•S 2516 PCS

1 ‘‘(2) BIOSIMILAR BIOLOGICAL PRODUCT APPLI2 CATION AND SUPPLEMENT FEE.— 

3 ‘‘(A) IN GENERAL.—Each person that sub4 mits, on or after October 1, 2012, a biosimilar 

5 biological product application or a supplement 

6 shall be subject to the following fees: 

7 ‘‘(i) A fee for a biosimilar biological 

8 product application that is equal to— 

9 ‘‘(I) the amount of the fee estab10 lished under subsection (b)(1)(D) for 

11 a biosimilar biological product applica12 tion; minus 

13 ‘‘(II) the cumulative amount of 

14 fees paid, if any, under subparagraphs 

15 (A), (B), and (D) of paragraph (1) 

16 for the product that is the subject of 

17 the application. 

18 ‘‘(ii) A fee for a biosimilar biological 

19 product application for which clinical data 

20 (other than comparative bioavailability 

21 studies) with respect to safety or effective22 ness are not required, that is equal to— 

23 ‘‘(I) half of the amount of the fee 

24 established under subsection (b)(1)(D) 

mstockstill on DSK4VPTVN1PROD with BILLS

99 

•S 2516 PCS

1 for a biosimilar biological product ap2 plication; minus 

3 ‘‘(II) the cumulative amount of 

4 fees paid, if any, under subparagraphs 

5 (A), (B), and (D) of paragraph (1) 

6 for that product. 

7 ‘‘(iii) A fee for a supplement for which 

8 clinical data (other than comparative bio9 availability studies) with respect to safety 

10 or effectiveness are required, that is equal 

11 to half of the amount of the fee established 

12 under subsection (b)(1)(D) for a biosimilar 

13 biological product application. 

14 ‘‘(B) REDUCTION IN FEES.—Notwith15 standing section 404 of the Biosimilars User 

16 Fee Act of 2012, any person who pays a fee 

17 under subparagraph (A), (B), or (D) of para18 graph (1) for a product before October 1, 2017, 

19 but submits a biosimilar biological product ap20 plication for that product after such date, shall 

21 be entitled to the reduction of any biosimilar bi22 ological product application fees that may be 

23 assessed at the time when such biosimilar bio24 logical product application is submitted, by the 

25 cumulative amount of fees paid under subparamstockstill on DSK4VPTVN1PROD with BILLS

100 

•S 2516 PCS

1 graphs (A), (B), and (D) of paragraph (1) for 

2 that product. 

3 ‘‘(C) PAYMENT DUE DATE.—Any fee re4 quired by subparagraph (A) shall be due upon 

5 submission of the application or supplement for 

6 which such fee applies. 

7 ‘‘(D) EXCEPTION FOR PREVIOUSLY FILED

8 APPLICATION OR SUPPLEMENT.—If a biosimilar 

9 biological product application or supplement 

10 was submitted by a person that paid the fee for 

11 such application or supplement, was accepted 

12 for filing, and was not approved or was with13 drawn (without a waiver), the submission of a 

14 biosimilar biological product application or a 

15 supplement for the same product by the same 

16 person (or the person’s licensee, assignee, or 

17 successor) shall not be subject to a fee under 

18 subparagraph (A). 

19 ‘‘(E) REFUND OF APPLICATION FEE IF AP20 PLICATION REFUSED FOR FILING OR WITH21 DRAWN BEFORE FILING.—The Secretary shall 

22 refund 75 percent of the fee paid under this 

23 paragraph for any application or supplement 

24 which is refused for filing or withdrawn without 

25 a waiver before filing. 

mstockstill on DSK4VPTVN1PROD with BILLS

101 

•S 2516 PCS

1 ‘‘(F) FEES FOR APPLICATIONS PRE2 VIOUSLY REFUSED FOR FILING OR WITHDRAWN

3 BEFORE FILING.—A biosimilar biological prod4 uct application or supplement that was sub5 mitted but was refused for filing, or was with6 drawn before being accepted or refused for fil7 ing, shall be subject to the full fee under sub8 paragraph (A) upon being resubmitted or filed 

9 over protest, unless the fee is waived under sub10 section (c). 

11 ‘‘(3) BIOSIMILAR BIOLOGICAL PRODUCT ESTAB12 LISHMENT FEE.— 

13 ‘‘(A) IN GENERAL.—Except as provided in 

14 subparagraph (E), each person that is named 

15 as the applicant in a biosimilar biological prod16 uct application shall be assessed an annual fee 

17 established under subsection (b)(1)(E) for each 

18 biosimilar biological product establishment that 

19 is listed in the approved biosimilar biological 

20 product application as an establishment that 

21 manufactures the biosimilar biological product 

22 named in such application. 

23 ‘‘(B) ASSESSMENT IN FISCAL YEARS.—The 

24 establishment fee shall be assessed in each fis25 cal year for which the biosimilar biological prodmstockstill on DSK4VPTVN1PROD with BILLS

102 

•S 2516 PCS

1 uct named in the application is assessed a fee 

2 under paragraph (4) unless the biosimilar bio3 logical product establishment listed in the appli4 cation does not engage in the manufacture of 

5 the biosimilar biological product during such 

6 fiscal year. 

7 ‘‘(C) DUE DATE.—The establishment fee 

8 for a fiscal year shall be due on the later of— 

9 ‘‘(i) the first business day on or after 

10 October 1 of such fiscal year; or 

11 ‘‘(ii) the first business day after the 

12 enactment of an appropriations Act pro13 viding for the collection and obligation of 

14 fees for such fiscal year under this section. 

15 ‘‘(D) APPLICATION TO ESTABLISHMENT.— 

16 ‘‘(i) Each biosimilar biological product 

17 establishment shall be assessed only one 

18 fee per biosimilar biological product estab19 lishment, notwithstanding the number of 

20 biosimilar biological products manufac21 tured at the establishment, subject to 

22 clause (ii). 

23 ‘‘(ii) In the event an establishment is 

24 listed in a biosimilar biological product ap25 plication by more than one applicant, the 

mstockstill on DSK4VPTVN1PROD with BILLS

103 

•S 2516 PCS

1 establishment fee for the fiscal year shall 

2 be divided equally and assessed among the 

3 applicants whose biosimilar biological prod4 ucts are manufactured by the establish5 ment during the fiscal year and assessed 

6 biosimilar biological product fees under 

7 paragraph (4). 

8 ‘‘(E) EXCEPTION FOR NEW PRODUCTS.— 

9 If, during the fiscal year, an applicant initiates 

10 or causes to be initiated the manufacture of a 

11 biosimilar biological product at an establish12 ment listed in its biosimilar biological product 

13 application— 

14 ‘‘(i) that did not manufacture the bio15 similar biological product in the previous 

16 fiscal year; and 

17 ‘‘(ii) for which the full biosimilar bio18 logical product establishment fee has been 

19 assessed in the fiscal year at a time before 

20 manufacture of the biosimilar biological 

21 product was begun, 

22 the applicant shall not be assessed a share of 

23 the biosimilar biological product establishment 

24 fee for the fiscal year in which the manufacture 

25 of the product began. 

mstockstill on DSK4VPTVN1PROD with BILLS

104 

•S 2516 PCS

1 ‘‘(4) BIOSIMILAR BIOLOGICAL PRODUCT FEE.— 

2 ‘‘(A) IN GENERAL.—Each person who is 

3 named as the applicant in a biosimilar biologi4 cal product application shall pay for each such 

5 biosimilar biological product the annual fee es6 tablished under subsection (b)(1)(F). 

7 ‘‘(B) DUE DATE.—The biosimilar biologi8 cal product fee for a fiscal year shall be due on 

9 the later of— 

10 ‘‘(i) the first business day on or after 

11 October 1 of each such year; or 

12 ‘‘(ii) the first business day after the 

13 enactment of an appropriations Act pro14 viding for the collection and obligation of 

15 fees for such year under this section. 

16 ‘‘(C) ONE FEE PER PRODUCT PER YEAR.— 

17 The biosimilar biological product fee shall be 

18 paid only once for each product for each fiscal 

19 year. 

20 ‘‘(b) FEE SETTING AND AMOUNTS.— 

21 ‘‘(1) IN GENERAL.—Subject to paragraph (2), 

22 the Secretary shall, 60 days before the start of each 

23 fiscal year that begins after September 30, 2012, es24 tablish, for the next fiscal year, the fees under submstockstill on DSK4VPTVN1PROD with BILLS

105 

•S 2516 PCS

1 section (a). Except as provided in subsection (c), 

2 such fees shall be in the following amounts: 

3 ‘‘(A) INITIAL BIOSIMILAR BIOLOGICAL

4 PRODUCT DEVELOPMENT FEE.—The initial bio5 similar biological product development fee under 

6 subsection (a)(1)(A) for a fiscal year shall be 

7 equal to 10 percent of the amount established 

8 under section 736(c)(4) for a human drug ap9 plication described in section 736(a)(1)(A)(i) 

10 for that fiscal year. 

11 ‘‘(B) ANNUAL BIOSIMILAR BIOLOGICAL

12 PRODUCT DEVELOPMENT FEE.—The annual 

13 biosimilar biological product development fee 

14 under subsection (a)(1)(B) for a fiscal year 

15 shall be equal to 10 percent of the amount es16 tablished under section 736(c)(4) for a human 

17 drug application described in section 

18 736(a)(1)(A)(i) for that fiscal year. 

19 ‘‘(C) REACTIVATION FEE.—The reactiva20 tion fee under subsection (a)(1)(D) for a fiscal 

21 year shall be equal to 20 percent of the amount 

22 of the fee established under section 736(c)(4) 

23 for a human drug application described in sec24 tion 736(a)(1)(A)(i) for that fiscal year. 

mstockstill on DSK4VPTVN1PROD with BILLS

106 

•S 2516 PCS

1 ‘‘(D) BIOSIMILAR BIOLOGICAL PRODUCT

2 APPLICATION FEE.—The biosimilar biological 

3 product application fee under subsection (a)(2) 

4 for a fiscal year shall be equal to the amount 

5 established under section 736(c)(4) for a 

6 human drug application described in section 

7 736(a)(1)(A)(i) for that fiscal year. 

8 ‘‘(E) BIOSIMILAR BIOLOGICAL PRODUCT

9 ESTABLISHMENT FEE.—The biosimilar biologi10 cal product establishment fee under subsection 

11 (a)(3) for a fiscal year shall be equal to the 

12 amount established under section 736(c)(4) for 

13 a prescription drug establishment for that fiscal 

14 year. 

15 ‘‘(F) BIOSIMILAR BIOLOGICAL PRODUCT

16 FEE.—The biosimilar biological product fee 

17 under subsection (a)(4) for a fiscal year shall be 

18 equal to the amount established under section 

19 736(c)(4) for a prescription drug product for 

20 that fiscal year. 

21 ‘‘(2) LIMIT.—The total amount of fees charged 

22 for a fiscal year under this section may not exceed 

23 the total amount for such fiscal year of the costs of 

24 resources allocated for the process for the review of 

25 biosimilar biological product applications. 

mstockstill on DSK4VPTVN1PROD with BILLS

107 

•S 2516 PCS

1 ‘‘(c) APPLICATION FEE WAIVER FOR SMALL BUSI2 NESS.— 

3 ‘‘(1) WAIVER OF APPLICATION FEE.—The Sec4 retary shall grant to a person who is named in a bio5 similar biological product application a waiver from 

6 the application fee assessed to that person under 

7 subsection (a)(2)(A) for the first biosimilar biologi8 cal product application that a small business or its 

9 affiliate submits to the Secretary for review. After a 

10 small business or its affiliate is granted such a waiv11 er, the small business or its affiliate shall pay— 

12 ‘‘(A) application fees for all subsequent 

13 biosimilar biological product applications sub14 mitted to the Secretary for review in the same 

15 manner as an entity that is not a small busi16 ness; and 

17 ‘‘(B) all supplement fees for all supple18 ments to biosimilar biological product applica19 tions submitted to the Secretary for review in 

20 the same manner as an entity that is not a 

21 small business. 

22 ‘‘(2) CONSIDERATIONS.—In determining wheth23 er to grant a waiver of a fee under paragraph (1), 

24 the Secretary shall consider only the circumstances 

mstockstill on DSK4VPTVN1PROD with BILLS

108 

•S 2516 PCS

1 and assets of the applicant involved and any affiliate 

2 of the applicant. 

3 ‘‘(3) SMALL BUSINESS DEFINED.—In this sub4 section, the term ‘small business’ means an entity 

5 that has fewer than 500 employees, including em6 ployees of affiliates, and does not have a drug prod7 uct that has been approved under a human drug ap8 plication (as defined in section 735) or a biosimilar 

9 biological product application (as defined in section 

10 744G(4)) and introduced or delivered for introduc11 tion into interstate commerce. 

12 ‘‘(d) EFFECT OF FAILURE TO PAY FEES.—A bio13 similar biological product application or supplement sub14 mitted by a person subject to fees under subsection (a) 

15 shall be considered incomplete and shall not be accepted 

16 for filing by the Secretary until all fees owed by such per17 son have been paid. 

18 ‘‘(e) CREDITING AND AVAILABILITY OF FEES.— 

19 ‘‘(1) IN GENERAL.—Subject to paragraph (2), 

20 fees authorized under subsection (a) shall be col21 lected and available for obligation only to the extent 

22 and in the amount provided in advance in appropria23 tions Acts. Such fees are authorized to remain avail24 able until expended. Such sums as may be necessary 

25 may be transferred from the Food and Drug Adminmstockstill on DSK4VPTVN1PROD with BILLS

109 

•S 2516 PCS

1 istration salaries and expenses appropriation account 

2 without fiscal year limitation to such appropriation 

3 account for salaries and expenses with such fiscal 

4 year limitation. The sums transferred shall be avail5 able solely for the process for the review of bio6 similar biological product applications. 

7 ‘‘(2) COLLECTIONS AND APPROPRIATION

8 ACTS.— 

9 ‘‘(A) IN GENERAL.—Subject to subpara10 graphs (C) and (D), the fees authorized by this 

11 section shall be collected and available in each 

12 fiscal year in an amount not to exceed the 

13 amount specified in appropriation Acts, or oth14 erwise made available for obligation for such 

15 fiscal year. 

16 ‘‘(B) USE OF FEES AND LIMITATION.— 

17 The fees authorized by this section shall be 

18 available for a fiscal year beginning after fiscal 

19 year 2012 to defray the costs of the process for 

20 the review of biosimilar biological product appli21 cations (including such costs for an additional 

22 number of full-time equivalent positions in the 

23 Department of Health and Human Services to 

24 be engaged in such process), only if the Sec25 retary allocates for such purpose an amount for 

mstockstill on DSK4VPTVN1PROD with BILLS

110 

•S 2516 PCS

1 such fiscal year (excluding amounts from fees 

2 collected under this section) no less than 

3 $20,000,000, multiplied by the adjustment fac4 tor applicable to the fiscal year involved. 

5 ‘‘(C) FEE COLLECTION DURING FIRST

6 PROGRAM YEAR.—Until the date of enactment 

7 of an Act making appropriations through Sep8 tember 30, 2013, for the salaries and expenses 

9 account of the Food and Drug Administration, 

10 fees authorized by this section for fiscal year 

11 2013 may be collected and shall be credited to 

12 such account and remain available until ex13 pended. 

14 ‘‘(D) PROVISION FOR EARLY PAYMENTS IN

15 SUBSEQUENT YEARS.—Payment of fees author16 ized under this section for a fiscal year (after 

17 fiscal year 2013), prior to the due date for such 

18 fees, may be accepted by the Secretary in ac19 cordance with authority provided in advance in 

20 a prior year appropriations Act. 

21 ‘‘(3) AUTHORIZATION OF APPROPRIATIONS.— 

22 For each of fiscal years 2013 through 2017, there 

23 is authorized to be appropriated for fees under this 

24 section an amount equivalent to the total amount of 

25 fees assessed for such fiscal year under this section. 

mstockstill on DSK4VPTVN1PROD with BILLS

111 

•S 2516 PCS

1 ‘‘(f) COLLECTION OF UNPAID FEES.—In any case 

2 where the Secretary does not receive payment of a fee as3 sessed under subsection (a) within 30 days after it is due, 

4 such fee shall be treated as a claim of the United States 

5 Government subject to subchapter II of chapter 37 of title 

6 31, United States Code. 

7 ‘‘(g) WRITTEN REQUESTS FOR WAIVERS AND RE8 FUNDS.—To qualify for consideration for a waiver under 

9 subsection (c), or for a refund of any fee collected in ac10 cordance with subsection (a)(2)(A), a person shall submit 

11 to the Secretary a written request for such waiver or re12 fund not later than 180 days after such fee is due. 

13 ‘‘(h) CONSTRUCTION.—This section may not be con14 strued to require that the number of full-time equivalent 

15 positions in the Department of Health and Human Serv16 ices, for officers, employers, and advisory committees not 

17 engaged in the process of the review of biosimilar biologi18 cal product applications, be reduced to offset the number 

19 of officers, employees, and advisory committees so en20 gaged.’’. 

21 SEC. 403. REAUTHORIZATION; REPORTING REQUIREMENTS. 

22 Part 8 of subchapter C of chapter VII, as added by 

23 section 402, is further amended by inserting after section 

24 744H the following: 

mstockstill on DSK4VPTVN1PROD with BILLS

112 

•S 2516 PCS

1 ‘‘SEC. 744I. REAUTHORIZATION; REPORTING REQUIRE2 MENTS. 

3 ‘‘(a) PERFORMANCE REPORT.—Beginning with fiscal 

4 year 2013, not later than 120 days after the end of each 

5 fiscal year for which fees are collected under this part, 

6 the Secretary shall prepare and submit to the Committee 

7 on Energy and Commerce of the House of Representatives 

8 and the Committee on Health, Education, Labor, and 

9 Pensions of the Senate a report concerning the progress 

10 of the Food and Drug Administration in achieving the 

11 goals identified in the letters described in section 401(b) 

12 of the Biosimilar User Fee Act of 2012 during such fiscal 

13 year and the future plans of the Food and Drug Adminis14 tration for meeting such goals. The report for a fiscal year 

15 shall include information on all previous cohorts for which 

16 the Secretary has not given a complete response on all 

17 biosimilar biological product applications and supplements 

18 in the cohort. 

19 ‘‘(b) FISCAL REPORT.—Not later than 120 days after 

20 the end of fiscal year 2013 and each subsequent fiscal year 

21 for which fees are collected under this part, the Secretary 

22 shall prepare and submit to the Committee on Energy and 

23 Commerce of the House of Representatives and the Com24 mittee on Health, Education, Labor, and Pensions of the 

25 Senate a report on the implementation of the authority 

26 for such fees during such fiscal year and the use, by the 

mstockstill on DSK4VPTVN1PROD with BILLS

113 

•S 2516 PCS

1 Food and Drug Administration, of the fees collected for 

2 such fiscal year. 

3 ‘‘(c) PUBLIC AVAILABILITY.—The Secretary shall 

4 make the reports required under subsections (a) and (b) 

5 available to the public on the Internet Web site of the 

6 Food and Drug Administration. 

7 ‘‘(d) STUDY.— 

8 ‘‘(1) IN GENERAL.—The Secretary shall con9 tract with an independent accounting or consulting 

10 firm to study the workload volume and full costs as11 sociated with the process for the review of biosimilar 

12 biological product applications. 

13 ‘‘(2) INTERIM RESULTS.—Not later than June 

14 1, 2015, the Secretary shall publish, for public com15 ment, interim results of the study described under 

16 paragraph (1). 

17 ‘‘(3) FINAL RESULTS.—Not later than Sep18 tember 30, 2016, the Secretary shall publish, for 

19 public comment, the final results of the study de20 scribed under paragraph (1). 

21 ‘‘(e) REAUTHORIZATION.— 

22 ‘‘(1) CONSULTATION.—In developing rec23 ommendations to present to the Congress with re24 spect to the goals described in subsection (a), and 

25 plans for meeting the goals, for the process for the 

mstockstill on DSK4VPTVN1PROD with BILLS

114 

•S 2516 PCS

1 review of biosimilar biological product applications 

2 for the first 5 fiscal years after fiscal year 2017, and 

3 for the reauthorization of this part for such fiscal 

4 years, the Secretary shall consult with— 

5 ‘‘(A) the Committee on Energy and Com6 merce of the House of Representatives; 

7 ‘‘(B) the Committee on Health, Education, 

8 Labor, and Pensions of the Senate; 

9 ‘‘(C) scientific and academic experts; 

10 ‘‘(D) health care professionals; 

11 ‘‘(E) representatives of patient and con12 sumer advocacy groups; and 

13 ‘‘(F) the regulated industry. 

14 ‘‘(2) PUBLIC REVIEW OF RECOMMENDA15 TIONS.—After negotiations with the regulated indus16 try, the Secretary shall— 

17 ‘‘(A) present the recommendations devel18 oped under paragraph (1) to the congressional 

19 committees specified in such paragraph; 

20 ‘‘(B) publish such recommendations in the 

21 Federal Register; 

22 ‘‘(C) provide for a period of 30 days for 

23 the public to provide written comments on such 

24 recommendations; 

mstockstill on DSK4VPTVN1PROD with BILLS

115 

•S 2516 PCS

1 ‘‘(D) hold a meeting at which the public 

2 may present its views on such recommenda3 tions; and 

4 ‘‘(E) after consideration of such public 

5 views and comments, revise such recommenda6 tions as necessary. 

7 ‘‘(3) TRANSMITTAL OF RECOMMENDATIONS.— 

8 Not later than January 15, 2017, the Secretary 

9 shall transmit to the Congress the revised rec10 ommendations under paragraph (2), a summary of 

11 the views and comments received under such para12 graph, and any changes made to the recommenda13 tions in response to such views and comments.’’. 

14 SEC. 404. SUNSET DATES. 

15 (a) AUTHORIZATION.—The amendment made by sec16 tion 402 shall cease to be effective October 1, 2017. 

17 (b) REPORTING REQUIREMENTS.—The amendment 

18 made by section 403 shall cease to be effective January 

19 31, 2018. 

20 SEC. 405. EFFECTIVE DATE. 

21 (a) IN GENERAL.—Except as provided under sub22 section (b), the amendments made by this title shall take 

23 effect on the later of— 

24 (1) October 1, 2012; or 

25 (2) the date of the enactment of this title. 

mstockstill on DSK4VPTVN1PROD with BILLS

116 

•S 2516 PCS

1 (b) EXCEPTION.—Fees under part 8 of subchapter 

2 C of chapter VII of the Federal Food, Drug, and Cosmetic 

3 Act, as added by this title, shall be assessed for all bio4 similar biological product applications received on or after 

5 October 1, 2012, regardless of the date of the enactment 

6 of this title. 

7 SEC. 406. SAVINGS CLAUSE. 

8 Notwithstanding the amendments made by this title, 

9 part 2 of subchapter C of chapter VII of the Federal Food, 

10 Drug, and Cosmetic Act, as in effect on the day before 

11 the date of the enactment of this title, shall continue to 

12 be in effect with respect to human drug applications and 

13 supplements (as defined in such part as of such day) that 

14 were accepted by the Food and Drug Administration for 

15 filing on or after October 1, 2007, but before October 1, 

16 2012, with respect to assessing and collecting any fee re17 quired by such part for a fiscal year prior to fiscal year 

18 2013. 

19 SEC. 407. CONFORMING AMENDMENT. 

20 Section 735(1)(B) (21 U.S.C. 379g(1)(B)) is amend21 ed by striking ‘‘or (k)’’. 

mstockstill on DSK4VPTVN1PROD with BILLS

117 

•S 2516 PCS

1 TITLE V—PEDIATRIC DRUGS 

2 AND DEVICES 

3 SEC. 501. PERMANENCE. 

4 (a) PEDIATRIC STUDIES OF DRUGS.—Subsection (q) 

5 of section 505A (21 U.S.C. 355a) is amended— 

6 (1) in the subsection heading, by striking 

7 ‘‘SUNSET’’ and inserting ‘‘PERMANENCE’’; 

8 (2) in paragraph (1), by striking ‘‘on or before 

9 October 1, 2012,’’; and 

10 (3) in paragraph (2), by striking ‘‘on or before 

11 October 1, 2012,’’. 

12 (b) RESEARCH INTO PEDIATRIC USES FOR DRUGS

13 AND BIOLOGICAL PRODUCTS.—Section 505B (21 U.S.C. 

14 355c) is amended— 

15 (1) by striking subsection (m); and 

16 (2) by redesignating subsection (n) as sub17 section (m). 

18 SEC. 502. WRITTEN REQUESTS. 

19 (a) FEDERAL FOOD, DRUG, AND COSMETIC ACT.— 

20 Subsection (h) of section 505A (21 U.S.C. 355a) is 

21 amended to read as follows: 

22 ‘‘(h) RELATIONSHIP TO PEDIATRIC RESEARCH RE23 QUIREMENTS.—Exclusivity under this section shall only be 

24 granted for the completion of a study or studies that are 

25 the subject of a written request and for which reports are 

mstockstill on DSK4VPTVN1PROD with BILLS

118 

•S 2516 PCS

1 submitted and accepted in accordance with subsection 

2 (d)(3). Written requests under this section may consist of 

3 a study or studies required under section 505B.’’. 

4 (b) PUBLIC HEALTH SERVICE ACT.—Section 

5 351(m)(1) of the Public Health Service Act (42 U.S.C. 

6 262(m)(1)) is amended by striking ‘‘(f), (i), (j), (k), (l), 

7 (p), and (q)’’ and inserting ‘‘(f), (h), (i), (j), (k), (l), (n), 

8 and (p)’’. 

9 SEC. 503. COMMUNICATION WITH PEDIATRIC REVIEW COM10 MITTEE. 

11 Not later than 1 year after the date of enactment 

12 of this Act, the Secretary of Health and Human Services 

13 (referred to in this title as the ‘‘Secretary’’) shall issue 

14 internal standard operating procedures that provide for 

15 the review by the internal review committee established 

16 under section 505C of the Federal Food, Drug, and Cos17 metic Act (21 U.S.C. 355d) of any significant modifica18 tions to initial pediatric study plans, agreed initial pedi19 atric study plans, and written requests under sections 

20 505A and 505B of the Federal Food, Drug, and Cosmetic 

21 Act (21 U.S.C. 355c). Such internal standard operating 

22 procedures shall be made publicly available on the Internet 

23 website of the Food and Drug Administration. 

mstockstill on DSK4VPTVN1PROD with BILLS

119 

•S 2516 PCS

1 SEC. 504. ACCESS TO DATA. 

2 Not later than 3 years after the date of enactment 

3 of this Act, the Secretary shall make available to the pub4 lic, including through posting on the Internet website of 

5 the Food and Drug Administration, the medical, statis6 tical, and clinical pharmacology reviews of, and cor7 responding written requests issued to an applicant, spon8 sor, or holder for, pediatric studies submitted between 

9 January 4, 2002 and September 27, 2007 under sub10 section (b) or (c) of section 505A of the Federal Food, 

11 Drug, and Cosmetic Act (21 U.S.C. 355a) for which 6 

12 months of market exclusivity was granted and that re13 sulted in a labeling change. The Secretary shall make pub14 lic the information described in the preceding sentence in 

15 a manner consistent with how the Secretary releases infor16 mation under section 505A(k) of the Federal Food, Drug, 

17 and Cosmetic Act (21 U.S.C. 355a(k)). 

18 SEC. 505. ENSURING THE COMPLETION OF PEDIATRIC 

19 STUDIES. 

20 (a) EXTENSION OF DEADLINE FOR DEFERRED

21 STUDIES.—Section 505B (21 U.S.C. 355c) is amended— 

22 (1) in subsection (a)(3)— 

23 (A) by redesignating subparagraph (B) as 

24 subparagraph (C); 

25 (B) by inserting after subparagraph (A) 

26 the following: 

mstockstill on DSK4VPTVN1PROD with BILLS

120 

•S 2516 PCS

1 ‘‘(B) DEFERRAL EXTENSION.— 

2 ‘‘(i) IN GENERAL.—On the initiative 

3 of the Secretary or at the request of the 

4 applicant, the Secretary may grant an ex5 tension of a deferral approved under sub6 paragraph (A) for submission of some or 

7 all assessments required under paragraph 

8 (1) if— 

9 ‘‘(I) the Secretary determines 

10 that the conditions described in sub11 clause (II) or (III) of subparagraph 

12 (A)(i) continue to be met; and 

13 ‘‘(II) the applicant submits a new 

14 timeline under subparagraph 

15 (A)(ii)(IV) and any significant up16 dates to the information required 

17 under subparagraph (A)(ii). 

18 ‘‘(ii) TIMING AND INFORMATION.—If 

19 the deferral extension under this subpara20 graph is requested by the applicant, the 

21 applicant shall submit the deferral exten22 sion request containing the information de23 scribed in this subparagraph not less than 

24 90 days prior to the date that the deferral 

25 would expire. The Secretary shall respond 

mstockstill on DSK4VPTVN1PROD with BILLS

121 

•S 2516 PCS

1 to such request not later than 45 days 

2 after the receipt of such letter. If the Sec3 retary grants such an extension, the speci4 fied date shall be the extended date. The 

5 sponsor of the required assessment under 

6 paragraph (1) shall not be issued a letter 

7 described in subsection (d) unless the spec8 ified or extended date of submission for 

9 such required studies has passed or if the 

10 request for an extension is pending. For a 

11 deferral that has expired prior to the date 

12 of enactment of the Food and Drug Ad13 ministration Safety and Innovation Act or 

14 that will expire prior to 270 days after the 

15 date of enactment of such Act, a deferral 

16 extension shall be requested by an appli17 cant not later than 180 days after the date 

18 of enactment of such Act. The Secretary 

19 shall respond to any such request as soon 

20 as practicable, but not later than 1 year 

21 after the date of enactment of such Act. 

22 Nothing in this clause shall prevent the 

23 Secretary from updating the status of a 

24 study or studies publicly if components of 

mstockstill on DSK4VPTVN1PROD with BILLS

122 

•S 2516 PCS

1 such study or studies are late or delayed.’’; 

2 and 

3 (C) in subparagraph (C), as so redesig4 nated— 

5 (i) in clause (i), by adding at the end 

6 the following: 

7 ‘‘(III) Projected completion date 

8 for pediatric studies. 

9 ‘‘(IV) The reason or reasons why 

10 a deferral or deferral extension con11 tinues to be necessary.’’; and 

12 (ii) in clause (ii)— 

13 (I) by inserting ‘‘, as well as the 

14 date of each deferral or deferral ex15 tension, as applicable,’’ after ‘‘clause 

16 (i)’’; and 

17 (II) by inserting ‘‘not later than 

18 90 days after submission to the Sec19 retary or with the next routine quar20 terly update’’ after ‘‘Administration’’; 

21 and 

22 (2) in subsection (f)— 

23 (A) in the subsection heading, by inserting 

24 ‘‘DEFERRAL EXTENSIONS,’’ after ‘‘DEFER25 RALS,’’; 

mstockstill on DSK4VPTVN1PROD with BILLS

123 

•S 2516 PCS

1 (B) in paragraph (1), by inserting ‘‘, defer2 ral extension,’’ after ‘‘deferral’’; and 

3 (C) in paragraph (4)— 

4 (i) in the paragraph heading, by in5 serting ‘‘DEFERRAL EXTENSIONS,’’ after 

6 ‘‘DEFERRALS,’’; and 

7 (ii) by inserting ‘‘, deferral exten8 sions,’’ after ‘‘deferrals’’. 

9 (b) TRACKING OF EXTENSIONS; ANNUAL INFORMA10 TION.—Section 505B(f)(6)(D) (21 U.S.C. 355c(f)(6)(D)) 

11 is amended to read as follows: 

12 ‘‘(D) aggregated on an annual basis— 

13 ‘‘(i) the total number of deferrals and 

14 deferral extensions requested and granted 

15 under this section and, if granted, the rea16 sons for each such deferral or deferral ex17 tension; 

18 ‘‘(ii) the timeline for completion of the 

19 assessments; and 

20 ‘‘(iii) the number of assessments com21 pleted and pending;’’. 

22 (c) ACTION ON FAILURE TO COMPLETE STUDIES.— 

23 (1) ISSUANCE OF LETTER.—Subsection (d) of 

24 section 505B (21 U.S.C. 355c) is amended to read 

25 as follows: 

mstockstill on DSK4VPTVN1PROD with BILLS

124 

•S 2516 PCS

1 ‘‘(d) SUBMISSION OF ASSESSMENTS.—If a person 

2 fails to submit a required assessment described in sub3 section (a)(2), fails to meet the applicable requirements 

4 in subsection (a)(3), or fails to submit a request for ap5 proval of a pediatric formulation described in subsection 

6 (a) or (b), in accordance with applicable provisions of sub7 sections (a) and (b), the following shall apply: 

8 ‘‘(1) Beginning 270 days after the date of en9 actment of the Food and Drug Administration Safe10 ty and Innovation Act, the Secretary shall issue a 

11 non-compliance letter to such person informing them 

12 of such failure to submit or meet the requirements 

13 of the applicable subsection. Such letter shall require 

14 the person to respond in writing within 45 calendar 

15 days of issuance of such letter. Such response may 

16 include the person’s request for a deferral extension 

17 if applicable. Such letter and the person’s written re18 sponse to such letter shall be made publicly available 

19 on the Internet Web site of the Food and Drug Ad20 ministration 45 calendar days after issuance, with 

21 redactions for any trade secrets and confidential 

22 commercial information. If the Secretary determines 

23 that the letter was issued in error, the requirements 

24 of this paragraph shall not apply. 

mstockstill on DSK4VPTVN1PROD with BILLS

125 

•S 2516 PCS

1 ‘‘(2) The drug or biological product that is the 

2 subject of an assessment described in subsection 

3 (a)(2), applicable requirements in subsection (a)(3), 

4 or request for approval of a pediatric formulation, 

5 may be considered misbranded solely because of that 

6 failure and subject to relevant enforcement action 

7 (except that the drug or biological product shall not 

8 be subject to action under section 303), but such 

9 failure shall not be the basis for a proceeding— 

10 ‘‘(A) to withdraw approval for a drug 

11 under section 505(e); or 

12 ‘‘(B) to revoke the license for a biological 

13 product under section 351 of the Public Health 

14 Service Act.’’. 

15 (2) TRACKING OF LETTERS ISSUED.—Subpara16 graph (D) of section 505B(f)(6) (21 U.S.C. 

17 355c(f)(6)), as amended by subsection (b), is further 

18 amended— 

19 (A) in clause (ii), by striking ‘‘; and’’ and 

20 inserting a semicolon; 

21 (B) in clause (iii), by adding ‘‘and’’ at the 

22 end; and 

23 (C) by adding at the end the following: 

24 ‘‘(iv) the number of postmarket non25 compliance letters issued pursuant to submstockstill on DSK4VPTVN1PROD with BILLS

126 

•S 2516 PCS

1 section (d), and the recipients of such let2 ters;’’. 

3 SEC. 506. PEDIATRIC STUDY PLANS. 

4 (a) IN GENERAL.—Subsection (e) of section 505B 

5 (21 U.S.C. 355c) is amended to read as follows: 

6 ‘‘(e) PEDIATRIC STUDY PLANS.— 

7 ‘‘(1) IN GENERAL.—An applicant subject to 

8 subsection (a) shall submit to the Secretary an ini9 tial pediatric study plan prior to the submission of 

10 the assessments described under subsection (a)(2). 

11 ‘‘(2) TIMING; CONTENT; MEETING.— 

12 ‘‘(A) TIMING.—An applicant shall submit 

13 an initial pediatric study plan to the Secretary 

14 not later than 60 calendar days after the date 

15 of the end of phase II meeting or such other 

16 equivalent time agreed upon between the Sec17 retary and the applicant. Nothing in this para18 graph shall preclude the Secretary from accept19 ing the submission of an initial pediatric study 

20 plan earlier than the date described under the 

21 preceding sentence. 

22 ‘‘(B) CONTENT OF INITIAL PLAN.—The 

23 initial pediatric study plan shall include— 

24 ‘‘(i) an outline of the pediatric study 

25 or studies that the applicant plans to conmstockstill on DSK4VPTVN1PROD with BILLS

127 

•S 2516 PCS

1 duct (including, to the extent practicable 

2 study objectives and design, age groups, 

3 relevant endpoints, and statistical ap4 proach); 

5 ‘‘(ii) any request for a deferral, partial 

6 waiver, or waiver under this section, if ap7 plicable, along with any supporting infor8 mation; and 

9 ‘‘(iii) other information specified in 

10 the regulations promulgated under para11 graph (4). 

12 ‘‘(C) MEETING.—The Secretary— 

13 ‘‘(i) shall meet with the applicant to 

14 discuss the initial pediatric study plan as 

15 soon as practicable, but not later than 90 

16 calendar days after the receipt of such plan 

17 under subparagraph (A); 

18 ‘‘(ii) may determine that a written re19 sponse to the initial pediatric study plan is 

20 sufficient to communicate comments on the 

21 initial pediatric study plan, and that no 

22 meeting is necessary; and 

23 ‘‘(iii) if the Secretary determines that 

24 no meeting is necessary, shall so notify the 

25 applicant and provide written comments of 

mstockstill on DSK4VPTVN1PROD with BILLS

128 

•S 2516 PCS

1 the Secretary as soon as practicable, but 

2 not later than 90 calendar days after the 

3 receipt of the initial pediatric study plan. 

4 ‘‘(3) AGREED INITIAL PEDIATRIC STUDY

5 PLAN.—Not later than 90 calendar days following 

6 the meeting under paragraph (2)(C)(i) or the receipt 

7 of a written response from the Secretary under para8 graph (2)(C)(iii), the applicant shall document 

9 agreement on the initial pediatric study plan in a 

10 submission to the Secretary marked ‘Agreed Initial 

11 Pediatric Study Plan’, and the Secretary shall con12 firm such agreement to the applicant in writing not 

13 later than 30 calendar days of receipt of such agreed 

14 initial pediatric study plan. 

15 ‘‘(4) DEFERRAL AND WAIVER.—If the agreed 

16 initial pediatric study plan contains a request from 

17 the applicant for a deferral, partial waiver, or waiver 

18 under this section, the written confirmation under 

19 paragraph (3) shall include a recommendation from 

20 the Secretary as to whether such request meets the 

21 standards under paragraphs (3) or (4) of subsection 

22 (a). 

23 ‘‘(5) AMENDMENTS TO THE PLAN.—At the ini24 tiative of the Secretary or the applicant, the agreed 

25 initial pediatric study plan may be amended at any 

mstockstill on DSK4VPTVN1PROD with BILLS

129 

•S 2516 PCS

1 time. The requirements of paragraph (2)(C) shall 

2 apply to any such proposed amendment in the same 

3 manner and to the same extent as such require4 ments apply to an initial pediatric study plan under 

5 paragraph (1). The requirements of paragraphs (3) 

6 and (4) shall apply to any agreement resulting from 

7 such proposed amendment in the same manner and 

8 to the same extent as such requirements apply to an 

9 agreed initial pediatric study plan. 

10 ‘‘(6) INTERNAL COMMITTEE.—The Secretary 

11 shall consult the internal committee under section 

12 505C on the review of the initial pediatric study 

13 plan, agreed initial pediatric plan, and any signifi14 cant amendments to such plans. 

15 ‘‘(7) REQUIRED RULEMAKING.—Not later than 

16 1 year after the date of enactment of the Food and 

17 Drug Administration Safety and Innovation Act, the 

18 Secretary shall promulgate proposed regulations and 

19 issue proposed guidance to implement the provisions 

20 of this subsection.’’. 

21 (b) CONFORMING AMENDMENTS.—Section 505B (21 

22 U.S.C. 355c)is amended— 

23 (1) by amending subclause (II) of subsection 

24 (a)(3)(A)(ii) to read as follows: 

mstockstill on DSK4VPTVN1PROD with BILLS

130 

•S 2516 PCS

1 ‘‘(II) a pediatric study plan as 

2 described in subsection (e);’’; and 

3 (2) in subsection (f)— 

4 (A) in the subsection heading, by striking 

5 ‘‘PEDIATRIC PLANS,’’ and inserting ‘‘PEDI6 ATRIC STUDY PLANS,’’; 

7 (B) in paragraph (1), by striking ‘‘all pedi8 atric plans’’ and inserting ‘‘initial pediatric 

9 study plans, agreed initial pediatric study 

10 plans,’’; and 

11 (C) in paragraph (4)— 

12 (i) in the paragraph heading, by strik13 ing ‘‘PEDIATRIC PLANS,’’ and inserting 

14 ‘‘PEDIATRIC STUDY PLANS,’’; and 

15 (ii) by striking ‘‘pediatric plans’’ and 

16 inserting ‘‘initial pediatric study plans, 

17 agreed initial pediatric study plans,’’. 

18 (c) EFFECTIVE DATES.— 

19 (1) PEDIATRIC STUDY PLANS.—Subsection (e) 

20 of section 505B of the Federal Food, Drug, and 

21 Cosmetic Act (other than paragraph (4) of such sub22 section), as amended by subsection (a), shall take ef23 fect 180 days after the date of enactment of this 

24 Act, without regard to whether the Secretary has 

mstockstill on DSK4VPTVN1PROD with BILLS

131 

•S 2516 PCS

1 promulgated final regulations under paragraph (4) 

2 of such subsection by such date. 

3 (2) CONFORMING AMENDMENTS.—The amend4 ments made by subsection (b) shall take effect 180 

5 days after the date of enactment of this Act. 

6 SEC. 507. REAUTHORIZATIONS. 

7 (a) PEDIATRIC ADVISORY COMMITTEE.—Section 

8 14(d) of the Best Pharmaceuticals for Children Act (42 

9 U.S.C. 284m note) is amended by striking ‘‘Notwith10 standing section 14 of the Federal Advisory Committee 

11 Act, the advisory committee shall continue to operate dur12 ing the five-year period beginning on the date of the enact13 ment of the Best Pharmaceuticals for Children Act of 

14 2007’’ and inserting ‘‘Section 14 of the Federal Advisory 

15 Committee Act shall not apply to the advisory committee’’. 

16 (b) PEDIATRIC SUBCOMMITTEE OF THE ONCOLOGIC

17 DRUGS ADVISORY COMMITTEE.—Section 15(a)(3) of the 

18 Best Pharmaceuticals for Children Act (42 U.S.C. 284m 

19 note) is amended by striking ‘‘during the five-year period 

20 beginning on the date of the enactment of the Best Phar21 maceuticals for Children Act of 2007’’ and inserting ‘‘for 

22 the duration of the operation of the Oncologic Drugs Advi23 sory Committee’’. 

24 (c) HUMANITARIAN DEVICE EXEMPTION EXTEN25 SION.—Section 520(m)(6)(A)(iv) of the Federal Food, 

mstockstill on DSK4VPTVN1PROD with BILLS

132 

•S 2516 PCS

1 Drug, and Cosmetic Act (21 U.S.C. 360j(m)(6)(A)(iv)) is 

2 amended by striking ‘‘2012’’ and inserting ‘‘2017’’. 

3 (d) DEMONSTRATION GRANTS TO IMPROVE PEDI4 ATRIC DEVICE AVAILABILITY.—Section 305(e) of Pedi5 atric Medical Device Safety and Improvement Act (Public 

6 Law 110–85; 42 U.S.C. 282 note)) is amended by striking 

7 ‘‘$6,000,000 for each of fiscal years 2008 through 2012’’ 

8 and inserting ‘‘$4,500,000 for each of fiscal years 2013 

9 through 2017’’. 

10 (e) PROGRAM FOR PEDIATRIC STUDY OF DRUGS IN

11 PHSA.—Section 409I(e)(1)(B) of the Public Health Serv12 ice Act (42 U.S.C. 284m((e)(1)(B)) is amended by strik13 ing ‘‘of the four succeeding fiscal years’’ and inserting 

14 ‘‘succeeding fiscal year’’. 

15 SEC. 508. REPORT. 

16 (a) IN GENERAL.—Not later than October 31, 2016, 

17 and at the end of each subsequent 5-year period, the Sec18 retary shall submit to Congress a report that evaluates 

19 the effectiveness of sections 505A and 505B of the Fed20 eral Food, Drug, and Cosmetic Act (21 U.S.C. 355a, 

21 355c) and section 409I of the Public Health Service Act 

22 (42 U.S.C. 284m) in ensuring that medicines used by chil23 dren are tested in pediatric populations and properly la24 beled for use in children. 

mstockstill on DSK4VPTVN1PROD with BILLS

133 

•S 2516 PCS

1 (b) CONTENTS.—The report under subsection (a) 

2 shall include— 

3 (1) the number and importance of drugs and 

4 biological products for children for which studies 

5 have been requested or required (as of the date of 

6 such report) under 505A and 505B of the Federal 

7 Food, Drug, and Cosmetic Act (21 U.S.C. 355a, 

8 355c) and section 409I of the Public Health Service 

9 Act (42 U.S.C. 284m), including— 

10 (A) the number of labeling changes made 

11 to drugs and biological products pursuant to 

12 such sections since the date of enactment of 

13 this Act; and 

14 (B) the importance of such drugs and bio15 logical products in the improvement of the 

16 health of children; 

17 (2) the number of required studies under such 

18 section 505B that have not met the initial deadline 

19 provided under such section, including— 

20 (A) the number of deferrals and deferral 

21 extensions granted and the reasons such exten22 sions were granted; 

23 (B) the number of waivers and partial 

24 waivers granted; and 

mstockstill on DSK4VPTVN1PROD with BILLS

134 

•S 2516 PCS

1 (C) the number of letters issued under 

2 subsection (d) of such section 505B; 

3 (3) the number of written requests issued, de4 clined, and referred to the National Institutes of 

5 Health under such section 505A since the date of 

6 enactment of this Act (including the reasons for 

7 such declination), and a description and status of re8 ferrals made under subsection (n) of such section 

9 505A; 

10 (4) the number of proposed pediatric study 

11 plans submitted and agreed to as identified in the 

12 marketing application under such section 505B; 

13 (5) any labeling changes recommended by the 

14 Pediatric Advisory Committee as a result of the re15 view by such Committee of adverse events reports; 

16 (6) the number and current status of pediatric 

17 postmarketing requirements; 

18 (7) the number and importance of drugs and 

19 biological products for children that are not being 

20 tested for use in pediatric populations, notwith21 standing the existence of the programs under such 

22 sections 505A and 505B and section 409I of the 

23 Public Health Service Act; 

24 (8) the possible reasons for the lack of testing 

25 reported under paragraph (7); 

mstockstill on DSK4VPTVN1PROD with BILLS

135 

•S 2516 PCS

1 (9) the number of drugs and biological products 

2 for which testing is being done (as of the date of the 

3 report) and for which a labeling change is required 

4 under the programs described in paragraph (7), in5 cluding— 

6 (A) the date labeling changes are made; 

7 (B) which labeling changes required the 

8 use of the dispute resolution process; and 

9 (C) for labeling changes that required such 

10 dispute resolution process, a description of— 

11 (i) the disputes; 

12 (ii) the recommendations of the Pedi13 atric Advisory Committee; and 

14 (iii) the outcomes of such process; and 

15 (D) an assessment of the effectiveness in 

16 improving information about pediatric uses of 

17 drugs and biological products; 

18 (10)(A) the efforts made by the Secretary to in19 crease the number of studies conducted in the neo20 natal population (including efforts made to encour21 age the conduct of appropriate studies in neonates 

22 by companies with products that have sufficient 

23 safety and other information to make the conduct of 

24 the studies ethical and safe); and 

25 (B) the results of such efforts; 

mstockstill on DSK4VPTVN1PROD with BILLS

136 

•S 2516 PCS

1 (11)(A) the number and importance of drugs 

2 and biological products for children with cancer that 

3 are being tested as a result of the programs de4 scribed in paragraph (7); and 

5 (B) any recommendations for modifications to 

6 such programs that would lead to new and better 

7 therapies for children with cancer, including a de8 tailed rationale for each recommendation; 

9 (12) an assessment of progress made in ad10 dressing the recommendations and findings of any 

11 prior report issued by the Comptroller General, the 

12 Institute of Medicine, or the Secretary regarding the 

13 topics addressed in the report under this section, in14 cluding with respect to— 

15 (A) improving public access to information 

16 from pediatric studies conducted under such 

17 sections 505A and 505B; and 

18 (B) improving the timeliness of pediatric 

19 studies and pediatric study planning under such 

20 sections 505A and 505B; 

21 (13) any recommendations for modification to 

22 the programs that would improve pediatric drug re23 search and increase pediatric labeling of drugs and 

24 biological products; and 

mstockstill on DSK4VPTVN1PROD with BILLS

137 

•S 2516 PCS

1 (14) an assessment of the successes of and limi2 tations to studying drugs for rare diseases under 

3 such sections 505A and 505B. 

4 (c) CONSULTATION ON RECOMMENDATIONS.—At 

5 least 180 days before the report is due under subsection 

6 (a), and no sooner than 4 years after the date of enact7 ment of this Act, the Secretary shall consult with rep8 resentatives of patient groups, including pediatric patient 

9 groups, consumer groups, regulated industry, scientific 

10 and medical communities, academia, and other interested 

11 parties to obtain any recommendations or information rel12 evant to the effectiveness of the programs described in 

13 subsection (b)(7), including suggestions for modifications 

14 to such programs. 

15 SEC. 509. TECHNICAL AMENDMENTS. 

16 (a) PEDIATRIC STUDIES OF DRUGS IN FFDCA.— 

17 Section 505A (21 U.S.C. 355a) is amended— 

18 (1) in subsection (k)(2), by striking ‘‘subsection 

19 (f)(3)(F)’’ and inserting ‘‘subsection (f)(6)(F)’’; 

20 (2) in subsection (n)— 

21 (A) in the subsection heading, by striking 

22 ‘‘COMPLETED’’ and inserting ‘‘SUBMITTED’’; 

23 and 

24 (B) in paragraph (1)— 

mstockstill on DSK4VPTVN1PROD with BILLS

138 

•S 2516 PCS

1 (i) in the matter preceding subpara2 graph (A), by striking ‘‘have not been com3 pleted’’ and inserting ‘‘have not been sub4 mitted by the date specified in the written 

5 request issued or if the applicant or holder 

6 does not agree to the request’’; 

7 (ii) in subparagraph (A)— 

8 (I) in the first sentence, by in9 serting ‘‘, or for which a period of ex10 clusivity eligible for extension under 

11 subsection (b)(1) or (c)(1) of this sec12 tion or under subsection (m)(2) or 

13 (m)(3) of section 351 of the Public 

14 Health Service Act has not ended’’ 

15 after ‘‘expired’’; and 

16 (II) by striking ‘‘Prior to’’ and 

17 all that follows through the period at 

18 the end; and 

19 (iii) in subparagraph (B), by striking 

20 ‘‘no listed patents or has 1 or more listed 

21 patents that have expired,’’ and inserting 

22 ‘‘no unexpired listed patents and for which 

23 no unexpired periods of exclusivity eligible 

24 for extension under subsection (b)(1) or 

25 (c)(1) of this section or under subsection 

mstockstill on DSK4VPTVN1PROD with BILLS

139 

•S 2516 PCS

1 (m)(2) or (m)(3) of section 351 of the 

2 Public Health Service Act apply,’’; and 

3 (3) in subsection (o)(2), by amendment sub4 paragraph (B) to read as follows: 

5 ‘‘(B) a statement of any appropriate pedi6 atric contraindications, warnings, precautions, 

7 or other information that the Secretary con8 siders necessary to assure safe use.’’. 

9 (b) RESEARCH INTO PEDIATRIC USES FOR DRUGS

10 AND BIOLOGICAL PROJECTS IN FFDCA.—Section 505B 

11 (21 U.S.C. 355c) is amended— 

12 (1) in subsection (a)— 

13 (A) in paragraph (1)— 

14 (i) in the matter preceding subpara15 graph (A), by inserting ‘‘for a drug’’ after 

16 ‘‘(or supplement to an application)’’; 

17 (ii) in subparagraph (A), by striking 

18 ‘‘for a’’ and inserting ‘‘, including, with re19 spect to a drug, an application (or supple20 ment to an application) for a’’; 

21 (iii) in subparagraph (B), by striking 

22 ‘‘for a’’ and inserting ‘‘, including, with re23 spect to a drug, an application (or supple24 ment to an application) for a’’; and 

mstockstill on DSK4VPTVN1PROD with BILLS

140 

•S 2516 PCS

1 (iv) in the matter following subpara2 graph (B), by inserting ‘‘(or supplement)’’ 

3 after ‘‘application’’; and 

4 (B) in paragraph (4)(C)— 

5 (i) in the first sentence, by inserting 

6 ‘‘partial’’ before ‘‘waiver is granted’’; and 

7 (ii) in the second sentence, by striking 

8 ‘‘either a full or’’ and inserting ‘‘such a’’; 

9 (2) in subsection (b)(1), in the matter pre10 ceding subparagraph (A), by striking ‘‘After pro11 viding notice’’ and all that follows through ‘‘studies), 

12 the’’ and inserting ‘‘The’’; 

13 (3) in subsection (g)— 

14 (A) in paragraph (1)(A), by inserting 

15 ‘‘that receives a priority review or 330 days 

16 after the date of the submission of an applica17 tion or supplement that receives a standard re18 view’’ after ‘‘after the date of the submission of 

19 the application or supplement’’; and 

20 (B) in paragraph (2), by striking ‘‘the 

21 label of such product’’ and inserting ‘‘the label22 ing of such product’’; and 

23 (4) in subsection (h)(1)— 

mstockstill on DSK4VPTVN1PROD with BILLS

141 

•S 2516 PCS

1 (A) by inserting ‘‘an application (or sup2 plement to an application) that contains’’ after 

3 ‘‘date of submission of’’; and 

4 (B) by inserting ‘‘, if the application (or 

5 supplement) receives a priority review, or not 

6 later than 330 days after the date of submis7 sion of an application (or supplement to an ap8 plication) that contains a pediatric assessment 

9 under this section, if the application (or supple10 ment) receives a standard review,’’ after ‘‘under 

11 this section,’’. 

12 (c) INTERNAL REVIEW COMMITTEE.—The heading of 

13 section 505C (21 U.S.C. 355d) is amended by inserting 

14 ‘‘AND DEFERRAL EXTENSIONS’’ after ‘‘DEFERRALS’’. 

15 (d) PROGRAM FOR PEDIATRIC STUDIES OF DRUGS.— 

16 Section 409I(c) of the Public Health Service Act (42 

17 U.S.C. 284m(c)) is amended— 

18 (1) in paragraph (1)— 

19 (A) in the matter preceding subparagraph 

20 (A), by inserting ‘‘or section 351(m) of this 

21 Act,’’ after ‘‘Cosmetic Act,’’; 

22 (B) in subparagraph (A)(i), by inserting 

23 ‘‘or section 351(k) of this Act’’ after ‘‘Cosmetic 

24 Act’’; and 

mstockstill on DSK4VPTVN1PROD with BILLS

142 

•S 2516 PCS

1 (C) by amending subparagraph (B) to read 

2 as follows: 

3 ‘‘(B) there remains no patent listed pursu4 ant to section 505(b)(1) of the Federal Food, 

5 Drug, and Cosmetic Act, and every three-year 

6 and five-year period referred to in subsection 

7 (c)(3)(E)(ii), (c)(3)(E)(iii), (c)(3)(E)(iv), 

8 (j)(5)(F)(ii), (j)(5)(F)(iii), or (j)(5)(F)(iv) of 

9 section 505 of the Federal Food, Drug, and 

10 Cosmetic Act, or applicable twelve-year period 

11 referred to in section 351(k)(7) of this Act, and 

12 any seven-year period referred to in section 527 

13 of the Federal Food, Drug, and Cosmetic Act 

14 has ended for at least one form of the drug; 

15 and’’; and 

16 (2) in paragraph (2)— 

17 (A) in the paragraph heading, by striking 

18 ‘‘FOR DRUGS LACKING EXCLUSIVITY’’; and 

19 (B) by striking ‘‘under section 505 of the 

20 Federal Food, Drug, and Cosmetic Act’’; and 

21 (C) by striking ‘‘505A of such Act’’ and 

22 inserting ‘‘505A of the Federal Food, Drug, 

23 and Cosmetic Act or section 351(m) of this 

24 Act’’. 

mstockstill on DSK4VPTVN1PROD with BILLS

143 

•S 2516 PCS

1 (e) PEDIATRIC SUBCOMMITTEE OF THE ONCOLOGIC

2 ADVISORY COMMITTEE.—Section 15(a) of the Best Phar3 maceuticals for Children Act (Public Law 107–109), as 

4 amended by section 502(e) of the Food and Drug Admin5 istration Amendments Act of 2007 (Public Law 110–85), 

6 is amended in paragraph (1)(D), by striking ‘‘section 

7 505B(f)’’ and inserting ‘‘ ‘section 505C’ ’’. 

8 (f) FOUNDATION OF NATIONAL INSTITUTES OF

9 HEALTH.—Section 499(c)(1)(C) of the Public Health 

10 Service Act (42 U.S.C. 290b(c)(1)(C)) is amended by 

11 striking ‘‘for which the Secretary issues a certification in 

12 the affirmative under section 505A(n)(1)(A) of the Fed13 eral Food, Drug, and Cosmetic Act’’. 

14 (g) APPLICATION.—Notwithstanding any provision of 

15 section 505A and 505B of the Federal Food, Drug, and 

16 Cosmetic Act (21 U.S.C. 355a, 355c) stating that a provi17 sion applies beginning on the date of the enactment of the 

18 Best Pharmaceuticals for Children Act of 2007 or the date 

19 of the enactment of the Pediatric Research Equity Act of 

20 2007, any amendment made by this title to such a provi21 sion applies beginning on the date of the enactment of this 

22 Act. 

mstockstill on DSK4VPTVN1PROD with BILLS

144 

•S 2516 PCS

1 SEC. 510. RELATIONSHIP BETWEEN PEDIATRIC LABELING 

2 AND NEW CLINICAL INVESTIGATION EXCLU3 SIVITY. 

4 (a) IN GENERAL.—Section 505 (21 U.S.C. 351) is 

5 amended by adding at the end the following: 

6 ‘‘(w) RELATIONSHIP BETWEEN PEDIATRIC LABEL7 ING AND NEW CLINICAL INVESTIGATION EXCLUSIVITY.— 

8 The period of market exclusivity described in clauses (iii) 

9 and (iv) of subsection (c)(3)(E) and clauses (iii) and (iv) 

10 of subsection (j)(5)(F) shall not apply to a pediatric study 

11 conducted under section 505A or 505B that results, pur12 suant to section 505B(g)(2), in the inclusion in the label13 ing of the product a determination that the product is not 

14 indicated for use in pediatric populations or subpopula15 tions or information indicating that the results of a study 

16 were inconclusive or did not demonstrate that the product 

17 is safe or effective in pediatric populations or subpopula18 tions.’’. 

19 (b) PEDIATRIC STUDIES OF DRUGS.—Section 

20 505A(m) (21 U.S.C. 355a(m)) is amended— 

21 (1) by striking ‘‘(m) CLARIFICATION OF INTER22 ACTION OF MARKET EXCLUSIVITY UNDER THIS

23 SECTION AND MARKET EXCLUSIVITY AWARDED TO

24 AN APPLICANT FOR APPROVAL OF A DRUG UNDER

25 SECTION 505(j).—If a’’ and all that follows through 

mstockstill on DSK4VPTVN1PROD with BILLS

145 

•S 2516 PCS

1 the end of the matter that precedes paragraph (1) 

2 and inserting the following: 

3 ‘‘(m) CLARIFICATION OF INTERACTION OF MARKET

4 EXCLUSIVITY UNDER THIS SECTION AND MARKET EX5 CLUSIVITY AWARDED TO AN APPLICATION OR SUPPLE6 MENT UNDER SUBSECTION (C) OR (J) OF SECTION 505.— 

7 ‘‘(1) 180-DAY EXCLUSIVITY PERIOD.—If a 180- 

8 day period under section 505(j)(5)(B)(iv) overlaps 

9 with a 6-month exclusivity period under this section, 

10 so that the applicant for approval of a drug under 

11 section 505(j) entitled to the 180-day period under 

12 that section loses a portion of the 180-day period to 

13 which the applicant is entitled for the drug, the 180- 

14 day period shall be extended from—’’; 

15 (2) by redesignating paragraphs (1) and (2) as 

16 subparagraphs (A) and (B) and moving such sub17 paragraphs, as so redesignated, 2 ems to the right; 

18 and 

19 (3) by adding at the end the following: 

20 ‘‘(2) 3-YEAR EXCLUSIVITY PERIOD.—The 3-year 

21 period of exclusivity under clauses (iii) and (iv) of 

22 subsection 505(c)(3)(E) and clauses (iii) and (iv) of 

23 subsection 505(j)(5)(F) are not available for ap24 proval of applications or supplements to applications 

25 based on reports of pediatric studies conducted 

mstockstill on DSK4VPTVN1PROD with BILLS

146 

•S 2516 PCS

1 under sections 505A or 505B that resulted, pursu2 ant to section 505A(j) or 505B(g)(2), in the inclu3 sion in the labeling of the product a determination 

4 that the product is not indicated for use in pediatric 

5 populations or subpopulations or information indi6 cating that the results of an assessment were incon7 clusive or did not demonstrate that the product is 

8 safe or effective in pediatric populations or sub9 population.’’. 

10 (c) PROMPT APPROVAL OF DRUGS.—Section 505A(o) 

11 (21 U.S.C. 355a(o)) is amended— 

12 (1) in the heading, by striking ‘‘SECTION

13 505(J)’’ and inserting ‘‘SUBSECTIONS (C) AND (J) 

14 OF SECTION 505’’; 

15 (2) in paragraph (1), by striking ‘‘under section 

16 505(j)’’ and inserting ‘‘under subsection (b)(2), (c), 

17 or (j) of section 505’’; 

18 (3) in paragraph (2), in the matter preceding 

19 subparagraph (A), by inserting ‘‘clauses (iii) and (iv) 

20 of section 505(c)(3)(E) or’’ after ‘‘Notwith21 standing’’; and 

22 (4) in paragraph (3)— 

23 (A) in subparagraph (B), by inserting 

24 ‘‘that differ from adult formulations’’ before the 

25 semicolon at the end; and 

mstockstill on DSK4VPTVN1PROD with BILLS

147 

•S 2516 PCS

1 (B) in subparagraph (C)— 

2 (i) by striking ‘‘under section 505(j)’’ 

3 and inserting ‘‘under subsection (c) or (j) 

4 of section 505’’; and 

5 (ii) by inserting ‘‘clauses (iii) or (iv) 

6 of section 505(c)(3)(E) or’’ after ‘‘exclu7 sivity under’’. 

8 TITLE VI—MEDICAL DEVICE 

9 REGULATORY IMPROVEMENTS 

10 SEC. 601. RECLASSIFICATION PROCEDURES. 

11 (a) CLASSIFICATION CHANGES.— 

12 (1) IN GENERAL.—Section 513(e)(1) (21 

13 U.S.C. 360c(e)(1)) is amended to read as follows: 

14 ‘‘(e)(1)(A) Based on new information respecting a de15 vice, the Secretary may, upon the initiative of the Sec16 retary or upon petition of an interested person, change 

17 the classification of such device, and revoke, on account 

18 of the change in classification, any regulation or require19 ment in effect under section 514 or 515 with respect to 

20 such device, by administrative order published in the Fed21 eral Register following publication of a proposed reclassi22 fication order in the Federal Register, a meeting of a de23 vice classification panel described in subsection (b), and 

24 consideration of comments to a public docket, notwith25 standing subchapter II of Chapter 5 of title 5 of the 

mstockstill on DSK4VPTVN1PROD with BILLS

148 

•S 2516 PCS

1 United States Code. An order under this subsection 

2 changing the classification of a device from class III to 

3 class II may provide that such classification shall not take 

4 effect until the effective date of a performance standard 

5 established under section 514 for such device. 

6 ‘‘(B) Authority to issue such administrative order 

7 shall not be delegated below the Commissioner. The Com8 missioner shall issue such an order as proposed by the Di9 rector of the Center for Devices and Radiological Health 

10 unless the Commissioner, in consultation with the Office 

11 of the Secretary of Health and Human Services, concludes 

12 that the order exceeds the legal authority of the Food and 

13 Drug Administration or that the order would be lawful, 

14 but unlikely to advance the public health.’’. 

15 (2) TECHNICAL AND CONFORMING AMEND16 MENTS.— 

17 (A) Section 513(e)(2) (21 U.S.C. 

18 360c(e)(2)) is amended by striking ‘‘regulation 

19 promulgated’’ and inserting ‘‘an order issued’’. 

20 (B) Section 514(a)(1) (21 U.S.C. 

21 360d(a)(1)) is amended by striking ‘‘under a 

22 regulation under section 513(e) but such regu23 lation’’ and inserting ‘‘under an administrative 

24 order under section 513(e) (or a regulation pro25 mulgated under such section prior to the date 

mstockstill on DSK4VPTVN1PROD with BILLS

149 

•S 2516 PCS

1 of enactment of the Food and Drug Adminis2 tration Safety and Innovation Act) but such 

3 order (or regulation)’’; 

4 (C) Section 517(a)(1) (21 U.S.C. 

5 360g(a)(1)) is amended by striking ‘‘or chang6 ing the classification of a device to class I’’ and 

7 inserting ‘‘, an administrative order changing 

8 the classification of a device to class I,’’. 

9 (3) DEVICES RECLASSIFIED PRIOR TO THE

10 DATE OF ENACTMENT OF THIS ACT.— 

11 (A) IN GENERAL.—The amendments made 

12 by this subsection shall have no effect on a reg13 ulation promulgated with respect to the classi14 fication of a device under section 513(e) of the 

15 Federal Food, Drug, and Cosmetic Act prior to 

16 the date of enactment of this Act. 

17 (B) APPLICABILITY OF OTHER PROVI18 SIONS.—In the case of a device reclassified 

19 under section 513(e) of the Federal Food, 

20 Drug, and Cosmetic Act by regulation prior to 

21 the date of enactment of this Act, section 

22 517(a)(1) of the Federal Food, Drug, and Cos23 metic Act (21 U.S.C. 360g(a)(1)) shall apply to 

24 such regulation promulgated under section 

25 513(e) of such Act with respect to such device 

mstockstill on DSK4VPTVN1PROD with BILLS

150 

•S 2516 PCS

1 in the same manner such section 517(a)(1) ap2 plies to an administrative order issued with re3 spect to a device reclassified after the date of 

4 enactment of this Act. 

5 (b) DEVICES MARKETED BEFORE MAY 28, 1976.— 

6 (1) PREMARKET APPROVAL.—Section 515 (21 

7 U.S.C. 360e) is amended— 

8 (A) in subsection (a), by striking ‘‘regula9 tion promulgated under subsection (b)’’ and in10 serting ‘‘an order issued under subsection (b) 

11 (or a regulation promulgated under such sub12 section prior to the date of enactment of the 

13 Food and Drug Administration Safety and In14 novation Act)’’; 

15 (B) in subsection (b)— 

16 (i) in paragraph (1)— 

17 (I) in the heading, by striking 

18 ‘‘Regulation’’ and inserting ‘‘Order’’; 

19 and 

20 (II) in the matter following sub21 paragraph (B)— 

22 (aa) by striking ‘‘by regula23 tion, promulgated in accordance 

24 with this subsection’’ and insert25 ing ‘‘by administrative order folmstockstill on DSK4VPTVN1PROD with BILLS

151 

•S 2516 PCS

1 lowing publication of a proposed 

2 order in the Federal Register, a 

3 meeting of a device classification 

4 panel described in section 513(b), 

5 and consideration of comments 

6 from all affected stakeholders, in7 cluding patients, payors, and pro8 viders, notwithstanding sub9 chapter II of chapter 5 of title 5, 

10 United States Code’’; and 

11 (bb) by adding at the end 

12 the following: 

13 ‘‘Authority to issue such administrative order shall not be 

14 delegated below the Commissioner. Before publishing such 

15 administrative order, the Commissioner shall consult with 

16 the Office of the Secretary. The Commissioner shall issue 

17 such an order as proposed by the Director of the Center 

18 for Devices and Radiological Health unless the Commis19 sioner, in consultation with the Office of the Secretary, 

20 concludes that the order exceeds the legal authority of the 

21 Food and Drug Administration or that the order would 

22 be lawful, but unlikely to advance the public health.’’; 

23

24 (ii) in paragraph (2)— 

mstockstill on DSK4VPTVN1PROD with BILLS

152 

•S 2516 PCS

1 (I) by striking subparagraph (B); 

2 and 

3 (II) in subparagraph (A)— 

4 (aa) by striking ‘‘(2)(A) A 

5 proceeding for the promulgation 

6 of a regulation under paragraph 

7 (1) respecting a device shall be 

8 initiated by the publication in the 

9 Federal Register of a notice of 

10 proposed rulemaking. Such notice 

11 shall contain—’’ and inserting 

12 ‘‘(2) A proposed order required 

13 under paragraph (1) shall con14 tain—’’; 

15 (bb) by redesignating 

16 clauses (i) through (iv) as sub17 paragraphs (A) through (D), re18 spectively; 

19 (cc) in subparagraph (A), as 

20 so redesignated, by striking ‘‘reg21 ulation’’ and inserting ‘‘order’’; 

22 and 

23 (dd) in subparagraph (C), as 

24 so redesignated, by striking ‘‘reg25 ulation’’ and inserting ‘‘order’’; 

mstockstill on DSK4VPTVN1PROD with BILLS

153 

•S 2516 PCS

1 (iii) in paragraph (3)— 

2 (I) by striking ‘‘proposed regula3 tion’’ each place such term appears 

4 and inserting ‘‘proposed order’’; 

5 (II) by striking ‘‘paragraph (2) 

6 and after’’ and inserting ‘‘paragraph 

7 (2),’’; 

8 (III) by inserting ‘‘and a meeting 

9 of a device classification panel de10 scribed in section 513(b),’’ after ‘‘such 

11 proposed regulation and findings,’’; 

12 (IV) by striking ‘‘(A) promulgate 

13 such regulation’’ and inserting ‘‘(A) 

14 issue an administrative order under 

15 paragraph (1)’’; 

16 (V) by striking ‘‘paragraph 

17 (2)(A)(ii)’’ and inserting ‘‘paragraph 

18 (2)(B)’’; and 

19 (VI) by striking ‘‘promulgation of 

20 the regulation’’ and inserting 

21 ‘‘issuance of the administrative 

22 order’’; and 

23 (iv) by striking paragraph (4); and 

24 (C) in subsection (i)— 

25 (i) in paragraph (2)— 

mstockstill on DSK4VPTVN1PROD with BILLS

154 

•S 2516 PCS

1 (I) in the matter preceding sub2 paragraph (A)— 

3 (aa) by striking ‘‘December 

4 1, 1995’’ and inserting ‘‘the date 

5 that is 2 years after the date of 

6 enactment of the Food and Drug 

7 Administration Safety and Inno8 vation Act’’; and 

9 (bb) by striking ‘‘publish a 

10 regulation in the Federal Reg11 ister’’ and inserting ‘‘issue an ad12 ministrative order following pub13 lication of a proposed order in 

14 the Federal Register, a meeting 

15 of a device classification panel 

16 described in section 513(b), and 

17 consideration of comments from 

18 all affected stakeholders, includ19 ing patients, payors, and pro20 viders, notwithstanding sub21 chapter II of chapter 5 of title 5, 

22 United States Code,’’; 

23 (II) in subparagraph (B), by 

24 striking ‘‘final regulation has been 

25 promulgated under section 515(b)’’ 

mstockstill on DSK4VPTVN1PROD with BILLS

155 

•S 2516 PCS

1 and inserting ‘‘administrative order 

2 has been issued under subsection (b) 

3 (or no regulation has been promul4 gated under such subsection prior to 

5 the date of enactment of the Food 

6 and Drug Administration Safety and 

7 Innovation Act)’’; 

8 (III) in the matter following sub9 paragraph (B), by striking ‘‘regula10 tion requires’’ and inserting ‘‘adminis11 trative order issued under this para12 graph requires’’; and 

13 (IV) by striking the third and 

14 fourth sentences; and 

15 (ii) in paragraph (3)— 

16 (I) by striking ‘‘regulation requir17 ing’’ each place such term appears 

18 and inserting ‘‘order requiring’’; and 

19 (II) by striking ‘‘promulgation of 

20 a section 515(b) regulation’’ and in21 serting ‘‘issuance of an administrative 

22 order under subsection (b)’’. 

23 (2) TECHNICAL AND CONFORMING AMEND24 MENTS.—Section 501(f) (21 U.S.C. 351(f)) is 

25 amended— 

mstockstill on DSK4VPTVN1PROD with BILLS

156 

•S 2516 PCS

1 (A) in subparagraph (1)(A)— 

2 (i) in subclause (i), by striking ‘‘a reg3 ulation promulgated’’ and inserting ‘‘an 

4 order issued’’; and 

5 (ii) in subclause (ii), by striking ‘‘pro6 mulgation of such regulation’’ and insert7 ing ‘‘issuance of such order’’; 

8 (B) in subparagraph (2)(B)— 

9 (i) by striking ‘‘a regulation promul10 gated’’ and inserting ‘‘an order issued’’; 

11 and 

12 (ii) by striking ‘‘promulgation of such 

13 regulation’’ and inserting ‘‘issuance of 

14 such order’’; and 

15 (C) by adding at the end the following: 

16 ‘‘(3) In the case of a device with respect to which 

17 a regulation was promulgated under section 515(b) prior 

18 to the date of enactment of the Food and Drug Adminis19 tration Safety and Innovation Act, a reference in this sub20 section to an order issued under section 515(b) shall be 

21 deemed to include such regulation.’’. 

22 (3) APPROVAL BY REGULATION PRIOR TO THE

23 DATE OF ENACTMENT OF THIS ACT.—The amend24 ments made by this subsection shall have no effect 

25 on a regulation that was promulgated prior to the 

mstockstill on DSK4VPTVN1PROD with BILLS

157 

•S 2516 PCS

1 date of enactment of this Act requiring that a device 

2 have an approval under section 515 of the Federal 

3 Food, Drug, and Cosmetic Act (21 U.S.C. 360e) of 

4 an application for premarket approval. 

5 (c) REPORTING.—The Secretary of Health and 

6 Human Services shall annually post on the Internet web 

7 site of the Food and Drug Administration— 

8 (1) the number and type of class I and class II 

9 devices reclassified as class II or class III in the pre10 vious calendar year under section 513(e)(1) of the 

11 Federal Food, Drug, and Cosmetic Act (21 U.S.C. 

12 360c(e)(1)); 

13 (2) the number and type of class II and class 

14 III devices reclassified as class I or class II in the 

15 previous calendar year under such section 513(e)(1); 

16 and 

17 (3) the number and type of devices reclassified 

18 in the previous calendar year under section 515 of 

19 the Federal Food, Drug, and Cosmetic Act (21 

20 U.S.C. 360e). 

21 SEC. 602. CONDITION OF APPROVAL STUDIES. 

22 Section 515(d)(1)(B)(ii) (21 U.S.C. 

23 360e(d)(1)(B)(ii)) is amended— 

24 (1) by striking ‘‘(ii)’’ and inserting ‘‘(ii)(I)’’; 

25 and 

mstockstill on DSK4VPTVN1PROD with BILLS

158 

•S 2516 PCS

1 (2) by adding at the end the following: 

2 ‘‘(II) An order approving an application for a device 

3 may require as a condition to such approval that the appli4 cant conduct a postmarket study regarding the device.’’. 

5 SEC. 603. POSTMARKET SURVEILLANCE. 

6 Section 522 (21 U.S.C. 360l) is amended— 

7 (1) in subsection (a)(1)(A), in the matter pre8 ceding clause (i), by inserting ‘‘, at the time of ap9 proval or clearance of a device or at any time there10 after,’’ after ‘‘by order’’; and 

11 (2) in subsection (b)(1), by inserting ‘‘The 

12 manufacturer shall commence surveillance under this 

13 section not later than 15 months after the day on 

14 which the Secretary issues an order under this sec15 tion.’’ after the second sentence. 

16 SEC. 604. SENTINEL. 

17 Section 519 (21 U.S.C. 360i) is amended by adding 

18 at the end the following: 

19 ‘‘(h) INCLUSION OF DEVICES IN THE POSTMARKET

20 RISK IDENTIFICATION AND ANALYSIS SYSTEM.— 

21 ‘‘(1) IN GENERAL.— 

22 ‘‘(A) APPLICATION TO DEVICES.—The Sec23 retary shall amend the procedures established 

24 and maintained under clauses (i), (ii), (iii), and 

25 (v) of section 505(k)(3)(C) in order to expand 

mstockstill on DSK4VPTVN1PROD with BILLS

159 

•S 2516 PCS

1 the postmarket risk identification and analysis 

2 system established under such section to include 

3 and apply to devices. 

4 ‘‘(B) EXCEPTION.—Subclause (II) of 

5 clause (i) of section 505(k)(3)(C) shall not 

6 apply to devices. 

7 ‘‘(C) CLARIFICATION.—With respect to de8 vices, the private sector health-related electronic 

9 data provided under section 

10 505(k)(3)(C)(i)(III)(bb) may include medical 

11 device utilization data, health insurance claims 

12 data, and procedure and device registries. 

13 ‘‘(2) DATA.—In expanding the system as de14 scribed in paragraph (1)(A), the Secretary shall use 

15 relevant data with respect to devices cleared under 

16 section 510(k) or approved under section 515, in17 cluding claims data, patient survey data, and any 

18 other data deemed appropriate by the Secretary. 

19 ‘‘(3) STAKEHOLDER INPUT.—To help ensure ef20 fective implementation of the system described in 

21 paragraph (1)(A), the Secretary shall engage outside 

22 stakeholders in development of the system through a 

23 public hearing, advisory committee meeting, public 

24 docket, or other like public measures, as appro25 priate. 

mstockstill on DSK4VPTVN1PROD with BILLS

160 

•S 2516 PCS

1 ‘‘(4) VOLUNTARY SURVEYS.—Chapter 35 of 

2 title 44, United States Code, shall not apply to the 

3 collection of voluntary information from health care 

4 providers, such as voluntary surveys or question5 naires, initiated by the Secretary for purposes of 

6 postmarket risk identification for devices.’’. 

7 SEC. 605. RECALLS. 

8 (a) ASSESSMENT OF DEVICE RECALL INFORMA9 TION.— 

10 (1) IN GENERAL.— 

11 (A) ASSESSMENT PROGRAM.—The Sec12 retary of Health and Human Services (referred 

13 to in this section as the ‘‘Secretary’’) shall en14 hance the Food and Drug Administration’s re15 call program to routinely and systematically as16 sess— 

17 (i) information submitted to the Sec18 retary pursuant to a device recall order 

19 under section 518(e) of the Federal Food, 

20 Drug, and Cosmetic Act (21 U.S.C. 

21 360h(e)); and 

22 (ii) information required to be re23 ported to the Secretary regarding a correc24 tion or removal of a device under section 

25 519(g) of such Act (21 U.S.C. 360i(g)). 

mstockstill on DSK4VPTVN1PROD with BILLS

161 

•S 2516 PCS

1 (B) USE.—The Secretary shall use the as2 sessment of information described under sub3 paragraph (A) to proactively identify strategies 

4 for mitigating health risks presented by defec5 tive or unsafe devices. 

6 (2) DESIGN.—The program under paragraph 

7 (1) shall, at a minimum, identify— 

8 (A) trends in the numbers and types of de9 vice recalls; 

10 (B) the types of devices in each device 

11 class that are most frequently recalled; 

12 (C) the causes of device recalls; and 

13 (D) any other information as the Secretary 

14 determines appropriate. 

15 (b) AUDIT CHECK PROCEDURES.—The Secretary 

16 shall clarify procedures for conducting device recall audit 

17 checks to improve the ability of investigators to perform 

18 these checks in a consistent manner. 

19 (c) ASSESSMENT CRITERIA.—The Secretary shall de20 velop explicit criteria for assessing whether a person sub21 ject to a recall order under section 518(e) of the Federal 

22 Food, Drug, and Cosmetic Act (21 U.S.C. 360h(e)) or to 

23 a requirement under section 519(g) of such Act (21 

24 U.S.C. 360i(g)) has performed an effective recall under 

mstockstill on DSK4VPTVN1PROD with BILLS

162 

•S 2516 PCS

1 such section 518(e) or an effective correction or removal 

2 action under such section 519(g), respectively. 

3 (d) TERMINATION OF RECALLS.—The Secretary shall 

4 document the basis for the termination by the Food and 

5 Drug Administration of— 

6 (1) an individual device recall ordered under 

7 section 518(e) of the Federal Food, Drug, and Cos8 metic Act (21 U.S.C. 360h(e)); and 

9 (2) any correction or removal action for which 

10 a report is required to be submitted to the Secretary 

11 under section 519(g) of such Act (21 U.S.C. 

12 360i(g)). 

13 SEC. 606. CLINICAL HOLDS ON INVESTIGATIONAL DEVICE 

14 EXEMPTIONS. 

15 Section 520(g) (21 U.S.C. 360j(g)) is amended by 

16 adding at the end the following: 

17 ‘‘(8)(A) At any time, the Secretary may prohibit the 

18 sponsor of an investigation from conducting the investiga19 tion (referred to in this paragraph as a ‘clinical hold’) if 

20 the Secretary makes a determination described in sub21 paragraph (B). The Secretary shall specify the basis for 

22 the clinical hold, including the specific information avail23 able to the Secretary which served as the basis for such 

24 clinical hold, and confirm such determination in writing. 

mstockstill on DSK4VPTVN1PROD with BILLS

163 

•S 2516 PCS

1 ‘‘(B) For purposes of subparagraph (A), a determina2 tion described in this subparagraph with respect to a clin3 ical hold is a determination that— 

4 ‘‘(i) the device involved represents an unreason5 able risk to the safety of the persons who are the 

6 subjects of the clinical investigation, taking into ac7 count the qualifications of the clinical investigators, 

8 information about the device, the design of the clin9 ical investigation, the condition for which the device 

10 is to be investigated, and the health status of the 

11 subjects involved; or 

12 ‘‘(ii) the clinical hold should be issued for such 

13 other reasons as the Secretary may by regulation es14 tablish. 

15 ‘‘(C) Any written request to the Secretary from the 

16 sponsor of an investigation that a clinical hold be removed 

17 shall receive a decision, in writing and specifying the rea18 sons therefor, within 30 days after receipt of such request. 

19 Any such request shall include sufficient information to 

20 support the removal of such clinical hold.’’. 

21 SEC. 607. UNIQUE DEVICE IDENTIFIER. 

22 Section 519(f) (21 U.S.C. 360i(f)) is amended— 

23 (1) by striking ‘‘The Secretary shall promul24 gate’’ and inserting ‘‘Not later than December 31, 

25 2012, the Secretary shall issue proposed’’; and 

mstockstill on DSK4VPTVN1PROD with BILLS

164 

•S 2516 PCS

1 (2) by adding at the end the following: ‘‘The 

2 Secretary shall finalize the proposed regulations not 

3 later than 6 months after the close of the comment 

4 period and shall implement the final regulations with 

5 respect to devices that are implantable, life-saving, 

6 and life sustaining not later than 2 years after the 

7 regulations are finalized.’’. 

8 SEC. 608. CLARIFICATION OF LEAST BURDENSOME STAND9 ARD. 

10 (a) PREMARKET APPROVAL.—Section 513(a)(3)(D) 

11 (21 U.S.C. 360c(a)(3)(D)) is amended— 

12 (1) by redesignating clause (iii) as clause (v); 

13 and 

14 (2) by inserting after clause (ii) the following: 

15 ‘‘(iii) For purposes of clause (ii), the term ‘necessary’ 

16 means the minimum required information that would sup17 port a determination by the Secretary that an application 

18 provides reasonable assurance of the effectiveness of the 

19 device. 

20 ‘‘(iv) Nothing in this subparagraph shall alter the cri21 teria for evaluating an application for premarket approval 

22 of a device.’’. 

23 (b) PREMARKET NOTIFICATION UNDER SECTION

24 510(K).—Section 513(i)(1)(D) (21 U.S.C. 360c(i)(1)(D)) 

25 is amended— 

mstockstill on DSK4VPTVN1PROD with BILLS

165 

•S 2516 PCS

1 (1) by striking ‘‘(D) Whenever’’ and inserting 

2 ‘‘(D)(i) Whenever’’; and 

3 (2) by adding at the end the following: 

4 ‘‘(ii) For purposes of clause (i), the term ‘necessary’ 

5 means the minimum required information that would sup6 port a determination of substantial equivalence between 

7 a new device and a predicate device. 

8 ‘‘(iii) Nothing in this subparagraph shall alter the 

9 standard for determining substantial equivalence between 

10 a new device and a predicate device.’’. 

11 SEC. 609. CUSTOM DEVICES. 

12 Section 520(b) (21 U.S.C. 360j(b)) is amended to 

13 read as follows: 

14 ‘‘(b) CUSTOM DEVICES.— 

15 ‘‘(1) IN GENERAL.—The requirements of sec16 tions 514 and 515 shall not apply to a device that— 

17 ‘‘(A) is created or modified in order to 

18 comply with the order of an individual physician 

19 or dentist (or any other specially qualified per20 son designated under regulations promulgated 

21 by the Secretary after an opportunity for an 

22 oral hearing); 

23 ‘‘(B) in order to comply with an order de24 scribed in subparagraph (A), necessarily devi25 ates from an otherwise applicable performance 

mstockstill on DSK4VPTVN1PROD with BILLS

166 

•S 2516 PCS

1 standard under section 514 or requirement 

2 under section 515; 

3 ‘‘(C) is not generally available in the 

4 United States in finished form through labeling 

5 or advertising by the manufacturer, importer, 

6 or distributor for commercial distribution; 

7 ‘‘(D) is designed to treat a unique pathol8 ogy or physiological condition that no other de9 vice is domestically available to treat; 

10 ‘‘(E)(i) is intended to meet the special 

11 needs of such physician or dentist (or other spe12 cially qualified person so designated) in the 

13 course of the professional practice of such phy14 sician or dentist (or other specially qualified 

15 person so designated); or 

16 ‘‘(ii) is intended for use by an individual 

17 patient named in such order of such physician 

18 or dentist (or other specially qualified person so 

19 designated); 

20 ‘‘(F) is assembled from components or 

21 manufactured and finished on a case-by-case 

22 basis to accommodate the unique needs de23 scribed in clause (i) or (ii) of subparagraph (E); 

24 and 

mstockstill on DSK4VPTVN1PROD with BILLS

167 

•S 2516 PCS

1 ‘‘(G) may have common, standardized de2 sign characteristics, chemical and material com3 positions, and manufacturing processes as com4 mercially distributed devices. 

5 ‘‘(2) LIMITATIONS.—Paragraph (1) shall apply 

6 to a device only if— 

7 ‘‘(A) such device is for the purpose of 

8 treating a sufficiently rare condition, such that 

9 conducting clinical investigations on such device 

10 would be impractical; and 

11 ‘‘(B) production of such device under para12 graph (1) is limited to no more than 5 units per 

13 year of a particular device type, provided that 

14 such replication otherwise complies with this 

15 section. 

16 ‘‘(3) EXCEPTION.—Paragraph (1) shall not 

17 apply to oral facial devices. 

18 ‘‘(4) GUIDANCE.—Not later than 2 years after 

19 the date of enactment of this section, the Secretary 

20 shall issue final guidance on replication of multiple 

21 devices described in paragraph (2)(B). 

22 ‘‘(5) NOTIFICATION TO THE SECRETARY.—The 

23 manufacturer of a device created or modified as de24 scribed in paragraph (1) shall notify the Secretary, 

mstockstill on DSK4VPTVN1PROD with BILLS

168 

•S 2516 PCS

1 in a manner prescribed by the Secretary, of the 

2 manufacture of such device.’’. 

3 SEC. 610. AGENCY DOCUMENTATION AND REVIEW OF CER4 TAIN DECISIONS REGARDING DEVICES. 

5 Chapter V (21 U.S.C. 351 et seq.) is amended by 

6 inserting after section 517 the following: 

7 ‘‘SEC. 517A. AGENCY DOCUMENTATION AND REVIEW OF 

8 CERTAIN DECISIONS REGARDING DEVICES. 

9 ‘‘(a) DOCUMENTATION OF RATIONALE FOR DE10 NIAL.—If the Secretary renders a final decision to deny 

11 clearance of a premarket notification under section 510(k) 

12 or approval of a premarket application under section 515, 

13 or when the Secretary disapproves an application for an 

14 investigational exemption under 520(g), the written cor15 respondence to the applicant communicating that decision 

16 shall provide a substantive summary of the scientific and 

17 regulatory rationale for the decision. 

18 ‘‘(b) REVIEW OF DENIAL.— 

19 ‘‘(1) IN GENERAL.—A person who has sub20 mitted a report under section 510(k), an application 

21 under section 515, or an application for an exemp22 tion under section 520(g) and for whom clearance of 

23 the report or approval of the application is denied 

24 may request a supervisory review of the decision to 

25 deny such clearance or approval. Such review shall 

mstockstill on DSK4VPTVN1PROD with BILLS

169 

•S 2516 PCS

1 be conducted by an individual at the organizational 

2 level above the organization level at which the deci3 sion to deny the clearance of the report or approval 

4 of the application is made. 

5 ‘‘(2) SUBMISSION OF REQUEST.—A person re6 questing a supervisory review under paragraph (1) 

7 shall submit such request to the Secretary not later 

8 than 30 days after such denial and shall indicate in 

9 the request whether such person seeks an in-person 

10 meeting or a teleconference review. 

11 ‘‘(3) TIMEFRAME.— 

12 ‘‘(A) IN GENERAL.—Except as provided in 

13 subparagraph (B), the Secretary shall schedule 

14 an in-person or teleconference review, if so re15 quested, not later than 30 days after such re16 quest is made. The Secretary shall issue a deci17 sion to the person requesting a review under 

18 this subsection not later than 45 days after the 

19 request is made under paragraph (1), or, in the 

20 case of a person who requests an in-person 

21 meeting or teleconference, 30 days after such 

22 meeting or teleconference. 

23 ‘‘(B) EXCEPTION.—Subparagraph (A) 

24 shall not apply in cases that involve consulta25 tion with experts outside of the Food and Drug 

mstockstill on DSK4VPTVN1PROD with BILLS

170 

•S 2516 PCS

1 Administration, or in cases in which the spon2 sor seeks to introduce evidence not already in 

3 the administrative record at the time the denial 

4 decision was made.’’. 

5 SEC. 611. GOOD GUIDANCE PRACTICES RELATING TO DE6 VICES. 

7 Subparagraph (C) of section 701(h)(1) (21 U.S.C. 

8 371(h)(1)) is amended— 

9 (1) by striking ‘‘(C) For guidance documents’’ 

10 and inserting ‘‘(C)(i) For guidance documents’’; and 

11 (2) by adding at the end the following: 

12 ‘‘(ii) With respect to devices, if a notice to in13 dustry guidance letter, a notice to industry advisory 

14 letter, or any similar notice sets forth initial inter15 pretations of a regulation or policy or sets forth 

16 changes in interpretation or policy, such notice shall 

17 be treated as a guidance document for purposes of 

18 this subparagraph.’’. 

19 SEC. 612. MODIFICATION OF DE NOVO APPLICATION PROC20 ESS. 

21 (a) IN GENERAL.—Section 513(f)(2) (21 U.S.C. 

22 360c(f)(2)) is amended— 

23 (1) by redesignating subparagraphs (B) and 

24 (C) as subparagraphs (C) and (D), respectively; 

mstockstill on DSK4VPTVN1PROD with BILLS

171 

•S 2516 PCS

1 (2) by amending subparagraph (A) to read as 

2 follows: 

3 ‘‘(A) In the case of a type of device that has not pre4 viously been classified under this Act, a person may do 

5 one of the following: 

6 ‘‘(i) Submit a report under section 510(k), and, 

7 if the device is classified into class III under para8 graph (1), such person may request, not later than 

9 30 days after receiving written notice of such a clas10 sification, the Secretary to classify the device under 

11 the criteria set forth in subparagraphs (A) through 

12 (C) of subsection (a)(1). The person may, in the re13 quest, recommend to the Secretary a classification 

14 for the device. Any such request shall describe the 

15 device and provide detailed information and reasons 

16 for the recommended classification. 

17 ‘‘(ii) Submit a request for initial classification 

18 of the device under this subparagraph, if the person 

19 declares that there is no legally marketed device 

20 upon which to base a substantial equivalence deter21 mination as that term is defined in subsection (i). 

22 Subject to subparagraph (B), the Secretary shall 

23 classify the device under the criteria set forth in sub24 paragraphs (A) through (C) of subsection (a)(1). 

25 The person submitting the request for classification 

mstockstill on DSK4VPTVN1PROD with BILLS

172 

•S 2516 PCS

1 under this subparagraph may recommend to the 

2 Secretary a classification for the device and shall, if 

3 recommending classification in class II, include in 

4 the request an initial draft proposal for applicable 

5 special controls, as described in subsection 

6 (a)(1)(B), that are necessary, in conjunction with 

7 general controls, to provide reasonable assurance of 

8 safety and effectiveness and a description of how the 

9 special controls provide such assurance. Requests 

10 under this clause shall be subject to the electronic 

11 copy requirements of section 745A(b).’’; 

12 (3) by inserting after subparagraph (A) the fol13 lowing: 

14 ‘‘(B) The Secretary may decline to undertake a clas15 sification request submitted under clause (2)(A)(ii) if the 

16 Secretary identifies a legally marketed device that could 

17 provide a reasonable basis for review of substantial equiva18 lence under paragraph (1), or when the Secretary deter19 mines that the device submitted is not of low-moderate 

20 risk or that general controls would be inadequate to con21 trol the risks and special controls to mitigate the risks 

22 cannot be developed.’’; and 

23 (4) in subparagraph (C), as so redesignated— 

24 (A) in clause (i), by striking ‘‘Not later 

25 than 60 days after the date of the submission 

mstockstill on DSK4VPTVN1PROD with BILLS

173 

•S 2516 PCS

1 of the request under subparagraph (A),’’ and 

2 inserting ‘‘Not later than 120 days after the 

3 date of the submission of the request under 

4 subparagraph (A)(i) or 150 days after the date 

5 of the submission of the request under subpara6 graph (A)(ii),’’; and 

7 (B) in clause (ii), by inserting ‘‘or is classi8 fied in’’ after ‘‘remains in’’. 

9 (b) GAO REPORT.—Not later than 2 years after the 

10 date of enactment of this Act, the Comptroller General 

11 of the United States shall complete a study and submit 

12 to Congress a report on the effectiveness of the review 

13 pathway under section 513(f)(2)(A) of the Federal Food, 

14 Drug, and Cosmetic Act, as amended by this Act. 

15 (c) CONFORMING AMENDMENT.—Section 

16 513(f)(1)(B) (21 U.S.C. 360c(f)(1)(B)) is amended by in17 serting ‘‘a request under paragraph (2) or’’ after ‘‘re18 sponse to’’. 

19 SEC. 613. HUMANITARIAN DEVICE EXEMPTIONS. 

20 (a) IN GENERAL.—Section 520(m) (21 U.S.C. 

21 360j(m)) is amended— 

22 (1) in paragraph (6)— 

23 (A) in subparagraph (A)— 

mstockstill on DSK4VPTVN1PROD with BILLS

174 

•S 2516 PCS

1 (i) in the matter preceding clause (i), 

2 by striking ‘‘subparagraph (D)’’ and in3 serting ‘‘subparagraph (C)’’; 

4 (ii) by striking clause (i) and inserting 

5 the following: 

6 ‘‘(i) The device with respect to which the ex7 emption is granted— 

8 ‘‘(I) is intended for the treatment or diag9 nosis of a disease or condition that occurs in 

10 pediatric patients or in a pediatric subpopula11 tion, and such device is labeled for use in pedi12 atric patients or in a pediatric subpopulation in 

13 which the disease or condition occurs; or 

14 ‘‘(II) is intended for the treatment or diag15 nosis of a disease or condition that does not 

16 occur in pediatric patients or that occurs in pe17 diatric patients in such numbers that the devel18 opment of the device for such patients is impos19 sible, highly impracticable, or unsafe.’’; and 

20 (iii) by striking clause (ii) and insert21 ing the following: 

22 ‘‘(ii) During any calendar year, the number of 

23 such devices distributed during that year under each 

24 exemption granted under this subsection does not 

25 exceed the number of such devices needed to treat, 

mstockstill on DSK4VPTVN1PROD with BILLS

175 

•S 2516 PCS

1 diagnose, or cure a population of 4,000 individuals 

2 in the United States (referred to in this paragraph 

3 as the ‘annual distribution number’).’’; 

4 (B) by striking subparagraph (C); 

5 (C) by redesignating subparagraphs (D) 

6 and (E) as subparagraphs (C) and (D), respec7 tively; and 

8 (D) in subparagraph (C), as so redesig9 nated, by striking ‘‘and modified under sub10 paragraph (C), if applicable,’’; 

11 (2) in paragraph (7), by striking ‘‘regarding a 

12 device’’ and inserting ‘‘regarding a device described 

13 in paragraph (6)(A)(i)(I)’’; and 

14 (3) in paragraph (8), by striking ‘‘of all devices 

15 described in paragraph (6)’’ and inserting ‘‘of all de16 vices described in paragraph (6)(A)(i)(I)’’. 

17 (b) APPLICABILITY TO EXISTING DEVICES.—A spon18 sor of a device for which an exemption was approved under 

19 paragraph (2) of section 520(m) of the Federal Food, 

20 Drug, and Cosmetic Act (21 U.S.C. 360j(m)) before the 

21 date of enactment of this Act may seek a determination 

22 under subclause (I) or (II) of section 520(m)(6)(A)(i) (as 

23 amended by subsection (a)). If the Secretary determines 

24 that such subclause (I) or (II) applies with respect to a 

25 device, clauses (ii), (iii), and (iv) of subparagraph (A) and 

mstockstill on DSK4VPTVN1PROD with BILLS

176 

•S 2516 PCS

1 subparagraphs (B), (C), and (D) of paragraph (6) of such 

2 section 520(m) shall apply to such device. 

3 (c) REPORT.—Not later than January 1, 2017, the 

4 Comptroller General of the United States shall submit to 

5 Congress a report that evaluates and describes— 

6 (1) the effectiveness of the amendments made 

7 by subsection (a) in stimulating innovation with re8 spect to medical devices, including any favorable or 

9 adverse impact on pediatric device development; 

10 (2) the impact of such amendments on pediatric 

11 device approvals for devices that received a humani12 tarian use designation under section 520(m) of the 

13 Federal Food, Drug, and Cosmetic Act (21 U.S.C. 

14 360j(m)) prior to the date of enactment of this Act; 

15 (3) the status of public and private insurance 

16 coverage of devices granted an exemption under 

17 paragraph (2) of such section 520(m) (as amended 

18 by subsection (a)) and costs to patients of such de19 vices; 

20 (4) the impact that paragraph (4) of such sec21 tion 520(m) has had on access to and insurance cov22 erage of devices granted an exemption under para23 graph (2) of such section 520(m); and 

mstockstill on DSK4VPTVN1PROD with BILLS

177 

•S 2516 PCS

1 (5) the effect of the amendments made by sub2 section (a) on patients described in such section 

3 520(m). 

4 SEC. 614. REAUTHORIZATION OF THIRD-PARTY REVIEW 

5 AND INSPECTIONS. 

6 (a) THIRD PARTY REVIEW.—Section 523(c) (21 

7 U.S.C. 360m(c)) is amended by striking ‘‘2012’’ and in8 serting ‘‘2017’’. 

9 (b) THIRD PARTY INSPECTIONS.—Section 

10 704(g)(11) (21 U.S.C. 374(g)(11)) is amended by striking 

11 ‘‘2012’’ and inserting ‘‘2017’’. 

12 SEC. 615. 510(K) DEVICE MODIFICATIONS. 

13 Having acknowledged to Congress potential unin14 tended consequences that may result from the implemen15 tation of the Food and Drug Administration guidance en16 titled ‘‘Guidance for Industry and FDA Staff—510(k) De17 vice Modifications: Deciding When to Submit a 510(k) for 

18 a Change to an Existing Device’’, the Secretary of Health 

19 and Human Services shall withdraw such guidance 

20 promptly and ensure that, before any future guidance doc21 ument on this issue is made final, affected stakeholders 

22 are provided with an opportunity to comment. 

mstockstill on DSK4VPTVN1PROD with BILLS

178 

•S 2516 PCS

1 TITLE VII—DRUG SUPPLY CHAIN 

2 SEC. 701. REGISTRATION OF DOMESTIC DRUG ESTABLISH3 MENTS. 

4 Section 510 (21 U.S.C. 360) is amended— 

5 (1) in subsection (b)— 

6 (A) in paragraph (1), by striking ‘‘On or 

7 before’’ and all that follows through the period 

8 at the end and inserting the following: ‘‘During 

9 the period beginning on October 1 and ending 

10 on December 31 of each year, every person who 

11 owns or operates any establishment in any 

12 State engaged in the manufacture, preparation, 

13 propagation, compounding, or processing of a 

14 drug or drugs shall register with the Sec15 retary— 

16 ‘‘(A) the name of such person, places of busi17 ness of such person, all such establishments, the 

18 unique facility identifier of each such establishment, 

19 and a point of contact e-mail address; and 

20 ‘‘(B) the name and place of business of each 

21 drug importer that takes physical possession of a 

22 drug (other than an excipient), with which the per23 son conducts business, including all establishments 

24 of each such drug importer, the unique facility iden25 tifier of each such establishment, and a point of conmstockstill on DSK4VPTVN1PROD with BILLS

179 

•S 2516 PCS

1 tact e-mail address for each such drug importer.’’; 

2 and 

3 (B) by adding at the end the following: 

4 ‘‘(3) The Secretary may specify the unique facility 

5 identifier system that shall be used by registrants under 

6 paragraph (1).’’; and 

7 (2) in subsection (c), by striking ‘‘with the Sec8 retary his name, place of business, and such estab9 lishment’’ and inserting ‘‘with the Secretary— 

10 ‘‘(1) with respect to drugs, the information de11 scribed under subsection (b)(1); and 

12 ‘‘(2) with respect to devices, the information de13 scribed under subsection (b)(2).’’. 

14 SEC. 702. REGISTRATION OF FOREIGN ESTABLISHMENTS. 

15 (a) ENFORCEMENT OF REGISTRATION OF FOREIGN

16 ESTABLISHMENTS.—Section 502(o) (21 U.S.C. 352(o)) is 

17 amended by striking ‘‘in any State’’. 

18 (b) REGISTRATION OF FOREIGN DRUG ESTABLISH19 MENTS.—Section 510(i) (U.S.C. 360(i)) is amended— 

20 (1) in paragraph (1)— 

21 (A) by amending the matter preceding sub22 paragraph (A) to read as follows: ‘‘Every per23 son who owns or operates any establishment 

24 within any foreign country engaged in the man25 ufacture, preparation, propagation, 

mstockstill on DSK4VPTVN1PROD with BILLS

180 

•S 2516 PCS

1 compounding, or processing of a drug or device 

2 that is imported or offered for import into the 

3 United States shall, through electronic means 

4 in accordance with the criteria of the Sec5 retary—’’; 

6 (B) by amending subparagraph (A) to read 

7 as follows: 

8 ‘‘(A) upon first engaging in any such activity, 

9 immediately submit a registration to the Secretary 

10 that includes— 

11 ‘‘(i) with respect to drugs, the name and 

12 place of business of such person, all such estab13 lishments, the unique facility identifier of each 

14 such establishment, a point of contact e-mail 

15 address, the name of the United States agent of 

16 each such establishment, the name and place of 

17 business of each drug importer with which such 

18 person conducts business, including all estab19 lishments of each such drug importer, the 

20 unique facility identifier of each such establish21 ment, and a point of contact e-mail address for 

22 each such drug importer; and 

23 ‘‘(ii) with respect to devices, the name and 

24 place of business of the establishment, the name 

25 of the United States agent for the establishmstockstill on DSK4VPTVN1PROD with BILLS

181 

•S 2516 PCS

1 ment, the name of each importer of such device 

2 in the United States that is known to the estab3 lishment, and the name of each person who im4 ports or offers for import such device to the 

5 United States for purposes of importation; 

6 and’’; and 

7 (C) by amending subparagraph (B) to read 

8 as follows: 

9 ‘‘(B) each establishment subject to the require10 ments of subparagraph (A) shall thereafter register 

11 with the Secretary during the period beginning on 

12 October 1 and ending on December 31 of each 

13 year.’’; and 

14 (2) by adding at the end the following: 

15 ‘‘(4) The Secretary may specify the unique facility 

16 identifier system that shall be used by registrants under 

17 paragraph (1) with respect to drugs.’’. 

18 SEC. 703. IDENTIFICATION OF DRUG EXCIPIENT INFORMA19 TION WITH PRODUCT LISTING. 

20 Section 510(j)(1) (21 U.S.C. 360(j)(1)) is amend21 ed— 

22 (1) in subparagraph (C), by striking ‘‘; and’’ 

23 and inserting a semicolon; 

24 (2) in subparagraph (D), by striking the period 

25 at the end and inserting ‘‘; and’’; and 

mstockstill on DSK4VPTVN1PROD with BILLS

182 

•S 2516 PCS

1 (3) by adding at the end the following: 

2 ‘‘(E) in the case of a drug contained in the ap3 plicable list and subject to section 505 or 512, the 

4 name and place of business of each manufacturer of 

5 an excipient of the listed drug with which the person 

6 listing the drug conducts business, including all es7 tablishments used in the production of such excip8 ient, the unique facility identifier of each such estab9 lishment, and a point of contact e-mail address for 

10 each such excipient manufacturer.’’. 

11 SEC. 704. ELECTRONIC SYSTEM FOR REGISTRATION AND 

12 LISTING. 

13 Section 510(p) (21 U.S.C. 360(p)) is amended— 

14 (1) by striking ‘‘(p) Registrations and listings’’ 

15 and inserting the following: 

16 ‘‘(p) ELECTRONIC REGISTRATION AND LISTING.— 

17 ‘‘(1) IN GENERAL.—Registration and listing’’; 

18 and 

19 (2) by adding at the end the following: 

20 ‘‘(2) ELECTRONIC DATABASE.—Not later than 

21 2 years after the Secretary specifies a unique facility 

22 identifier system under subsections (b) and (i), the 

23 Secretary shall maintain an electronic database, 

24 which shall not be subject to inspection under submstockstill on DSK4VPTVN1PROD with BILLS

183 

•S 2516 PCS

1 section (f), populated with the information submitted 

2 as described under paragraph (1) that— 

3 ‘‘(A) enables personnel of the Food and 

4 Drug Administration to search the database by 

5 any field of information submitted in a registra6 tion described under paragraph (1), or com7 bination of such fields; and 

8 ‘‘(B) uses the unique facility identifier sys9 tem to link with other relevant databases within 

10 the Food and Drug Administration, including 

11 the database for submission of information 

12 under section 801(r). 

13 ‘‘(3) RISK-BASED INFORMATION AND COORDI14 NATION.—The Secretary shall ensure the accuracy 

15 and coordination of relevant Food and Drug Admin16 istration databases in order to identify and inform 

17 risk-based inspections under section 510(h).’’. 

18 SEC. 705. RISK-BASED INSPECTION FREQUENCY. 

19 Section 510(h) (21 U.S.C. 360(h)) is amended to 

20 read as follows: 

21 ‘‘(h) INSPECTIONS.— 

22 ‘‘(1) IN GENERAL.—Every establishment that is 

23 required to be registered with the Secretary under 

24 this section shall be subject to inspection pursuant 

25 to section 704. 

mstockstill on DSK4VPTVN1PROD with BILLS

184 

•S 2516 PCS

1 ‘‘(2) BIENNIAL INSPECTIONS FOR DEVICES.— 

2 Every establishment described in paragraph (1) that 

3 is engaged in the manufacture, propagation, 

4 compounding, or processing of a device or devices 

5 classified in class II or III shall be so inspected by 

6 one or more officers or employees duly designated by 

7 the Secretary, or by persons accredited to conduct 

8 inspections under section 704(g), at least once in the 

9 2-year period beginning with the date of registration 

10 of such establishment pursuant to this section and 

11 at least once in every successive 2-year period there12 after. 

13 ‘‘(3) RISK-BASED SCHEDULE FOR DRUGS.—The 

14 Secretary, acting through one or more officers or 

15 employees duly designated by the Secretary, shall in16 spect establishments described in paragraph (1) that 

17 are engaged in the manufacture, preparation, propa18 gation, compounding, or processing of a drug or 

19 drugs (referred to in this subsection as ‘drug estab20 lishments’) in accordance with a risk-based schedule 

21 established by the Secretary. 

22 ‘‘(4) RISK FACTORS.—In establishing the risk23 based scheduled under paragraph (3), the Secretary 

24 shall inspect establishments according to the known 

mstockstill on DSK4VPTVN1PROD with BILLS

185 

•S 2516 PCS

1 safety risks of such establishments, which shall be 

2 based on the following factors: 

3 ‘‘(A) The compliance history of the estab4 lishment. 

5 ‘‘(B) The record, history, and nature of re6 calls linked to the establishment. 

7 ‘‘(C) The inherent risk of the drug manu8 factured, prepared, propagated, compounded, or 

9 processed at the establishment. 

10 ‘‘(D) The certifications described under 

11 sections 801(r) and 809 for the establishment. 

12 ‘‘(E) Whether the establishment has been 

13 inspected in the preceding 4-year period. 

14 ‘‘(F) Any other criteria deemed necessary 

15 and appropriate by the Secretary for purposes 

16 of allocating inspection resources. 

17 ‘‘(5) EFFECT OF STATUS.—In determining the 

18 risk associated with an establishment for purposes of 

19 establishing a risk-based schedule under paragraph 

20 (3), the Secretary shall not consider whether the 

21 drugs manufactured, prepared, propagated, com22 pounded, or processed by such establishment are 

23 drugs described in section 503(b). 

24 ‘‘(6) ANNUAL REPORT ON INSPECTIONS OF ES25 TABLISHMENTS.—Not later than February 1 of each 

mstockstill on DSK4VPTVN1PROD with BILLS

186 

•S 2516 PCS

1 year, the Secretary shall submit a report to Con2 gress regarding— 

3 ‘‘(A)(i) the number of domestic and foreign 

4 establishments registered pursuant to this sec5 tion in the previous fiscal year; and 

6 ‘‘(ii) the number of such domestic estab7 lishments and the number of such foreign es8 tablishments that the Secretary inspected in the 

9 previous fiscal year; 

10 ‘‘(B) with respect to establishments that 

11 manufacture, prepare, propagate, compound, or 

12 process an active ingredient of a drug, a fin13 ished drug product, or an excipient of a drug, 

14 the number of each such type of establishment; 

15 and 

16 ‘‘(C) the percentage of the budget of the 

17 Food and Drug Administration used to fund 

18 the inspections described under subparagraph 

19 (A). 

20 ‘‘(7) PUBLIC AVAILABILITY OF ANNUAL RE21 PORTS.—The Secretary shall make the report re22 quired under paragraph (6) available to the public 

23 on the Internet Web site of the Food and Drug Ad24 ministration.’’. 

mstockstill on DSK4VPTVN1PROD with BILLS

187 

•S 2516 PCS

1 SEC. 706. RECORDS FOR INSPECTION. 

2 Section 704(a) (21 U.S.C. 374(a)) is amended by 

3 adding at the end the following: 

4 ‘‘(4)(A) Any records or other information that the 

5 Secretary is entitled to request under this section from 

6 a person that owns or operates an establishment that is 

7 engaged in the manufacture, preparation, propagation, 

8 compounding, or processing of a drug shall, upon the re9 quest of the Secretary, be provided to the Secretary by 

10 such person within a reasonable time frame, within rea11 sonable limits and in a reasonable manner, and in elec12 tronic form, at the expense of such person. The Sec13 retary’s request shall include a clear description of the 

14 records requested. 

15 ‘‘(B) Upon receipt of the records requested under 

16 subparagraph (A), the Secretary shall provide to the per17 son confirmation of the receipt of such records. 

18 ‘‘(C) Nothing in this paragraph supplants the author19 ity of the Secretary to conduct inspections otherwise per20 mitted under this Act in order to ensure compliance by 

21 an establishment with this Act.’’. 

22 SEC. 707. FAILURE TO ALLOW FOREIGN INSPECTION. 

23 Section 801(a) (21 U.S.C. 381(a)) is amended by 

24 adding at the end the following: ‘‘Notwithstanding any 

25 other provision of this subsection, the Secretary of Home26 land Security shall, upon request from the Secretary of 

mstockstill on DSK4VPTVN1PROD with BILLS

188 

•S 2516 PCS

1 Health and Human Services refuse to admit into the 

2 United States any article if the article was manufactured, 

3 prepared, propagated, compounded, processed, or held at 

4 an establishment that has refused to permit the Secretary 

5 of Health and Human Services to enter or inspect the es6 tablishment in the same manner and to the same extent 

7 as the Secretary may inspect establishments under section 

8 704.’’. 

9 SEC. 708. EXCHANGE OF INFORMATION. 

10 Section 708 (21 U.S.C. 379) is amended— 

11 (1) by striking ‘‘CONFIDENTIAL INFORMATION’’ 

12 and all that follows through ‘‘The Secretary’’ and in13 serting ‘‘CONFIDENTIAL INFORMATION. 

14 ‘‘(a) CONTRACTORS.—The Secretary’’; and 

15 (2) by adding at the end the following: 

16 ‘‘(b) ABILITY TO RECEIVE AND PROTECT CONFIDEN17 TIAL INFORMATION.—The Secretary shall not be required 

18 to disclose under section 552 of title 5, United States 

19 Code, or any other provision of law, any information relat20 ing to drugs obtained from a Federal, State or local gov21 ernment agency, or from a foreign government agency, if 

22 the agency has requested that the information be kept con23 fidential, except pursuant to an order of a court of the 

24 United States. For purposes of section 552 of title 5, 

mstockstill on DSK4VPTVN1PROD with BILLS

189 

•S 2516 PCS

1 United States Code, this subsection shall be considered a 

2 statute described in section 552(b)(3)(B). 

3 ‘‘(c) AUTHORITY TO ENTER INTO MEMORANDA OF

4 UNDERSTANDING FOR PURPOSES OF INFORMATION EX5 CHANGE.—The Secretary may enter into written agree6 ments regarding the exchange of information referenced 

7 in section 301(j) subject to the following criteria: 

8 ‘‘(1) CERTIFICATION.—The Secretary may only 

9 enter into written agreements under this subsection 

10 with foreign governments that the Secretary has cer11 tified as having the authority and demonstrated abil12 ity to protect trade secret information from disclo13 sure. Responsibility for this certification shall not be 

14 delegated to any officer or employee other than the 

15 Commissioner. 

16 ‘‘(2) WRITTEN AGREEMENT.—The written 

17 agreement under this subsection shall include a com18 mitment by the foreign government to protect infor19 mation exchanged under this subsection from disclo20 sure unless and until the sponsor gives written per21 mission for disclosure or the Secretary makes a dec22 laration of a public health emergency pursuant to 

23 section 319 of the Public Health Service Act that is 

24 relevant to the information. 

mstockstill on DSK4VPTVN1PROD with BILLS

190 

•S 2516 PCS

1 ‘‘(3) INFORMATION EXCHANGE.—The Secretary 

2 may provide to a foreign government that has been 

3 certified under paragraph (1) and that has executed 

4 a written agreement under paragraph (2) informa5 tion referenced in section 301(j) in the following cir6 cumstances: 

7 ‘‘(A) Information concerning the inspection 

8 of a facility may be provided if— 

9 ‘‘(i) the Secretary reasonably believes, 

10 or that the written agreement described in 

11 paragraph (2) establishes, that the govern12 ment has authority to otherwise obtain 

13 such information; and 

14 ‘‘(ii) the written agreement executed 

15 under paragraph (2) limits the recipient’s 

16 use of the information to the recipient’s 

17 civil regulatory purposes. 

18 ‘‘(B) Information not described in sub19 paragraph (A) may be provided as part of an 

20 investigation, or to alert the foreign government 

21 to the potential need for an investigation, if the 

22 Secretary has reasonable grounds to believe 

23 that a drug has a reasonable probability of 

24 causing serious adverse health consequences or 

25 death to humans or animals. 

mstockstill on DSK4VPTVN1PROD with BILLS

191 

•S 2516 PCS

1 ‘‘(4) EFFECT OF SUBSECTION.—Nothing in this 

2 subsection affects the ability of the Secretary to 

3 enter into any written agreement authorized by 

4 other provisions of law to share confidential informa5 tion.’’. 

6 SEC. 709. ENHANCING THE SAFETY AND QUALITY OF THE 

7 DRUG SUPPLY. 

8 Section 501 (21 U.S.C. 351) is amended by adding 

9 at the end the following flush text: 

10 ‘‘For purposes of subsection (a)(2)(B), the term ‘current 

11 good manufacturing practice’ includes the implementation 

12 of oversight and controls over the manufacture of drugs 

13 to ensure quality, including managing the risk of and es14 tablishing the safety of raw materials, materials used in 

15 the manufacturing of drugs, and finished drug products.’’. 

16 SEC. 710. ACCREDITATION OF THIRD-PARTY AUDITORS FOR 

17 DRUG ESTABLISHMENTS. 

18 (a) IN GENERAL.—Chapter VIII (21 U.S.C. 381 et 

19 seq.) is amended by adding at the end the following: 

20 ‘‘SEC. 809. ACCREDITATION OF THIRD-PARTY AUDITORS 

21 FOR DRUG ESTABLISHMENTS. 

22 ‘‘(a) DEFINITIONS.—In this section: 

23 ‘‘(1) ACCREDITATION BODY.—The term ‘ac24 creditation body’ means an authority that performs 

25 accreditation of third-party auditors. 

mstockstill on DSK4VPTVN1PROD with BILLS

192 

•S 2516 PCS

1 ‘‘(2) ACCREDITED THIRD-PARTY AUDITOR.— 

2 The term ‘accredited third-party auditor’ means a 

3 third-party auditor (which may be an individual) ac4 credited by an accreditation body to conduct drug 

5 safety and quality audits. 

6 ‘‘(3) AUDIT AGENT.—The term ‘audit agent’ 

7 means an individual who is an employee or agent of 

8 an accredited third-party auditor and, although not 

9 individually accredited, is qualified to conduct drug 

10 safety and quality audits on behalf of an accredited 

11 third-party auditor. 

12 ‘‘(4) CONSULTATIVE AUDIT.—The term ‘con13 sultative audit’ means an audit of an eligible entity 

14 intended for internal purposes only to determine 

15 whether an establishment is in compliance with the 

16 provisions of this Act and applicable industry prac17 tices, or any other such service. 

18 ‘‘(5) DRUG SAFETY AND QUALITY AUDIT.—The 

19 term ‘drug safety and quality audit’— 

20 ‘‘(A) means an audit of an eligible entity 

21 to certify that the eligible entity meets the re22 quirements of this Act applicable to drugs, in23 cluding the requirements of section 501 with re24 spect to drugs; and 

25 ‘‘(B) is not a consultative audit. 

mstockstill on DSK4VPTVN1PROD with BILLS

193 

•S 2516 PCS

1 ‘‘(6) ELIGIBLE ENTITY.—The term ‘eligible en2 tity’ means an entity, including a foreign drug estab3 lishment registered under section 510(c), in the drug 

4 supply chain that chooses to be audited by an ac5 credited third-party auditor or the audit agent of 

6 such accredited third-party auditor. 

7 ‘‘(7) THIRD-PARTY AUDITOR.—The term ‘third8 party auditor’ means a foreign government, agency 

9 of a foreign government or any other third party 

10 (which may be an individual), as the Secretary de11 termines appropriate in accordance with the criteria 

12 described in subsection (c)(1), that is eligible to be 

13 considered for accreditation to conduct drug safety 

14 and quality audits. 

15 ‘‘(b) ACCREDITATION SYSTEM.— 

16 ‘‘(1) RECOGNITION OF ACCREDITATION BOD17 IES.— 

18 ‘‘(A) IN GENERAL.—Not later than 2 years 

19 after date of enactment of the Food and Drug 

20 Administration Safety and Innovation Act, the 

21 Secretary shall establish a system for the rec22 ognition of accreditation bodies that accredit 

23 third-party auditors to conduct drug safety and 

24 quality audits. 

25 ‘‘(B) DIRECT ACCREDITATION.— 

mstockstill on DSK4VPTVN1PROD with BILLS

194 

•S 2516 PCS

1 ‘‘(i) IN GENERAL.—If, by the date 

2 that is 2 years after the date of establish3 ment of the system described in subpara4 graph (A), the Secretary has not identified 

5 and recognized an accreditation body to 

6 meet the requirements of this section, the 

7 Secretary may directly accredit third-party 

8 auditors. 

9 ‘‘(ii) CERTAIN DIRECT ACCREDITA10 TIONS.—Notwithstanding subparagraph 

11 (A) or clause (i), the Secretary may di12 rectly accredit any foreign government or 

13 any agency of a foreign government as a 

14 third-party auditor at any time after the 

15 date of enactment of the Food and Drug 

16 Administration Safety and Innovation Act. 

17 ‘‘(2) NOTIFICATION.—Each accreditation body 

18 recognized by the Secretary shall submit to the Sec19 retary— 

20 ‘‘(A) a list of all accredited third-party 

21 auditors accredited by such body (including the 

22 name, contact information, and scope and dura23 tion of accreditation for each such auditor), and 

24 the audit agents of such auditors; and 

mstockstill on DSK4VPTVN1PROD with BILLS

195 

•S 2516 PCS

1 ‘‘(B) updated lists as needed to ensure the 

2 list held by the Secretary is accurate. 

3 ‘‘(3) REVOCATION OF RECOGNITION AS AN AC4 CREDITATION BODY.—The Secretary shall promptly 

5 revoke, after the opportunity for an informal hear6 ing, the recognition of any accreditation body found 

7 not to be in compliance with the requirements of this 

8 section. 

9 ‘‘(4) REINSTATEMENT.—The Secretary shall es10 tablish procedures to reinstate recognition of an ac11 creditation body if the Secretary determines, based 

12 on evidence presented by such accreditation body, 

13 that revocation was inappropriate or that the body 

14 meets the requirements for recognition under this 

15 section. 

16 ‘‘(5) MODEL ACCREDITATION STANDARDS.— 

17 ‘‘(A) IN GENERAL.—Not later than 18 

18 months after the date of enactment of the Food 

19 and Drug Administration Safety and Innova20 tion Act, the Secretary shall develop model 

21 standards, including standards for drug safety 

22 and quality audit results, reports, and certifi23 cations, and each recognized accreditation body 

24 shall ensure that third-party auditors and audit 

25 agents of such auditors meet such standards in 

mstockstill on DSK4VPTVN1PROD with BILLS

196 

•S 2516 PCS

1 order to qualify such third-party auditors as ac2 credited third-party auditors under this section. 

3 ‘‘(B) CONTENT.—The standards developed 

4 under subparagraph (A) may— 

5 ‘‘(i) include a description of required 

6 standards relating to the training proce7 dures, competency, management respon8 sibilities, quality control, and conflict of in9 terest requirements of accredited third10 party auditors; and 

11 ‘‘(ii) set forth procedures for the peri12 odic renewal of the accreditation of accred13 ited third-party auditors. 

14 ‘‘(C) REQUIREMENT TO PROVIDE RESULTS

15 AND REPORTS TO THE SECRETARY.—An ac16 creditation body (or, in the case of direct ac17 creditation under subsection (b)(1)(B), the Sec18 retary) may not accredit a third-party auditor 

19 unless such third-party auditor agrees to pro20 vide to the Secretary, upon request, the results 

21 and reports of any drug safety and quality 

22 audit conducted pursuant to the accreditation 

23 provided under this section. 

24 ‘‘(6) DISCLOSURE.—The Secretary shall main25 tain on the Internet Web site of the Food and Drug 

mstockstill on DSK4VPTVN1PROD with BILLS

197 

•S 2516 PCS

1 Administration a list of recognized accreditation 

2 bodies and accredited third-party auditors under this 

3 section. 

4 ‘‘(c) ACCREDITED THIRD-PARTY AUDITORS.— 

5 ‘‘(1) REQUIREMENTS FOR ACCREDITATION AS A

6 THIRD-PARTY AUDITOR.— 

7 ‘‘(A) FOREIGN GOVERNMENTS.—Prior to 

8 accrediting a foreign government or an agency 

9 of a foreign government as an accredited third10 party auditor, the accreditation body (or, in the 

11 case of direct accreditation under subsection 

12 (b)(1)(B), the Secretary) shall perform such re13 views and audits of drug safety programs, sys14 tems, and standards of the government or agen15 cy of the government as the Secretary deems 

16 necessary, including requirements under the 

17 standards developed under subsection (b)(5), to 

18 determine that the foreign government or agen19 cy of the foreign government is capable of ade20 quately ensuring that eligible entities or drugs 

21 certified by such government or agency meet 

22 the requirements of this Act. 

23 ‘‘(B) OTHER THIRD PARTIES.—Prior to 

24 accrediting any other third party to be an ac25 credited third-party auditor, the accreditation 

mstockstill on DSK4VPTVN1PROD with BILLS

198 

•S 2516 PCS

1 body (or, in the case of direct accreditation 

2 under subsection (b)(1)(B), the Secretary) shall 

3 perform such reviews and audits of the training 

4 and qualifications of audit agents used by that 

5 party and conduct such reviews of internal sys6 tems and such other investigation of the party 

7 as the Secretary deems necessary, including re8 quirements under the standards developed 

9 under subsection (b)(5), to determine that the 

10 third-party auditor is capable of adequately en11 suring that an eligible entity or drug certified 

12 by such third-party auditor meets the require13 ments of this Act. 

14 ‘‘(2) USE OF AUDIT AGENTS.—An accredited 

15 third-party auditor may conduct drug safety and 

16 quality audits and may employ or use audit agents 

17 to conduct drug safety and quality audits, but must 

18 ensure that such audit agents comply with all re19 quirements the Secretary deems necessary, including 

20 requirements under paragraph (1) and subsection 

21 (b)(5). 

22 ‘‘(3) REVOCATION OF ACCREDITATION.— 

23 ‘‘(A) IN GENERAL.—The Secretary shall 

24 promptly revoke, after the opportunity for an 

mstockstill on DSK4VPTVN1PROD with BILLS

199 

•S 2516 PCS

1 informal hearing, the accreditation of an ac2 credited third-party auditor— 

3 ‘‘(i) if, following an evaluation, the 

4 Secretary finds that the accredited third5 party auditor is not in compliance with the 

6 requirements of this section; or 

7 ‘‘(ii) following a refusal to allow 

8 United States officials to conduct such au9 dits and investigations as may be necessary 

10 to determine compliance with the require11 ments set forth in this section. 

12 ‘‘(B) ADDITIONAL BASIS FOR REVOCATION

13 OF ACCREDITATION.—The Secretary may re14 voke accreditation from an accredited third15 party auditor in the case that such third-party 

16 auditor is accredited by an accreditation body 

17 for which recognition as an accreditation body 

18 under subsection (b)(3) is revoked, if the Sec19 retary determines that there is good cause for 

20 the revocation of accreditation. 

21 ‘‘(4) REACCREDITATION.—The Secretary shall 

22 establish procedures to reinstate the accreditation of 

23 a third-party auditor for which accreditation has 

24 been revoked under paragraph (3)— 

mstockstill on DSK4VPTVN1PROD with BILLS

200 

•S 2516 PCS

1 ‘‘(A) if the Secretary determines, based on 

2 evidence presented, that— 

3 ‘‘(i) the third-party auditor satisfies 

4 the requirements of this section; and 

5 ‘‘(ii) adequate grounds for revocation 

6 no longer exist; and 

7 ‘‘(B) in the case of a third-party auditor 

8 accredited by an accreditation body for which 

9 recognition as an accreditation body is revoked 

10 under subsection (b)(3)— 

11 ‘‘(i) if the third-party auditor becomes 

12 accredited not later than 1 year after rev13 ocation of accreditation under paragraph 

14 (3), through direct accreditation under 

15 subsection (b)(1)(B), or by an accredita16 tion body in good standing; or 

17 ‘‘(ii) under such other conditions as 

18 the Secretary may require. 

19 ‘‘(5) REQUIREMENT TO ISSUE CERTIFICATION

20 OF ELIGIBLE ENTITIES FOR COMPLIANCE WITH CUR21 RENT GOOD MANUFACTURING PRACTICE.— 

22 ‘‘(A) IN GENERAL.—An accreditation body 

23 (or, in the case of direct accreditation under 

24 subsection (b)(1)(B), the Secretary) may not 

25 accredit a third-party auditor unless such thirdmstockstill on DSK4VPTVN1PROD with BILLS

201 

•S 2516 PCS

1 party auditor agrees to issue a written and, as 

2 appropriate, electronic, document or certifi3 cation, as the Secretary may require under this 

4 Act, regarding compliance with section 501. 

5 The Secretary may consider any such document 

6 or certification to satisfy requirements under 

7 section 801(r) and to target inspection re8 sources under section 510(h). 

9 ‘‘(B) REQUIREMENTS FOR ISSUING CER10 TIFICATION.— 

11 ‘‘(i) IN GENERAL.—An accredited 

12 third-party auditor shall issue a drug cer13 tification described in subparagraph (A) 

14 only after conducting a drug safety and 

15 quality audit and such other activities that 

16 may be necessary to establish compliance 

17 with the provisions of section 501. 

18 ‘‘(ii) PROVISION OF CERTIFICATION.— 

19 Only an accredited third-party auditor or 

20 the Secretary may provide a drug certifi21 cation described in subparagraph (A). 

22 ‘‘(C) RECORDS.—Following any accredita23 tion of a third-party auditor, the Secretary 

24 may, at any time, require the accredited third25 party auditor or any audit agent of such audimstockstill on DSK4VPTVN1PROD with BILLS

202 

•S 2516 PCS

1 tor to submit to the Secretary a drug safety 

2 and quality audit report and such other reports 

3 or documents required as part of the drug safe4 ty and quality audit process, for any eligible en5 tity for which the accredited third-party auditor 

6 or audit agent of such auditor performed a 

7 drug safety and quality audit. The Secretary 

8 may require documentation that the eligible en9 tity is in compliance with any applicable reg10 istration requirements. 

11 ‘‘(D) LIMITATION.—The requirement 

12 under subparagraph (C) shall not include any 

13 report or other documents resulting from a con14 sultative audit, except that the Secretary may 

15 access the results of a consultative audit in ac16 cordance with section 704. 

17 ‘‘(E) DECLARATION OF AUDIT TYPE.—Be18 fore an accredited third-party auditor begins 

19 any audit or provides any consultative service to 

20 an eligible entity, both the accredited third21 party auditor and eligible entity shall establish 

22 in writing whether the audit is intended to be 

23 a drug safety and quality audit. Any audit, in24 spection, or consultative service of any type pro25 vided by an accredited third-party auditor on 

mstockstill on DSK4VPTVN1PROD with BILLS

203 

•S 2516 PCS

1 behalf of an eligible entity shall be presumed to 

2 be a drug safety and quality audit in the ab3 sence of such a written agreement. Once a drug 

4 safety and quality audit is initiated, it shall be 

5 subject to the requirements of this section, and 

6 no person may withhold from the Secretary any 

7 document subject to subparagraph (C) on the 

8 grounds that the audit was a consultative audit 

9 or otherwise not a drug safety and quality 

10 audit. 

11 ‘‘(F) RULE OF CONSTRUCTION.—Nothing 

12 in this section shall be construed to limit the 

13 authority of the Secretary under section 704. 

14 ‘‘(6) REQUIREMENTS REGARDING SERIOUS

15 RISKS TO THE PUBLIC HEALTH.—If, at any time 

16 during a drug safety and quality audit, an accredited 

17 third-party auditor or an audit agent of such auditor 

18 discovers a condition that could cause or contribute 

19 to a serious risk to the public health, such auditor 

20 shall immediately notify the Secretary of— 

21 ‘‘(A) the identity and location of the eligi22 ble entity subject to the drug safety and quality 

23 audit; and 

24 ‘‘(B) such condition. 

25 ‘‘(7) LIMITATIONS.— 

mstockstill on DSK4VPTVN1PROD with BILLS

204 

•S 2516 PCS

1 ‘‘(A) IN GENERAL.—An audit agent of an 

2 accredited third-party auditor may not perform 

3 a drug safety and quality audit of an eligible 

4 entity if such audit agent has performed a drug 

5 safety and quality audit or consultative audit of 

6 such eligible entity during the previous 13- 

7 month period. 

8 ‘‘(B) WAIVER.—The Secretary may waive 

9 the application of subparagraph (A) if the Sec10 retary determines that there is insufficient ac11 cess to accredited third-party auditors in a 

12 country or region or that the use of the same 

13 audit agent or accredited third-party auditor is 

14 otherwise necessary. 

15 ‘‘(8) CONFLICTS OF INTEREST.— 

16 ‘‘(A) ACCREDITATION BODIES.—A recog17 nized accreditation body shall— 

18 ‘‘(i) not be owned, managed, or con19 trolled by any person that owns or operates 

20 a third-party auditor to be accredited by 

21 such body; 

22 ‘‘(ii) in carrying out accreditation of 

23 third-party auditors under this section, 

24 have procedures to ensure against the use 

25 of any officer or employee of such body 

mstockstill on DSK4VPTVN1PROD with BILLS

205 

•S 2516 PCS

1 that has a financial conflict of interest re2 garding a third-party auditor to be accred3 ited by such body; and 

4 ‘‘(iii) annually make available to the 

5 Secretary disclosures of the extent to 

6 which such body and the officers and em7 ployees of such body have maintained com8 pliance with clauses (i) and (ii) relating to 

9 financial conflicts of interest. 

10 ‘‘(B) ACCREDITED THIRD-PARTY AUDI11 TORS.—An accredited third-party auditor 

12 shall— 

13 ‘‘(i) not be owned, managed, or con14 trolled by any person that owns or operates 

15 an eligible entity to be certified by such 

16 auditor; 

17 ‘‘(ii) in carrying out drug safety and 

18 quality audits of eligible entities under this 

19 section, have procedures to ensure against 

20 the use of any officer or employee of such 

21 auditor that has a financial conflict of in22 terest regarding an eligible entity to be 

23 certified by such auditor; and 

24 ‘‘(iii) annually make available to the 

25 Secretary disclosures of the extent to 

mstockstill on DSK4VPTVN1PROD with BILLS

206 

•S 2516 PCS

1 which such auditor and the officers and 

2 employees of such auditor have maintained 

3 compliance with clauses (i) and (ii) relat4 ing to financial conflicts of interest. 

5 ‘‘(C) AUDIT AGENTS.—An audit agent 

6 shall— 

7 ‘‘(i) not own or operate an eligible en8 tity to be audited by such agent; 

9 ‘‘(ii) in carrying out audits of eligible 

10 entities under this section, have procedures 

11 to ensure that such agent does not have a 

12 financial conflict of interest regarding an 

13 eligible entity to be audited by such agent; 

14 and 

15 ‘‘(iii) annually make available to the 

16 Secretary disclosures of the extent to 

17 which such agent has maintained compli18 ance with clauses (i) and (ii) relating to fi19 nancial conflicts of interest. 

20 ‘‘(d) FALSE STATEMENTS.—Any statement or rep21 resentation made— 

22 ‘‘(1) by an employee or agent of an eligible enti23 ty to an accredited third-party auditor or audit 

24 agent; or 

mstockstill on DSK4VPTVN1PROD with BILLS

207 

•S 2516 PCS

1 ‘‘(2) by an accreditation body, accredited third2 party auditor, or audit agent of such auditor to the 

3 Secretary, shall be subject to section 1001 of title 

4 18, United States Code. 

5 ‘‘(e) MONITORING.—To ensure compliance with the 

6 requirements of this section, the Secretary— 

7 ‘‘(1) shall periodically, or at least once every 4 

8 years, reevaluate the accreditation bodies described 

9 in subsection (b)(1); 

10 ‘‘(2) shall periodically, or at least once every 4 

11 years, evaluate the performance of each accredited 

12 third-party auditor, through the review of regulatory 

13 audit reports by such auditors, the compliance his14 tory as available of eligible entities certified by such 

15 auditors, and any other measures deemed necessary 

16 by the Secretary; 

17 ‘‘(3) may at any time, conduct an onsite audit 

18 of any eligible entity certified by an accredited third19 party auditor, with or without the auditor present; 

20 and 

21 ‘‘(4) shall take any other measures deemed nec22 essary by the Secretary. 

23 ‘‘(f) EFFECT OF AUDIT.—The results of a drug safe24 ty and quality audit by an accredited third-party auditor 

25 under this section— 

mstockstill on DSK4VPTVN1PROD with BILLS

208 

•S 2516 PCS

1 ‘‘(1) may be used by the eligible entity— 

2 ‘‘(A) as documentation of compliance with 

3 section 501(a)(2)(B) or section 801(r); and 

4 ‘‘(B) for other purposes as determined ap5 propriate by the Secretary; and 

6 ‘‘(2) shall be used by the Secretary in estab7 lishing the risk-based inspection schedules under sec8 tion 510(h). 

9 ‘‘(g) COSTS.— 

10 ‘‘(1) AUTHORIZED FEES OF SECRETARY.—The 

11 Secretary may assess fees on accreditation bodies 

12 and accredited third-party auditors in such an 

13 amount necessary to establish and administer the 

14 recognition and accreditation program under this 

15 section. The Secretary may require accredited third16 party auditors and audit agents to reimburse the 

17 Food and Drug Administration for the work per18 formed to carry out this section. The Secretary shall 

19 not generate surplus revenue from such a reimburse20 ment mechanism. Fees authorized under this para21 graph shall be collected and available for obligation 

22 only to the extent and in the amount provided in ad23 vance in appropriation Acts. Such fees are author24 ized to remain available until expended. 

mstockstill on DSK4VPTVN1PROD with BILLS

209 

•S 2516 PCS

1 ‘‘(2) AUTHORIZED FEES FOR RECOGNIZED AC2 CREDITATION BODIES.—An accreditation body rec3 ognized by the Secretary under subsection (b) may 

4 assess a reasonable fee to accredit third-party audi5 tors. 

6 ‘‘(h) LIMITATIONS.— 

7 ‘‘(1) NO EFFECT ON SECTION 704 INSPEC8 TIONS.—The drug safety and quality audits per9 formed under this section shall not be considered in10 spections under section 704. 

11 ‘‘(2) NO EFFECT ON INSPECTION AUTHOR12 ITY.—Nothing in this section affects the authority of 

13 the Secretary to inspect any eligible entity pursuant 

14 to this Act. 

15 ‘‘(i) REGULATIONS.— 

16 ‘‘(1) IN GENERAL.—Not later than 18 months 

17 after the date of enactment of the Food and Drug 

18 Administration Safety and Innovation Act, the Sec19 retary shall adopt final regulations implementing 

20 this section. 

21 ‘‘(2) PROCEDURE.—In promulgating the regula22 tions implementing this section, the Secretary 

23 shall— 

24 ‘‘(A) issue a notice of proposed rulemaking 

25 that includes the proposed regulation; 

mstockstill on DSK4VPTVN1PROD with BILLS

210 

•S 2516 PCS

1 ‘‘(B) provide a period of not less than 60 

2 days for comments on the proposed regulation; 

3 and 

4 ‘‘(C) publish the final regulation not less 

5 than 30 days before the effective date of the 

6 regulation. 

7 ‘‘(3) CONTENT.—Such regulations shall in8 clude— 

9 ‘‘(A) requirements that, to the extent prac10 ticable, drug safety and quality audits per11 formed under this section be unannounced; 

12 ‘‘(B) a structure to decrease the potential 

13 for conflicts of interest, including timing and 

14 public disclosure, for fees paid by eligible enti15 ties to accredited third-party auditors; and 

16 ‘‘(C) appropriate limits on financial affili17 ations between an accredited third-party audi18 tor or audit agents of such auditor and any per19 son that owns or operates an eligible entity to 

20 be audited by such auditor, as described in sub21 paragraphs (A) and (B). 

22 ‘‘(4) RESTRICTIONS.—Notwithstanding any 

23 other provision of law, the Secretary shall promul24 gate regulations implementing this section only as 

25 described in paragraph (2).’’. 

mstockstill on DSK4VPTVN1PROD with BILLS

211 

•S 2516 PCS

1 (b) REPORT ON ACCREDITED THIRD-PARTY AUDI2 TORS.—Not later than January 20, 2017, the Comptroller 

3 General of the United States shall submit to Congress a 

4 report that addresses the following, with respect to the pe5 riod beginning on the date of implementation of section 

6 809 of the Federal Food, Drug, and Cosmetic Act (as 

7 added by subsection (a)) and ending on the date of such 

8 report: 

9 (1) The extent to which drug safety and quality 

10 audits completed by accredited third-party auditors 

11 under such section 809 are being used by the Sec12 retary of Health and Human Services (referred to in 

13 this subsection as the ‘‘Secretary’’) in establishing or 

14 applying the risk-based inspection schedules under 

15 section 510(h) of such Act (as amended by section 

16 705). 

17 (2) The extent to which drug safety and quality 

18 audits completed by accredited third-party auditors 

19 or agents are assisting the Food and Drug Adminis20 tration in evaluating compliance with sections 

21 501(a)(2)(B) of such Act (21 U.S.C. 351(a)(2)(B)) 

22 and 801(r) of such Act (as added by section 711). 

23 (3) Whether the Secretary has been able to ac24 cess drug safety and quality audit reports completed 

mstockstill on DSK4VPTVN1PROD with BILLS

212 

•S 2516 PCS

1 by accredited third-party auditors under such section 

2 809. 

3 (4) Whether accredited third-party auditors ac4 credited under such section 809 have adhered to the 

5 conflict of interest provisions set forth in such sec6 tion. 

7 (5) The extent to which the Secretary has au8 dited recognized accreditation bodies or accredited 

9 third-party auditors to ensure compliance with the 

10 requirements of such section 809. 

11 (6) The number of waivers under subsection 

12 (c)(7)(B) of such section 809 issued during the most 

13 recent 12-month period and the official justification 

14 by the Secretary for each determination that there 

15 was insufficient access to an accredited third-party 

16 auditor. 

17 (7) The number of times a manufacturer has 

18 used the same accredited third-party auditor for 2 or 

19 more consecutive drug safety and quality audits 

20 under such section 809. 

21 (8) Recommendations to Congress regarding 

22 the accreditation program under such section 809, 

23 including whether Congress should continue, modify, 

24 or terminate the program. 

mstockstill on DSK4VPTVN1PROD with BILLS

213 

•S 2516 PCS

1 SEC. 711. STANDARDS FOR ADMISSION OF IMPORTED 

2 DRUGS. 

3 Section 801 (21 U.S.C. 381) is amended— 

4 (1) in subsection (o), by striking ‘‘drug or’’; 

5 and 

6 (2) by adding at the end the following: 

7 ‘‘(r)(1) The Secretary may require, as a condition of 

8 granting admission to a drug imported or offered for im9 port into the United States, that the importer electroni10 cally submit information demonstrating that the drug 

11 complies with applicable requirements of this Act. 

12 ‘‘(2) The information described under paragraph (1) 

13 may include— 

14 ‘‘(A) information demonstrating the regulatory 

15 status of the drug, such as the new drug application, 

16 abbreviated new drug application, or investigational 

17 new drug or drug master file number; 

18 ‘‘(B) facility information, such as proof of reg19 istration and the unique facility identifier; 

20 ‘‘(C) indication of compliance with current good 

21 manufacturing practice, testing results, certifications 

22 relating to satisfactory inspections, and compliance 

23 with the country of export regulations; and 

24 ‘‘(D) any other information deemed necessary 

25 and appropriate by the Secretary to assess compli26 ance of the article being offered for import. 

mstockstill on DSK4VPTVN1PROD with BILLS

214 

•S 2516 PCS

1 ‘‘(3) Information requirements referred to in para2 graph (2)(C) may, at the discretion of the Secretary, be 

3 satisfied— 

4 ‘‘(A) by certifications from accredited third par5 ties, as described under section 809; 

6 ‘‘(B) through representation by a foreign gov7 ernment, if such inspection is conducted using 

8 standards and practices as agreed to by the Sec9 retary; or 

10 ‘‘(C) other appropriate documentation or evi11 dence as described by the Secretary. 

12 ‘‘(4)(A) Not later than 18 months after the date of 

13 enactment of the Food and Drug Administration Safety 

14 and Innovation Act, the Secretary shall adopt final regula15 tions implementing this subsection. Such requirements 

16 shall be appropriate for the type of import, such as wheth17 er the drug is for import into the United States for use 

18 in preclinical research or in a clinical investigation under 

19 an investigational new drug exemption under 505(i). 

20 ‘‘(B) In promulgating the regulations implementing 

21 this subsection, the Secretary shall— 

22 ‘‘(i) issue a notice of proposed rulemaking that 

23 includes the proposed regulation; 

24 ‘‘(ii) provide a period of not less than 60 days 

25 for comments on the proposed regulation; and 

mstockstill on DSK4VPTVN1PROD with BILLS

215 

•S 2516 PCS

1 ‘‘(iii) publish the final regulation not less than 

2 30 days before the effective date of the regulation. 

3 ‘‘(C) Notwithstanding any other provision of law, the 

4 Secretary shall promulgate regulations implementing this 

5 subsection only as described in subparagraph (B).’’. 

6 SEC. 712. NOTIFICATION. 

7 (a) PROHIBITED ACTS.—Section 301 (21 U.S.C. 

8 331) is amended by adding at the end the following: 

9 ‘‘(aaa) The failure to notify the Secretary in violation 

10 of section 568.’’. 

11 (b) NOTIFICATION.— 

12 (1) IN GENERAL.—Subchapter E of chapter V 

13 (21 U.S.C. 360bbb et seq.) is amended by adding at 

14 the end the following: 

15 ‘‘SEC. 568. NOTIFICATION. 

16 ‘‘(a) NOTIFICATION TO SECRETARY.—With respect 

17 to a drug, the Secretary may require notification to the 

18 Secretary by a covered person if the covered person 

19 knows— 

20 ‘‘(1) of a substantial loss or theft of such drug; 

21 or 

22 ‘‘(2) that such drug— 

23 ‘‘(A) has been or is being counterfeited; 

24 and 

mstockstill on DSK4VPTVN1PROD with BILLS

216 

•S 2516 PCS

1 ‘‘(B)(i) is the counterfeit product in com2 merce in the United States; or 

3 ‘‘(ii) is offered for import into the United 

4 States. 

5 ‘‘(b) MANNER OF NOTIFICATION.—Notification 

6 under this section shall be made in a reasonable time, in 

7 such reasonable manner, and by such reasonable means 

8 as the Secretary may require by regulation or specify in 

9 guidance. 

10 ‘‘(c) DEFINITION.—In this section, the term ‘covered 

11 person’ means— 

12 ‘‘(1) a person who is required to register under 

13 section 510 with respect to an establishment en14 gaged in the manufacture, preparation, propagation, 

15 compounding, or processing of a drug; or 

16 ‘‘(2) a person engaged in the wholesale distribu17 tion (as defined in section 503(e)(3)(B)) of a drug.’’. 

18 (2) APPLICABILITY.—Notifications under sec19 tion 568 of the Federal Food, Drug, and Cosmetic 

20 Act (as added by paragraph (1)) apply to losses, 

21 thefts, or counterfeiting, as described in subsection 

22 (a) of such section 568, that occur on or after the 

23 date of enactment of this Act. 

mstockstill on DSK4VPTVN1PROD with BILLS

217 

•S 2516 PCS

1 SEC. 713. PROTECTION AGAINST INTENTIONAL ADULTERA2 TION. 

3 Section 303(b) (21 U.S.C. 333(b)) is amended by 

4 adding at the end the following: 

5 ‘‘(7) Notwithstanding subsection (a)(2), any person 

6 that knowingly and intentionally adulterates a drug such 

7 that the drug is adulterated under subsection (a)(1), (b), 

8 (c), or (d) of section 501 and has a reasonable probability 

9 of causing serious adverse health consequences or death 

10 to humans or animals shall be imprisoned for not more 

11 than 20 years or fined not more than $1,000,000, or 

12 both.’’. 

13 SEC. 714. ENHANCED CRIMINAL PENALTY FOR COUNTER14 FEITING DRUGS. 

15 Section 303(b) (21 U.S.C. 333(b)), as amended by 

16 section 713, is further amended by adding at the end the 

17 following: 

18 ‘‘(8) Notwithstanding subsection (a)(2), any person 

19 who knowingly and intentionally violates section 301(i) 

20 shall be imprisoned for not more than 20 years or fined 

21 not more than $4,000,000 or both.’’. 

22 SEC. 715. EXTRATERRITORIAL JURISDICTION. 

23 Chapter III (21 U.S.C. 331 et seq.) is amended by 

24 adding at the end the following: 

mstockstill on DSK4VPTVN1PROD with BILLS

218 

•S 2516 PCS

1 ‘‘SEC. 311. EXTRATERRITORIAL JURISDICTION. 

2 ‘‘There is extraterritorial jurisdiction over any viola3 tion of this Act relating to any article regulated under this 

4 Act if such article was intended for import into the United 

5 States or if any act in furtherance of the violation was 

6 committed in the United States.’’. 

7 SEC. 716. COMPLIANCE WITH INTERNATIONAL AGREE8 MENTS. 

9 The provisions of this title (and the amendments 

10 made by this title) shall be applied in a manner that the 

11 Secretary of Health and Human Services, in consultation 

12 with the United States Trade Representative, considers 

13 necessary to comply with the obligations of the United 

14 States under international agreements. 

15 TITLE VIII—GENERATING 

16 ANTIBIOTIC INCENTIVES NOW 

17 SEC. 801. EXTENSION OF EXCLUSIVITY PERIOD FOR DRUGS. 

18 (a) IN GENERAL.—Chapter V (21 U.S.C. 351 et seq.) 

19 is amended by inserting after section 505D the following: 

20 ‘‘SEC. 505E. EXTENSION OF EXCLUSIVITY PERIOD FOR NEW 

21 QUALIFIED INFECTIOUS DISEASE PRODUCTS. 

22 ‘‘(a) EXTENSION.—If the Secretary approves an ap23 plication pursuant to section 505 for a drug that has been 

24 designated as a qualified infectious disease product under 

25 subsection (d), the 4- and 5-year periods described in sub26 sections (c)(3)(E)(ii) and (j)(5)(F)(ii) of section 505, the 

mstockstill on DSK4VPTVN1PROD with BILLS

219 

•S 2516 PCS

1 3-year periods described in clauses (iii) and (iv) of sub2 section (c)(3)(E) and clauses (iii) and (iv) of subsection 

3 (j)(5)(F) of section 505, or the 7-year period described 

4 in section 527, as applicable, shall be extended by 5 years. 

5 ‘‘(b) RELATION TO PEDIATRIC EXCLUSIVITY.—Any 

6 extension under subsection (a) of a period shall be in addi7 tion to any extension of the period under section 505A 

8 with respect to the drug. 

9 ‘‘(c) LIMITATIONS.—Subsection (a) does not apply to 

10 the approval of— 

11 ‘‘(1) a supplement to an application under sec12 tion 505(b) for any qualified infectious disease prod13 uct for which an extension described in subsection 

14 (a) is in effect or has expired; 

15 ‘‘(2) a subsequent application filed with respect 

16 to a product approved under section 505 for a 

17 change that results in a new indication, route of ad18 ministration, dosing schedule, dosage form, delivery 

19 system, delivery device, or strength; or 

20 ‘‘(3) an application for a product that is not ap21 proved for the use for which it received a designa22 tion under subsection (d). 

23 ‘‘(d) DESIGNATION.— 

24 ‘‘(1) IN GENERAL.—The manufacturer or spon25 sor of a drug may request the Secretary to designate 

mstockstill on DSK4VPTVN1PROD with BILLS

220 

•S 2516 PCS

1 a drug as a qualified infectious disease product at 

2 any time before the submission of an application 

3 under section 505(b) for such drug. The Secretary 

4 shall, not later than 60 days after the submission of 

5 such a request, determine whether the drug is a 

6 qualified infectious disease product. 

7 ‘‘(2) LIMITATION.—Except as provided in para8 graph (3), a designation under this subsection shall 

9 not be withdrawn for any reason, including modifica10 tions to the list of qualifying pathogens under sub11 section (f)(2)(C). 

12 ‘‘(3) REVOCATION OF DESIGNATION.—The Sec13 retary may revoke a designation of a drug as a 

14 qualified infectious disease product if the Secretary 

15 finds that the request for such designation contained 

16 an untrue statement of material fact. 

17 ‘‘(e) REGULATIONS.— 

18 ‘‘(1) IN GENERAL.—Not later than 2 years 

19 after the date of enactment of the Food and Drug 

20 Administration Safety and Innovation Act, the Sec21 retary shall adopt final regulations implementing 

22 this section. 

23 ‘‘(2) PROCEDURE.—In promulgating a regula24 tion implementing this section, the Secretary shall— 

mstockstill on DSK4VPTVN1PROD with BILLS

221 

•S 2516 PCS

1 ‘‘(A) issue a notice of proposed rulemaking 

2 that includes the proposed regulation; 

3 ‘‘(B) provide a period of not less than 60 

4 days for comments on the proposed regulation; 

5 and 

6 ‘‘(C) publish the final regulation not less 

7 than 30 days before the effective date of the 

8 regulation. 

9 ‘‘(3) RESTRICTIONS.—Notwithstanding any 

10 other provision of law, the Secretary shall promul11 gate regulations implementing this section only as 

12 described in paragraph (2), except that the Sec13 retary may issue interim guidance for sponsors seek14 ing designation under subsection (d) prior to the 

15 promulgation of such regulations. 

16 ‘‘(4) DESIGNATION PRIOR TO REGULATIONS.— 

17 The Secretary may designate drugs as qualified in18 fectious disease products under subsection (d) prior 

19 to the promulgation of regulations under this sub20 section. 

21 ‘‘(f) QUALIFYING PATHOGEN.— 

22 ‘‘(1) DEFINITION.—In this section, the term 

23 ‘qualifying pathogen’ means a pathogen identified 

24 and listed by the Secretary under paragraph (2) that 

mstockstill on DSK4VPTVN1PROD with BILLS

222 

•S 2516 PCS

1 has the potential to pose a serious threat to public 

2 health, such as— 

3 ‘‘(A) resistant gram positive pathogens, in4 cluding methicillin-resistant Staphylococcus 

5 aureus, vancomycin-resistant Staphylococcus 

6 aureus, and vancomycin-resistant enterococcus; 

7 ‘‘(B) multi-drug resistant gram negative 

8 bacteria, including Acinetobacter, Klebsiella, 

9 Pseudomonas, and E. coli species; 

10 ‘‘(C) multi-drug resistant tuberculosis; and 

11 ‘‘(D) Clostridium difficile. 

12 ‘‘(2) LIST OF QUALIFYING PATHOGENS.— 

13 ‘‘(A) IN GENERAL.—The Secretary shall 

14 establish and maintain a list of qualifying 

15 pathogens, and shall make public the method16 ology for developing such list. 

17 ‘‘(B) CONSIDERATIONS.—In establishing 

18 and maintaining the list of pathogens described 

19 under this section the Secretary shall— 

20 ‘‘(i) consider— 

21 ‘‘(I) the impact on the public 

22 health due to drug-resistant orga23 nisms in humans; 

24 ‘‘(II) the rate of growth of drug25 resistant organisms in humans; 

mstockstill on DSK4VPTVN1PROD with BILLS

223 

•S 2516 PCS

1 ‘‘(III) the increase in resistance 

2 rates in humans; and 

3 ‘‘(IV) the morbidity and mor4 tality in humans; and 

5 ‘‘(ii) consult with experts in infectious 

6 diseases and antibiotic resistance, includ7 ing the Centers for Disease Control and 

8 Prevention, the Food and Drug Adminis9 tration, medical professionals, and the clin10 ical research community. 

11 ‘‘(C) REVIEW.—Every 5 years, or more 

12 often as needed, the Secretary shall review, pro13 vide modifications to, and publish the list of 

14 qualifying pathogens under subparagraph (A) 

15 and shall by regulation revise the list as nec16 essary, in accordance with subsection (e). 

17 ‘‘(g) QUALIFIED INFECTIOUS DISEASE PRODUCT.— 

18 The term ‘qualified infectious disease product’ means an 

19 antibacterial or antifungal drug for human use intended 

20 to treat serious or life-threatening infections, including 

21 those caused by— 

22 ‘‘(1) an antibacterial or antifungal resistant 

23 pathogen, including novel or emerging infectious 

24 pathogens; or 

mstockstill on DSK4VPTVN1PROD with BILLS

224 

•S 2516 PCS

1 ‘‘(2) qualifying pathogens listed by the Sec2 retary under subsection (f).’’. 

3 (b) APPLICATION.—Section 505E of the Federal 

4 Food, Drug, and Cosmetic Act, as added by subsection 

5 (a), applies only with respect to a drug that is first ap6 proved under section 505(c) of such Act (21 U.S.C. 

7 355(c)) on or after the date of the enactment of this Act. 

8 SEC. 802. PRIORITY REVIEW. 

9 (a) AMENDMENT.—Chapter V (21 U.S.C. 351 et 

10 seq.) is amended by inserting after section 524 the fol11 lowing: 

12 ‘‘SEC. 524A. PRIORITY REVIEW FOR QUALIFIED INFECTIOUS 

13 DISEASE PRODUCTS. 

14 ‘‘If the Secretary designates a drug under section 

15 505E(d) as a qualified infectious disease product, then the 

16 Secretary shall give priority review to any application sub17 mitted for approval for such drug under section 505(b).’’. 

18 (b) APPLICATION.—Section 524A of the Federal 

19 Food, Drug, and Cosmetic Act, as added by subsection 

20 (a), applies only with respect to an application that is sub21 mitted under section 505(b) of such Act (21 U.S.C. 

22 355(b)) on or after the date of the enactment of this Act. 

23 SEC. 803. FAST TRACK PRODUCT. 

24 Section 506(a)(1) (21 U.S.C. 356(a)(1)), as amended 

25 by section 901(b), is amended by inserting ‘‘, or if the 

mstockstill on DSK4VPTVN1PROD with BILLS

225 

•S 2516 PCS

1 Secretary designates the drug as a qualified infectious dis2 ease product under section 505E(d)’’ before the period at 

3 the end of the first sentence. 

4 SEC. 804. GAO STUDY. 

5 (a) IN GENERAL.—The Comptroller General of the 

6 United States shall— 

7 (1) conduct a study— 

8 (A) on the need for, and public health im9 pact of, incentives to encourage the research, 

10 development, and marketing of qualified infec11 tious disease biological products and antifungal 

12 products; and 

13 (B) consistent with trade and confiden14 tiality data protections, assessing, for all anti15 bacterial and antifungal drugs, including bio16 logical products, the average or aggregate— 

17 (i) costs of all clinical trials for each 

18 phase; 

19 (ii) percentage of success or failure at 

20 each phase of clinical trials; and 

21 (iii) public versus private funding lev22 els of the trials for each phase; and 

23 (2) not later than 1 year after the date of en24 actment of this Act, submit a report to Congress on 

25 the results of such study, including any recmstockstill on DSK4VPTVN1PROD with BILLS

226 

•S 2516 PCS

1 ommendations of the Comptroller General on appro2 priate incentives for addressing such need. 

3 (b) CONTENTS.—The part of the study described in 

4 subsection (a)(1)(A) shall include— 

5 (1) an assessment of any underlying regulatory 

6 issues related to qualified infectious disease prod7 ucts, including qualified infectious disease biological 

8 products; 

9 (2) an assessment of the management by the 

10 Food and Drug Administration of the review of 

11 qualified infectious disease products, including quali12 fied infectious disease biological products and the 

13 regulatory certainty of related regulatory pathways 

14 for such products; 

15 (3) a description of any regulatory impediments 

16 to the clinical development of new qualified infec17 tious disease products, including qualified infectious 

18 disease biological products, and the efforts of the 

19 Food and Drug Administration to address such im20 pediments; and 

21 (4) recommendations with respect to— 

22 (A) improving the review and predictability 

23 of regulatory pathways for such products; and 

24 (B) overcoming any regulatory impedi25 ments identified in paragraph (3). 

mstockstill on DSK4VPTVN1PROD with BILLS

227 

•S 2516 PCS

1 (c) DEFINITIONS.—In this section: 

2 (1) The term ‘‘biological product’’ has the 

3 meaning given to such term in section 351 of the 

4 Public Health Service Act (42 U.S.C. 262). 

5 (2) The term ‘‘qualified infectious disease bio6 logical product’’ means a biological product intended 

7 to treat a serious or life-threatening infection de8 scribed in section 505E(g) of the Federal Food, 

9 Drug, and Cosmetic Act, as added by section 801. 

10 (3) The term ‘‘qualified infectious disease prod11 uct’’ has the meaning given such term in section 

12 505E(g) of the Federal Food, Drug, and Cosmetic 

13 Act, as added by section 801. 

14 SEC. 805. CLINICAL TRIALS. 

15 (a) REVIEW AND REVISION OF GUIDANCE DOCU16 MENTS.— 

17 (1) IN GENERAL.—The Secretary of Health and 

18 Human Services (referred to in this section as the 

19 ‘‘Secretary’’) shall review and, as appropriate, revise 

20 not fewer than 3 guidance documents per year, 

21 which shall include— 

22 (A) reviewing the guidance documents of 

23 the Food and Drug Administration for the con24 duct of clinical trials with respect to anti25 bacterial and antifungal drugs; and 

mstockstill on DSK4VPTVN1PROD with BILLS

228 

•S 2516 PCS

1 (B) as appropriate, revising such guidance 

2 documents to reflect developments in scientific 

3 and medical information and technology and to 

4 ensure clarity regarding the procedures and re5 quirements for approval of antibacterial and 

6 antifungal drugs under chapter V of the Fed7 eral Food, Drug, and Cosmetic Act (21 U.S.C. 

8 351 et seq.). 

9 (2) ISSUES FOR REVIEW.—At a minimum, the 

10 review under paragraph (1) shall address the appro11 priate animal models of infection, in vitro tech12 niques, valid micro-biological surrogate markers, the 

13 use of non-inferiority versus superiority trials, trial 

14 enrollment, data requirements, and appropriate delta 

15 values for non-inferiority trials. 

16 (3) RULE OF CONSTRUCTION.—Except to the 

17 extent to which the Secretary makes revisions under 

18 paragraph (1)(B), nothing in this section shall be 

19 construed to repeal or otherwise effect the guidance 

20 documents of the Food and Drug Administration. 

21 (b) RECOMMENDATIONS FOR INVESTIGATIONS.— 

22 (1) REQUEST.—The sponsor of a drug intended 

23 to be designated as a qualified infectious disease 

24 product may request that the Secretary provide writ25 ten recommendations for nonclinical and clinical inmstockstill on DSK4VPTVN1PROD with BILLS

229 

•S 2516 PCS

1 vestigations which the Secretary believes may be 

2 necessary to be conducted with the drug before such 

3 drug may be approved under section 505 of the Fed4 eral Food, Drug, and Cosmetic Act (21 U.S.C. 355) 

5 for use in treating, detecting, preventing, or identi6 fying a qualifying pathogen, as defined in section 

7 505E of such Act. 

8 (2) RECOMMENDATIONS.—If the Secretary has 

9 reason to believe that a drug for which a request is 

10 made under this subsection is a qualified infectious 

11 disease product, the Secretary shall provide the per12 son making the request written recommendations for 

13 the nonclinical and clinical investigations which the 

14 Secretary believes, on the basis of information avail15 able to the Secretary at the time of the request, 

16 would be necessary for approval under section 505 

17 of the Federal Food, Drug, and Cosmetic Act (21 

18 U.S.C. 355) of such drug for the use described in 

19 paragraph (1). 

20 (c) GAO STUDY.—Not later than January 1, 2016, 

21 the Comptroller General of the United States shall submit 

22 to Congress a report— 

23 (1) regarding the review and revision of the 

24 clinical trial guidance documents required under 

25 subsection (a) and the impact such review and revimstockstill on DSK4VPTVN1PROD with BILLS

230 

•S 2516 PCS

1 sion has had on the review and approval of qualified 

2 infectious disease products; 

3 (2) assessing— 

4 (A) the effectiveness of the results-oriented 

5 metrics managers employ to ensure that review6 ers of such products are familiar with, and con7 sistently applying, clinical trial guidance docu8 ments; and 

9 (B) the predictability of related regulatory 

10 pathways and review; 

11 (3) identifying any outstanding regulatory im12 pediments to the clinical development of qualified in13 fectious disease products; 

14 (4) reporting on the progress the Food and 

15 Drug Administration has made in addressing the im16 pediments identified under paragraph (3); and 

17 (5) containing recommendations regarding how 

18 to improve the review of, and regulatory pathway 

19 for, such products. 

20 (d) QUALIFIED INFECTIOUS DISEASE PRODUCT.— 

21 For purposes of this section, the term ‘‘qualified infectious 

22 disease product’’ has the meaning given such term in sec23 tion 505E(g) of the Federal Food, Drug, and Cosmetic 

24 Act, as added by section 801. 

mstockstill on DSK4VPTVN1PROD with BILLS

231 

•S 2516 PCS

1 SEC. 806. REGULATORY CERTAINTY AND PREDICTABILITY. 

2 (a) INITIAL STRATEGY AND IMPLEMENTATION

3 PLAN.—Not later than 1 year after the date of enactment 

4 of this Act, the Secretary of Health and Human Services 

5 (referred to in this section as the ‘‘Secretary’’) shall sub6 mit to Congress a strategy and implementation plan with 

7 respect to the requirements of this Act. The strategy and 

8 implementation plan shall include— 

9 (1) a description of the regulatory challenges to 

10 clinical development, approval, and licensure of 

11 qualified infectious disease products; 

12 (2) the regulatory and scientific priorities of the 

13 Secretary with respect to such challenges; and 

14 (3) the steps the Secretary will take to ensure 

15 regulatory certainty and predictability with respect 

16 to qualified infectious disease products, including 

17 steps the Secretary will take to ensure managers and 

18 reviewers are familiar with related regulatory path19 ways, requirements of the Food and Drug Adminis20 tration, guidance documents related to such prod21 ucts, and applying such requirements consistently. 

22 (b) SUBSEQUENT REPORT.—Not later than 3 years 

23 after the date of enactment of this Act, the Secretary shall 

24 submit to Congress a report on— 

25 (1) the progress made toward the priorities 

26 identified under subsection (a)(2); 

mstockstill on DSK4VPTVN1PROD with BILLS

232 

•S 2516 PCS

1 (2) the number of qualified infectious disease 

2 products that have been submitted for approval or li3 censure on or after the date of enactment of this 

4 Act; 

5 (3) a list of qualified infectious disease products 

6 with information on the types of exclusivity granted 

7 for each product, consistent with the information 

8 published under section 505(j)(7)(A)(iii) of the Fed9 eral Food, Drug, and Cosmetic Act (21 U.S.C. 

10 355(j)(7)(A)(iii)); 

11 (4) the number of such qualified infectious dis12 ease products and that have been approved or li13 censed on or after the date of enactment of this Act; 

14 and 

15 (5) the number of calendar days it took for the 

16 approval or licensure of the qualified infectious dis17 ease products approved or licensed on or after the 

18 date of enactment of this Act. 

19 (c) QUALIFIED INFECTIOUS DISEASE PRODUCT.— 

20 For purposes of this section, the term ‘‘qualified infectious 

21 disease product’’ has the meaning given such term in sec22 tion 505E(g) of the Federal Food, Drug, and Cosmetic 

23 Act, as added by section 801. 

mstockstill on DSK4VPTVN1PROD with BILLS

233 

•S 2516 PCS

1 TITLE IX—DRUG APPROVAL AND 

2 PATIENT ACCESS 

3 SEC. 901. ENHANCEMENT OF ACCELERATED PATIENT AC4 CESS TO NEW MEDICAL TREATMENTS. 

5 (a) FINDINGS; SENSE OF CONGRESS.— 

6 (1) FINDINGS.—Congress finds as follows: 

7 (A) The Food and Drug Administration 

8 (referred to in this section as the ‘‘FDA’’) 

9 serves a critical role in helping to assure that 

10 new medicines are safe and effective. Regu11 latory innovation is 1 element of the Nation’s 

12 strategy to address serious and life-threatening 

13 diseases or conditions by promoting investment 

14 in and development of innovative treatments for 

15 unmet medical needs. 

16 (B) During the 2 decades following the es17 tablishment of the accelerated approval mecha18 nism, advances in medical sciences, including 

19 genomics, molecular biology, and bioinformatics, 

20 have provided an unprecedented understanding 

21 of the underlying biological mechanism and 

22 pathogenesis of disease. A new generation of 

23 modern, targeted medicines is under develop24 ment to treat serious and life-threatening dis25 eases, some applying drug development stratemstockstill on DSK4VPTVN1PROD with BILLS

234 

•S 2516 PCS

1 gies based on biomarkers or pharmacogenomics, 

2 predictive toxicology, clinical trial enrichment 

3 techniques, and novel clinical trial designs, such 

4 as adaptive clinical trials. 

5 (C) As a result of these remarkable sci6 entific and medical advances, the FDA should 

7 be encouraged to implement more broadly effec8 tive processes for the expedited development 

9 and review of innovative new medicines in10 tended to address unmet medical needs for seri11 ous or life-threatening diseases or conditions, 

12 including those for rare diseases or conditions, 

13 using a broad range of surrogate or clinical 

14 endpoints and modern scientific tools earlier in 

15 the drug development cycle when appropriate. 

16 This may result in fewer, smaller, or shorter 

17 clinical trials for the intended patient popu18 lation or targeted subpopulation without com19 promising or altering the high standards of the 

20 FDA for the approval of drugs. 

21 (D) Patients benefit from expedited access 

22 to safe and effective innovative therapies to 

23 treat unmet medical needs for serious or life24 threatening diseases or conditions. 

mstockstill on DSK4VPTVN1PROD with BILLS

235 

•S 2516 PCS

1 (E) For these reasons, the statutory au2 thority in effect on the day before the date of 

3 enactment of this Act governing expedited ap4 proval of drugs for serious or life-threatening 

5 diseases or conditions should be amended in 

6 order to enhance the authority of the FDA to 

7 consider appropriate scientific data, methods, 

8 and tools, and to expedite development and ac9 cess to novel treatments for patients with a 

10 broad range of serious or life-threatening dis11 eases or conditions. 

12 (2) SENSE OF CONGRESS.—It is the sense of 

13 Congress that the Food and Drug Administration 

14 should apply the accelerated approval and fast track 

15 provisions set forth in section 506 of the Federal 

16 Food, Drug, and Cosmetic Act (21 U.S.C. 356), as 

17 amended by this section, to help expedite the devel18 opment and availability to patients of treatments for 

19 serious or life-threatening diseases or conditions 

20 while maintaining safety and effectiveness standards 

21 for such treatments. 

22 (b) EXPEDITED APPROVAL OF DRUGS FOR SERIOUS

23 OR LIFE-THREATENING DISEASES OR CONDITIONS.—Sec24 tion 506 (21 U.S.C. 356) is amended to read as follows: 

mstockstill on DSK4VPTVN1PROD with BILLS

236 

•S 2516 PCS

1 ‘‘SEC. 506. EXPEDITED APPROVAL OF DRUGS FOR SERIOUS 

2 OR LIFE-THREATENING DISEASES OR CONDI3 TIONS. 

4 ‘‘(a) DESIGNATION OF DRUG AS FAST TRACK PROD5 UCT.— 

6 ‘‘(1) IN GENERAL.—The Secretary shall, at the 

7 request of the sponsor of a new drug, facilitate the 

8 development and expedite the review of such drug if 

9 it is intended, whether alone or in combination with 

10 one or more other drugs, for the treatment of a seri11 ous or life-threatening disease or condition, and it 

12 demonstrates the potential to address unmet medical 

13 needs for such a disease or condition. (In this sec14 tion, such a drug is referred to as a ‘fast track prod15 uct’.) 

16 ‘‘(2) REQUEST FOR DESIGNATION.—The spon17 sor of a new drug may request the Secretary to des18 ignate the drug as a fast track product. A request 

19 for the designation may be made concurrently with, 

20 or at any time after, submission of an application 

21 for the investigation of the drug under section 505(i) 

22 or section 351(a)(3) of the Public Health Service 

23 Act. 

24 ‘‘(3) DESIGNATION.—Within 60 calendar days 

25 after the receipt of a request under paragraph (2), 

26 the Secretary shall determine whether the drug that 

mstockstill on DSK4VPTVN1PROD with BILLS

237 

•S 2516 PCS

1 is the subject of the request meets the criteria de2 scribed in paragraph (1). If the Secretary finds that 

3 the drug meets the criteria, the Secretary shall des4 ignate the drug as a fast track product and shall 

5 take such actions as are appropriate to expedite the 

6 development and review of the application for ap7 proval of such product. 

8 ‘‘(b) ACCELERATED APPROVAL OF A DRUG FOR A

9 SERIOUS OR LIFE-THREATENING DISEASE OR CONDI10 TION, INCLUDING A FAST TRACK PRODUCT.— 

11 ‘‘(1) IN GENERAL.— 

12 ‘‘(A) ACCELERATED APPROVAL.—The Sec13 retary may approve an application for approval 

14 of a product for a serious or life-threatening 

15 disease or condition, including a fast track 

16 product, under section 505(c) or section 351(a) 

17 of the Public Health Service Act upon a deter18 mination that the product has an effect on a 

19 surrogate endpoint that is reasonably likely to 

20 predict clinical benefit, or on a clinical endpoint 

21 that can be measured earlier than irreversible 

22 morbidity or mortality, that is reasonably likely 

23 to predict an effect on irreversible morbidity or 

24 mortality or other clinical benefit, taking into 

25 account the severity, rarity, or prevalence of the 

mstockstill on DSK4VPTVN1PROD with BILLS

238 

•S 2516 PCS

1 condition and the availability or lack of alter2 native treatments. The approval described in 

3 the preceding sentence is referred to in this sec4 tion as ‘accelerated approval’. 

5 ‘‘(B) EVIDENCE.—The evidence to support 

6 that an endpoint is reasonably likely to predict 

7 clinical benefit under subparagraph (A) may in8 clude epidemiological, pathophysiological, thera9 peutic, pharmacologic, or other evidence devel10 oped using biomarkers, for example, or other 

11 scientific methods or tools. 

12 ‘‘(2) LIMITATION.—Approval of a product 

13 under this subsection may be subject to 1 or both 

14 of the following requirements: 

15 ‘‘(A) That the sponsor conduct appropriate 

16 post-approval studies to verify and describe the 

17 predicted effect on irreversible morbidity or 

18 mortality or other clinical benefit. 

19 ‘‘(B) That the sponsor submit copies of all 

20 promotional materials related to the product 

21 during the preapproval review period and, fol22 lowing approval and for such period thereafter 

23 as the Secretary determines to be appropriate, 

24 at least 30 days prior to dissemination of the 

25 materials. 

mstockstill on DSK4VPTVN1PROD with BILLS

239 

•S 2516 PCS

1 ‘‘(3) EXPEDITED WITHDRAWAL OF AP2 PROVAL.—The Secretary may withdraw approval of 

3 a product approved under accelerated approval using 

4 expedited procedures (as prescribed by the Secretary 

5 in regulations which shall include an opportunity for 

6 an informal hearing) if— 

7 ‘‘(A) the sponsor fails to conduct any re8 quired post-approval study of the drug with due 

9 diligence; 

10 ‘‘(B) a study required to verify and de11 scribe the predicted effect on irreversible mor12 bidity or mortality or other clinical benefit of 

13 the product fails to verify and describe such ef14 fect or benefit; 

15 ‘‘(C) other evidence demonstrates that the 

16 product is not safe or effective under the condi17 tions of use; or 

18 ‘‘(D) the sponsor disseminates false or 

19 misleading promotional materials with respect 

20 to the product. 

21 ‘‘(c) REVIEW OF INCOMPLETE APPLICATIONS FOR

22 APPROVAL OF A FAST TRACK PRODUCT.— 

23 ‘‘(1) IN GENERAL.—If the Secretary deter24 mines, after preliminary evaluation of clinical data 

25 submitted by the sponsor, that a fast track product 

mstockstill on DSK4VPTVN1PROD with BILLS

240 

•S 2516 PCS

1 may be effective, the Secretary shall evaluate for fil2 ing, and may commence review of portions of, an ap3 plication for the approval of the product before the 

4 sponsor submits a complete application. The Sec5 retary shall commence such review only if the appli6 cant— 

7 ‘‘(A) provides a schedule for submission of 

8 information necessary to make the application 

9 complete; and 

10 ‘‘(B) pays any fee that may be required 

11 under section 736. 

12 ‘‘(2) EXCEPTION.—Any time period for review 

13 of human drug applications that has been agreed to 

14 by the Secretary and that has been set forth in goals 

15 identified in letters of the Secretary (relating to the 

16 use of fees collected under section 736 to expedite 

17 the drug development process and the review of 

18 human drug applications) shall not apply to an ap19 plication submitted under paragraph (1) until the 

20 date on which the application is complete. 

21 ‘‘(d) AWARENESS EFFORTS.—The Secretary shall— 

22 ‘‘(1) develop and disseminate to physicians, pa23 tient organizations, pharmaceutical and bio24 technology companies, and other appropriate persons 

25 a description of the provisions of this section applimstockstill on DSK4VPTVN1PROD with BILLS

241 

•S 2516 PCS

1 cable to accelerated approval and fast track prod2 ucts; and 

3 ‘‘(2) establish a program to encourage the de4 velopment of surrogate and clinical endpoints, in5 cluding biomarkers, and other scientific methods and 

6 tools that can assist the Secretary in determining 

7 whether the evidence submitted in an application is 

8 reasonably likely to predict clinical benefit for seri9 ous or life-threatening conditions for which signifi10 cant unmet medical needs exist. 

11 ‘‘(e) CONSTRUCTION.— 

12 ‘‘(1) PURPOSE.—The amendments made by the 

13 Food and Drug Administration Safety and Innova14 tion Act to this section are intended to encourage 

15 the Secretary to utilize innovative and flexible ap16 proaches to the assessment of products under accel17 erated approval for treatments for patients with seri18 ous or life-threatening diseases or conditions and 

19 unmet medical needs. 

20 ‘‘(2) CONSTRUCTION.—Nothing in this section 

21 shall be construed to alter the standards of evidence 

22 under subsection (c) or (d) of section 505 (including 

23 the substantial evidence standard in section 505(d)) 

24 of this Act or under section 351(a) of the Public 

25 Health Service Act. Such sections and standards of 

mstockstill on DSK4VPTVN1PROD with BILLS

242 

•S 2516 PCS

1 evidence apply to the review and approval of prod2 ucts under this section, including whether a product 

3 is safe and effective. Nothing in this section alters 

4 the ability of the Secretary to rely on evidence that 

5 does not come from adequate and well-controlled in6 vestigations for the purpose of determining whether 

7 an endpoint is reasonably likely to predict clinical 

8 benefit as described in subsection (b)(1)(B).’’. 

9 (c) GUIDANCE; AMENDED REGULATIONS.— 

10 (1) DRAFT GUIDANCE.—Not later than 1 year 

11 after the date of enactment of this Act, the Sec12 retary of Health and Human Services (referred to in 

13 this section as the ‘‘Secretary’’) shall issue draft 

14 guidance to implement the amendments made by 

15 this section. In developing such guidance, the Sec16 retary shall specifically consider issues arising under 

17 the accelerated approval and fast track processes 

18 under section 506 of the Federal Food, Drug, and 

19 Cosmetic Act, as amended by subsection (b), for 

20 drugs designated for a rare disease or condition 

21 under section 526 of such Act (21 U.S.C. 360bb) 

22 and shall also consider any unique issues associated 

23 with very rare diseases. 

24 (2) FINAL GUIDANCE.—Not later than 1 year 

25 after the issuance of draft guidance under paramstockstill on DSK4VPTVN1PROD with BILLS

243 

•S 2516 PCS

1 graph (1), and after an opportunity for public com2 ment, the Secretary shall issue final guidance. 

3 (3) CONFORMING CHANGES.—The Secretary 

4 shall issue, as necessary, conforming amendments to 

5 the applicable regulations under title 21, Code of 

6 Federal Regulations, governing accelerated approval. 

7 (4) NO EFFECT OF INACTION ON REQUESTS.— 

8 If the Secretary fails to issue final guidance or 

9 amended regulations as required by this subsection, 

10 such failure shall not preclude the review of, or ac11 tion on, a request for designation or an application 

12 for approval submitted pursuant to section 506 of 

13 the Federal Food, Drug, and Cosmetic Act, as 

14 amended by subsection (b). 

15 (d) INDEPENDENT REVIEW.—The Secretary may, in 

16 conjunction with other planned reviews, contract with an 

17 independent entity with expertise in assessing the quality 

18 and efficiency of biopharmaceutical development and regu19 latory review programs to evaluate the Food and Drug Ad20 ministration’s application of the processes described in 

21 section 506 of the Federal Food, Drug, and Cosmetic Act, 

22 as amended by subsection (b), and the impact of such 

23 processes on the development and timely availability of in24 novative treatments for patients suffering from serious or 

25 life-threatening conditions. Any such evaluation shall inmstockstill on DSK4VPTVN1PROD with BILLS

244 

•S 2516 PCS

1 clude consultation with regulated industries, patient advo2 cacy and disease research foundations, and relevant aca3 demic medical centers. 

4 SEC. 902. BREAKTHROUGH THERAPIES. 

5 (a) IN GENERAL.—Section 506 (21 U.S.C. 356), as 

6 amended by section 901, is further amended— 

7 (1) by redesignating subsections (a) through (c) 

8 as subsections (b) through (d), respectively; 

9 (2) by redesignating subsection (d) as sub10 section (f); 

11 (3) by inserting before subsection (b), as so re12 designated, the following: 

13 ‘‘(a) DESIGNATION OF A DRUG AS A BREAKTHROUGH

14 THERAPY.— 

15 ‘‘(1) IN GENERAL.—The Secretary shall, at the 

16 request of the sponsor of a drug, expedite the devel17 opment and review of such drug if the drug is in18 tended, alone or in combination with 1 or more other 

19 drugs, to treat a serious or life-threatening disease 

20 or condition and preliminary clinical evidence indi21 cates that the drug may demonstrate substantial im22 provement over existing therapies on 1 or more clini23 cally significant endpoints, such as substantial treat24 ment effects observed early in clinical development. 

mstockstill on DSK4VPTVN1PROD with BILLS

245 

•S 2516 PCS

1 (In this section, such a drug is referred to as a 

2 ‘breakthrough therapy’.) 

3 ‘‘(2) REQUEST FOR DESIGNATION.—The spon4 sor of a drug may request the Secretary to designate 

5 the drug as a breakthrough therapy. A request for 

6 the designation may be made concurrently with, or 

7 at any time after, the submission of an application 

8 for the investigation of the drug under section 505(i) 

9 or section 351(a)(3) of the Public Health Service 

10 Act. 

11 ‘‘(3) DESIGNATION.— 

12 ‘‘(A) IN GENERAL.—Not later than 60 cal13 endar days after the receipt of a request under 

14 paragraph (2), the Secretary shall determine 

15 whether the drug that is the subject of the re16 quest meets the criteria described in paragraph 

17 (1). If the Secretary finds that the drug meets 

18 the criteria, the Secretary shall designate the 

19 drug as a breakthrough therapy and shall take 

20 such actions as are appropriate to expedite the 

21 development and review of the application for 

22 approval of such drug. 

23 ‘‘(B) ACTIONS.—The actions to expedite 

24 the development and review of an application 

mstockstill on DSK4VPTVN1PROD with BILLS

246 

•S 2516 PCS

1 under subparagraph (A) may include, as appro2 priate— 

3 ‘‘(i) holding meetings with the sponsor 

4 and the review team throughout the devel5 opment of the drug; 

6 ‘‘(ii) providing timely advice to, and 

7 interactive communication with, the spon8 sor regarding the development of the drug 

9 to ensure that the development program to 

10 gather the non-clinical and clinical data 

11 necessary for approval is as efficient as 

12 practicable; 

13 ‘‘(iii) involving senior managers and 

14 experienced review staff, as appropriate, in 

15 a collaborative, cross-disciplinary review; 

16 ‘‘(iv) assigning a cross-disciplinary 

17 project lead for the Food and Drug Ad18 ministration review team to facilitate an 

19 efficient review of the development pro20 gram and to serve as a scientific liaison be21 tween the review team and the sponsor; 

22 and 

23 ‘‘(v) taking steps to ensure that the 

24 design of the clinical trials is as efficient as 

25 practicable, when scientifically appropriate, 

mstockstill on DSK4VPTVN1PROD with BILLS

247 

•S 2516 PCS

1 such as by minimizing the number of pa2 tients exposed to a potentially less effica3 cious treatment.’’; 

4 (4) in subsection (f)(1), as so redesignated, by 

5 striking ‘‘applicable to accelerated approval’’ and in6 serting ‘‘applicable to breakthrough therapies, accel7 erated approval, and’’; and 

8 (5) by adding at the end the following: 

9 ‘‘(g) REPORT.—Beginning in fiscal year 2013, the 

10 Secretary shall annually prepare and submit to the Com11 mittee on Health, Education, Labor, and Pensions of the 

12 Senate and the Committee on Energy and Commerce of 

13 the House of Representatives, and make publicly available, 

14 with respect to this section for the previous fiscal year— 

15 ‘‘(1) the number of drugs for which a sponsor 

16 requested designation as a breakthrough therapy; 

17 ‘‘(2) the number of products designated as a 

18 breakthrough therapy; and 

19 ‘‘(3) for each product designated as a break20 through therapy, a summary of the actions taken 

21 under subsection (a)(3).’’. 

22 (b) GUIDANCE; AMENDED REGULATIONS.— 

23 (1) IN GENERAL.— 

24 (A) GUIDANCE.—Not later than 18 

25 months after the date of enactment of this Act, 

mstockstill on DSK4VPTVN1PROD with BILLS

248 

•S 2516 PCS

1 the Secretary of Health and Human Services 

2 (referred to in this section as the ‘‘Secretary’’) 

3 shall issue draft guidance on implementing the 

4 requirements with respect to breakthrough 

5 therapies, as set forth in section 506(a) of the 

6 Federal Food, Drug, and Cosmetic Act (21 

7 U.S.C. 356(a)), as amended by this section. 

8 The Secretary shall issue final guidance not 

9 later than 1 year after the close of the comment 

10 period for the draft guidance. 

11 (B) AMENDED REGULATIONS.— 

12 (i) IN GENERAL.—If the Secretary de13 termines that it is necessary to amend the 

14 regulations under title 21, Code of Federal 

15 Regulations in order to implement the 

16 amendments made by this section to sec17 tion 506(a) of the Federal Food, Drug, 

18 and Cosmetic Act, the Secretary shall 

19 amend such regulations not later than 2 

20 years after the date of enactment of this 

21 Act. 

22 (ii) PROCEDURE.—In amending regu23 lations under clause (i), the Secretary 

24 shall— 

mstockstill on DSK4VPTVN1PROD with BILLS

249 

•S 2516 PCS

1 (I) issue a notice of proposed 

2 rulemaking that includes the proposed 

3 regulation; 

4 (II) provide a period of not less 

5 than 60 days for comments on the 

6 proposed regulation; and 

7 (III) publish the final regulation 

8 not less than 30 days before the effec9 tive date of the regulation. 

10 (iii) RESTRICTIONS.—Notwithstanding 

11 any other provision of law, the Secretary 

12 shall promulgate regulations implementing 

13 the amendments made by section only as 

14 described in clause (ii). 

15 (2) REQUIREMENTS.—Guidance issued under 

16 this section shall— 

17 (A) specify the process and criteria by 

18 which the Secretary makes a designation under 

19 section 506(a)(3) of the Federal Food, Drug, 

20 and Cosmetic Act; and 

21 (B) specify the actions the Secretary shall 

22 take to expedite the development and review of 

23 a breakthrough therapy pursuant to such des24 ignation under such section 506(a)(3), includmstockstill on DSK4VPTVN1PROD with BILLS

250 

•S 2516 PCS

1 ing updating good review management practices 

2 to reflect breakthrough therapies. 

3 (c) INDEPENDENT REVIEW.—Not later than 3 years 

4 after the date of enactment of this Act, the Comptroller 

5 General of the United States, in consultation with appro6 priate experts, shall assess the manner by which the Food 

7 and Drug Administration has applied the processes de8 scribed in section 506(a) of the Federal Food, Drug, and 

9 Cosmetic Act, as amended by this section, and the impact 

10 of such processes on the development and timely avail11 ability of innovative treatments for patients affected by se12 rious or life-threatening conditions. Such assessment shall 

13 be made publicly available upon completion. 

14 (d) CONFORMING AMENDMENTS.—Section 506B(e) 

15 (21 U.S.C. 356b) is amended by striking ‘‘section 

16 506(b)(2)(A)’’ each place such term appears and inserting 

17 ‘‘section 506(c)(2)(A)’’. 

18 SEC. 903. CONSULTATION WITH EXTERNAL EXPERTS ON 

19 RARE DISEASES, TARGETED THERAPIES, AND 

20 GENETIC TARGETING OF TREATMENTS. 

21 Subchapter E of chapter V (21 U.S.C. 360bbb et 

22 seq.), as amended by section 712, is further amended by 

23 adding at the end the following: 

mstockstill on DSK4VPTVN1PROD with BILLS

251 

•S 2516 PCS

1 ‘‘SEC. 569. CONSULTATION WITH EXTERNAL EXPERTS ON 

2 RARE DISEASES, TARGETED THERAPIES, AND 

3 GENETIC TARGETING OF TREATMENTS. 

4 ‘‘(a) IN GENERAL.—For the purpose of promoting 

5 the efficiency of and informing the review by the Food 

6 and Drug Administration of new drugs and biological 

7 products for rare diseases and drugs and biological prod8 ucts that are genetically targeted, the following shall 

9 apply: 

10 ‘‘(1) CONSULTATION WITH STAKEHOLDERS.— 

11 Consistent with sections X.C and IX.E.4 of the 

12 PDUFA Reauthorization Performance Goals and 

13 Procedures Fiscal Years 2013 through 2017, as ref14 erenced in the letters described in section 101(b) of 

15 the Prescription Drug User Fee Amendments of 

16 2012, the Secretary shall ensure that opportunities 

17 exist, at a time the Secretary determines appro18 priate, for consultations with stakeholders on the 

19 topics described in subsection (c). 

20 ‘‘(2) CONSULTATION WITH EXTERNAL EX21 PERTS.—The Secretary shall develop and maintain a 

22 list of external experts who, because of their special 

23 expertise, are qualified to provide advice on rare dis24 ease issues, including topics described in subsection 

25 (c). The Secretary may, when appropriate to address 

26 a specific regulatory question, consult such external 

mstockstill on DSK4VPTVN1PROD with BILLS

252 

•S 2516 PCS

1 experts on issues related to the review of new drugs 

2 and biological products for rare diseases and drugs 

3 and biological products that are genetically targeted, 

4 including the topics described in subsection (c), 

5 when such consultation is necessary because the Sec6 retary lacks specific scientific, medical, or technical 

7 expertise necessary for the performance of its regu8 latory responsibilities and the necessary expertise 

9 can be provided by the external experts. 

10 ‘‘(b) EXTERNAL EXPERTS.—For purposes of sub11 section (a)(2), external experts are those who possess sci12 entific or medical training that the Secretary lacks with 

13 respect to one or more rare diseases. 

14 ‘‘(c) TOPICS FOR CONSULTATION.—Topics for con15 sultation pursuant to this section may include— 

16 ‘‘(1) rare diseases; 

17 ‘‘(2) the severity of rare diseases; 

18 ‘‘(3) the unmet medical need associated with 

19 rare diseases; 

20 ‘‘(4) the willingness and ability of individuals 

21 with a rare disease to participate in clinical trials; 

22 ‘‘(5) an assessment of the benefits and risks of 

23 therapies to treat rare diseases; 

24 ‘‘(6) the general design of clinical trials for rare 

25 disease populations and subpopulations; and 

mstockstill on DSK4VPTVN1PROD with BILLS

253 

•S 2516 PCS

1 ‘‘(7) demographics and the clinical description 

2 of patient populations. 

3 ‘‘(d) CLASSIFICATION AS SPECIAL GOVERNMENT EM4 PLOYEES.—The external experts who are consulted under 

5 this section may be considered special government employ6 ees, as defined under section 202 of title 18, United States 

7 Code. 

8 ‘‘(e) PROTECTION OF PROPRIETARY INFORMA9 TION.—Nothing in this section shall be construed to alter 

10 the protections offered by laws, regulations, and policies 

11 governing disclosure of confidential commercial or trade 

12 secret information, and any other information exempt 

13 from disclosure pursuant to section 552(b) of title 5, 

14 United States Code, as such provisions would be applied 

15 to consultation with individuals and organizations prior to 

16 the date of enactment of this section. 

17 ‘‘(f) OTHER CONSULTATION.—Nothing in this sec18 tion shall be construed to limit the ability of the Secretary 

19 to consult with individuals and organizations as authorized 

20 prior to the date of enactment of this section. 

21 ‘‘(g) NO RIGHT OR OBLIGATION.—Nothing in this 

22 section shall be construed to create a legal right for a con23 sultation on any matter or require the Secretary to meet 

24 with any particular expert or stakeholder. Nothing in this 

25 section shall be construed to alter agreed upon goals and 

mstockstill on DSK4VPTVN1PROD with BILLS

254 

•S 2516 PCS

1 procedures identified in the letters described in section 

2 101(b) of the Prescription Drug User Fee Amendments 

3 of 2012. Nothing in this section is intended to increase 

4 the number of review cycles as in effect before the date 

5 of enactment of this section.’’. 

6 SEC. 904. ACCESSIBILITY OF INFORMATION ON PRESCRIP7 TION DRUG CONTAINER LABELS BY VIS8 UALLY-IMPAIRED AND BLIND CONSUMERS. 

9 (a) ESTABLISHMENT OF WORKING GROUP.— 

10 (1) IN GENERAL.—The Architectural and 

11 Transportation Barriers Compliance Board (referred 

12 to in this section as the ‘‘Access Board’’) shall con13 vene a stakeholder working group (referred to in this 

14 section as the ‘‘working group’’) to develop best 

15 practices on access to information on prescription 

16 drug container labels for individuals who are blind 

17 or visually impaired. 

18 (2) MEMBERS.—The working group shall be 

19 comprised of representatives of national organiza20 tions representing blind and visually-impaired indi21 viduals, national organizations representing the el22 derly, and industry groups representing stake23 holders, including retail, mail order, and independent 

24 community pharmacies, who would be impacted by 

25 such best practices. Representation within the workmstockstill on DSK4VPTVN1PROD with BILLS

255 

•S 2516 PCS

1 ing group shall be divided equally between consumer 

2 and industry advocates. 

3 (3) BEST PRACTICES.— 

4 (A) IN GENERAL.—The working group 

5 shall develop, not later than 1 year after the 

6 date of the enactment of this Act, best practices 

7 for pharmacies to ensure that blind and vis8 ually-impaired individuals have safe, consistent, 

9 reliable, and independent access to the informa10 tion on prescription drug container labels. 

11 (B) PUBLIC AVAILABILITY.—The best 

12 practices developed under subparagraph (A) 

13 may be made publicly available, including 

14 through the Internet Web sites of the working 

15 group participant organizations, and through 

16 other means, in a manner that provides access 

17 to interested individuals, including individuals 

18 with disabilities. 

19 (C) LIMITATIONS.—The best practices de20 veloped under subparagraph (A) shall not be 

21 construed as accessibility guidelines or stand22 ards of the Access Board, and shall not confer 

23 any rights or impose any obligations on working 

24 group participants or other persons. Nothing in 

25 this section shall be construed to limit or condimstockstill on DSK4VPTVN1PROD with BILLS

256 

•S 2516 PCS

1 tion any right, obligation, or remedy available 

2 under the Americans with Disabilities Act of 

3 1990 (42 U.S.C. 12101 et seq.) or any other 

4 Federal or State law requiring effective commu5 nication, barrier removal, or nondiscrimination 

6 on the basis of disability. 

7 (4) CONSIDERATIONS.—In developing and 

8 issuing the best practices under paragraph (3)(A), 

9 the working group shall consider— 

10 (A) the use of— 

11 (i) Braille; 

12 (ii) auditory means, such as— 

13 (I) ‘‘talking bottles’’ that provide 

14 audible container label information; 

15 (II) digital voice recorders at16 tached to the prescription drug con17 tainer; and 

18 (III) radio frequency identifica19 tion tags; 

20 (iii) enhanced visual means, such as— 

21 (I) large font labels or large font 

22 ‘‘duplicate’’ labels that are affixed or 

23 matched to a prescription drug con24 tainer; 

25 (II) high-contrast printing; and 

mstockstill on DSK4VPTVN1PROD with BILLS

257 

•S 2516 PCS

1 (III) sans-serf font; and 

2 (iv) other relevant alternatives as de3 termined by the working group; 

4 (B) whether there are technical, financial, 

5 manpower, or other factors unique to phar6 macies with 20 or fewer retail locations which 

7 may pose significant challenges to the adoption 

8 of the best practices; and 

9 (C) such other factors as the working 

10 group determines to be appropriate. 

11 (5) INFORMATION CAMPAIGN.—Upon comple12 tion of development of the best practices under sub13 section (a)(3), the National Council on Disability, in 

14 consultation with the working group, shall conduct 

15 an informational and educational campaign designed 

16 to inform individuals with disabilities, pharmacists, 

17 and the public about such best practices. 

18 (6) FACA WAIVER.—The Federal Advisory 

19 Committee Act (5 U.S.C. App.) shall not apply to 

20 the working group. 

21 (b) GAO STUDY.— 

22 (1) IN GENERAL.—Beginning 18 months after 

23 the completion of the development of best practices 

24 under subsection (a)(3)(A), the Comptroller General 

25 of the United States shall conduct a review of the 

mstockstill on DSK4VPTVN1PROD with BILLS

258 

•S 2516 PCS

1 extent to which pharmacies are utilizing such best 

2 practices, and the extent to which barriers to acces3 sible information on prescription drug container la4 bels for blind and visually-impaired individuals con5 tinue. 

6 (2) REPORT.—Not later than September 30, 

7 2016, the Comptroller General of the United States 

8 shall submit to Congress a report on the review con9 ducted under paragraph (1). Such report shall in10 clude recommendations about how best to reduce the 

11 barriers experienced by blind and visually-impaired 

12 individuals to independently accessing information 

13 on prescription drug container labels. 

14 (c) DEFINITIONS.—In this section— 

15 (1) the term ‘‘pharmacy’’ includes a pharmacy 

16 that receives prescriptions and dispenses prescription 

17 drugs through an Internet Web site or by mail; 

18 (2) the term ‘‘prescription drug’’ means a drug 

19 subject to section 503(b)(1) of the Federal Food, 

20 Drug, and Cosmetic Act (21 U.S.C. 353(b)(1)); and 

21 (3) the term ‘‘prescription drug container label’’ 

22 means the label with the directions for use that is 

23 affixed to the prescription drug container by the 

24 pharmacist and dispensed to the consumer. 

mstockstill on DSK4VPTVN1PROD with BILLS

259 

•S 2516 PCS

1 SEC. 905. RISK-BENEFIT FRAMEWORK. 

2 Section 505(d) (21 U.S.C. 355(d)) is amended by 

3 adding at the end the following: ‘‘The Secretary shall im4 plement a structured risk-benefit assessment framework 

5 in the new drug approval process to facilitate the balanced 

6 consideration of benefits and risks, a consistent and sys7 tematic approach to the discussion and regulatory deci8 sionmaking, and the communication of the benefits and 

9 risks of new drugs. Nothing in the preceding sentence 

10 shall alter the criteria for evaluating an application for 

11 premarket approval of a drug.’’. 

12 SEC. 906. INDEPENDENT STUDY ON MEDICAL INNOVATION 

13 INDUCEMENT MODEL. 

14 (a) IN GENERAL.—The Secretary of Health and 

15 Human Services shall enter into an agreement with the 

16 National Academies to provide expert consultation and 

17 conduct a study that evaluates the feasibility and possible 

18 consequences of the use of innovation inducement prizes 

19 to reward successful medical innovations. Under the 

20 agreement, the National Academies shall submit to the 

21 Secretary a report on such study not later than 15 months 

22 after the date of enactment of this Act. 

23 (b) REQUIREMENTS.— 

24 (1) IN GENERAL.—The study conducted under 

25 subsection (a) shall model at least 3 separate seg26 ments on the medical technologies market as canmstockstill on DSK4VPTVN1PROD with BILLS

260 

•S 2516 PCS

1 didate targets for the new incentive system and con2 sider different medical innovation inducement prize 

3 design issues, including the challenges presented in 

4 the implementation of prizes for end products, open 

5 source dividend prizes, and prizes for upstream re6 search. 

7 (2) MARKET SEGMENTS.—The segments on the 

8 medical technologies market that shall be considered 

9 under paragraph (1) include— 

10 (A) all pharmaceutical and biologic drugs 

11 and vaccines; 

12 (B) drugs and vaccines used solely for the 

13 treatment of HIV/AIDS; and 

14 (C) antibiotics. 

15 (c) ELEMENTS.—The study conducted under sub16 section (a) shall include consideration of each of the fol17 lowing: 

18 (1) Whether a system of large innovation in19 ducement prizes could work as a replacement for the 

20 existing product monopoly/patent-based system, as 

21 in effect on the date of enactment of this Act. 

22 (2) How large the innovation prize funds would 

23 have to be in order to induce at least as much re24 search and development investment in innovation as 

25 is induced under the current system of time-limited 

mstockstill on DSK4VPTVN1PROD with BILLS

261 

•S 2516 PCS

1 market exclusivity, as in effect on the date of enact2 ment of this Act. 

3 (3) Whether a system of large innovation in4 ducement prizes would be more or less expensive 

5 than the current system of time-limited market ex6 clusivity, as in effect on the date of enactment of 

7 this Act, calculated over different time periods. 

8 (4) Whether a system of large innovation in9 ducement prizes would expand access to new prod10 ucts and improve health outcomes. 

11 (5) The type of information and decisionmaking 

12 skills that would be necessary to manage end prod13 uct prizes. 

14 (6) Whether there would there be major advan15 tages in rewarding the incremental impact of innova16 tions, as benchmarked against existing products. 

17 (7) How open-source dividend prizes could be 

18 managed, and whether such prizes would increase 

19 access to knowledge, materials, data and tech20 nologies. 

21 (8) Whether a system of competitive inter22 mediaries for interim research prizes would provide 

23 an acceptable solution to the valuation challenges for 

24 interim prizes. 

mstockstill on DSK4VPTVN1PROD with BILLS

262 

•S 2516 PCS

1 TITLE X—DRUG SHORTAGES 

2 SEC. 1001. DRUG SHORTAGES. 

3 (a) IN GENERAL.—Section 506C (21 U.S.C. 356c) 

4 is amended to read as follows: 

5 ‘‘SEC. 506C. DISCONTINUANCE OR INTERRUPTION IN THE 

6 PRODUCTION OF LIFE-SAVING DRUGS. 

7 ‘‘(a) IN GENERAL.—A manufacturer of a drug— 

8 ‘‘(1) that is— 

9 ‘‘(A) life-supporting; 

10 ‘‘(B) life-sustaining; 

11 ‘‘(C) intended for use in the prevention of 

12 a debilitating disease or condition; 

13 ‘‘(D) a sterile injectable product; or 

14 ‘‘(E) used in emergency medical care or 

15 during surgery; and 

16 ‘‘(2) that is not a radio pharmaceutical drug 

17 product, a human tissue replaced by a recombinant 

18 product, a product derived from human plasma pro19 tein, or any other product as designated by the Sec20 retary, 

21 shall notify the Secretary, in accordance with subsection 

22 (b), of a permanent discontinuance in the manufacture of 

23 the drug or an interruption of the manufacture of the drug 

24 that could lead to a meaningful disruption in the supply 

25 of that drug in the United States. 

mstockstill on DSK4VPTVN1PROD with BILLS

263 

•S 2516 PCS

1 ‘‘(b) TIMING.—A notice required under subsection (a) 

2 shall be submitted to the Secretary— 

3 ‘‘(1) at least 6 months prior to the date of the 

4 discontinuance or interruption; or 

5 ‘‘(2) if compliance with paragraph (1) is not 

6 possible, as soon as practicable. 

7 ‘‘(c) EXPEDITED INSPECTIONS AND REVIEWS.—If, 

8 based on notifications described in subsection (a) or any 

9 other relevant information, the Secretary concludes that 

10 there is, or is likely to be, a drug shortage of a drug de11 scribed in subsection (a), the Secretary may— 

12 ‘‘(1) expedite the review of a supplement to a 

13 new drug application submitted under section 

14 505(b), an abbreviated new drug application sub15 mitted under section 505(j), or a supplement to such 

16 an application submitted under section 505(j) that 

17 could help mitigate or prevent such shortage; or 

18 ‘‘(2) expedite an inspection or reinspection of 

19 an establishment that could help mitigate or prevent 

20 such drug shortage. 

21 ‘‘(d) COORDINATION.— 

22 ‘‘(1) TASK FORCE AND STRATEGIC PLAN.— 

23 ‘‘(A) IN GENERAL.— 

24 ‘‘(i) TASK FORCE.—As soon as prac25 ticable after the date of enactment of the 

mstockstill on DSK4VPTVN1PROD with BILLS

264 

•S 2516 PCS

1 Food and Drug Administration Safety and 

2 Innovation Act, the Secretary shall estab3 lish a Task Force to develop and imple4 ment a strategic plan for enhancing the 

5 Secretary’s response to preventing and 

6 mitigating drug shortages. 

7 ‘‘(ii) STRATEGIC PLAN.—The strategic 

8 plan described in clause (i) shall include— 

9 ‘‘(I) plans for enhanced inter10 agency and intraagency coordination, 

11 communication, and decisionmaking; 

12 ‘‘(II) plans for ensuring that 

13 drug shortages are considered when 

14 the Secretary initiates a regulatory 

15 action that could precipitate a drug 

16 shortage or exacerbate an existing 

17 drug shortage; 

18 ‘‘(III) plans for effective commu19 nication with outside stakeholders, in20 cluding who the Secretary should alert 

21 about potential or actual drug short22 ages, how the communication should 

23 occur, and what types of information 

24 should be shared; and 

mstockstill on DSK4VPTVN1PROD with BILLS

265 

•S 2516 PCS

1 ‘‘(IV) plans for considering the 

2 impact of drug shortages on research 

3 and clinical trials. 

4 ‘‘(iii) CONSULTATION.—In carrying 

5 out this subparagraph, the Task Force 

6 shall ensure consultation with the appro7 priate offices within the Food and Drug 

8 Administration, including the Office of the 

9 Commissioner, the Center for Drug Eval10 uation and Research, the Office of Regu11 latory Affairs, and employees within the 

12 Department of Health and Human Serv13 ices with expertise regarding drug short14 ages. The Secretary shall engage external 

15 stakeholders and experts as appropriate. 

16 ‘‘(B) TIMING.—Not later than 1 year after 

17 the date of enactment Food and Drug Adminis18 tration Safety and Innovation Act, the Task 

19 Force shall— 

20 ‘‘(i) publish the strategic plan de21 scribed in subparagraph (A); and 

22 ‘‘(ii) submit such plan to Congress. 

23 ‘‘(2) COMMUNICATION.—The Secretary shall 

24 ensure that, prior to any enforcement action or 

25 issuance of a warning letter that the Secretary demstockstill on DSK4VPTVN1PROD with BILLS

266 

•S 2516 PCS

1 termines could reasonably be anticipated to lead to 

2 a meaningful disruption in the supply in the United 

3 States of a drug described under subsection (a), 

4 there is communication with the appropriate office 

5 of the Food and Drug Administration with expertise 

6 regarding drug shortages regarding whether the ac7 tion or letter could cause, or exacerbate, a shortage 

8 of the drug. 

9 ‘‘(3) ACTION.—If the Secretary determines, 

10 after the communication described in paragraph (2), 

11 that an enforcement action or a warning letter could 

12 reasonably cause or exacerbate a shortage of a drug 

13 described under subsection (a), then the Secretary 

14 shall evaluate the risks associated with the impact of 

15 such shortage upon patients and those risks associ16 ated with the violation involved before taking such 

17 action or issuing such letter, unless there is immi18 nent risk of serious adverse health consequences or 

19 death to humans. 

20 ‘‘(4) REPORTING BY OTHER ENTITIES.—The 

21 Secretary shall identify or establish a mechanism by 

22 which healthcare providers and other third-party or23 ganizations may report to the Secretary evidence of 

24 a drug shortage. 

mstockstill on DSK4VPTVN1PROD with BILLS

267 

•S 2516 PCS

1 ‘‘(5) REVIEW AND CONSTRUCTION.—No deter2 mination, finding, action, or omission of the Sec3 retary under this subsection shall— 

4 ‘‘(A) be subject to judicial review; or 

5 ‘‘(B) be construed to establish a defense to 

6 an enforcement action by the Secretary. 

7 ‘‘(e) RECORDKEEPING AND REPORTING.— 

8 ‘‘(1) RECORDKEEPING.—The Secretary shall 

9 maintain records related to drug shortages, includ10 ing with respect to each of the following: 

11 ‘‘(A) The number of manufacturers that 

12 submitted a notification to the Secretary under 

13 subsection (a) in each calendar year. 

14 ‘‘(B) The number of drug shortages that 

15 occurred in each calendar year and a list of 

16 drug names, drug types, and classes that were 

17 the subject of such shortages. 

18 ‘‘(C) A list of the known factors contrib19 uting to the drug shortages described in sub20 paragraph (B). 

21 ‘‘(D)(i) A list of major actions taken by 

22 the Secretary to prevent or mitigate the drug 

23 shortages described in subparagraph (B). 

24 ‘‘(ii) The Secretary shall include in the list 

25 under clause (i) the following: 

mstockstill on DSK4VPTVN1PROD with BILLS

268 

•S 2516 PCS

1 ‘‘(I) The number of applications for 

2 which the Secretary expedited review under 

3 subsection (c)(1) in each calendar year. 

4 ‘‘(II) The number of establishment in5 spections or reinspections that the Sec6 retary expedited under subsection (c)(2) in 

7 each calendar year. 

8 ‘‘(E) The number of notifications sub9 mitted to the Secretary under subsection (a) in 

10 each calendar year. 

11 ‘‘(F) The names of manufacturers that the 

12 Secretary has learned did not comply with the 

13 notification requirement under subsection (a) in 

14 each calendar year. 

15 ‘‘(G) The number of times in each cal16 endar year that the Secretary determined under 

17 subsection (d)(3) that an enforcement action or 

18 a warning letter could reasonably cause or exac19 erbate a shortage of a drug described under 

20 subsection (a), but did not evaluate the risks 

21 associated with the impact of such shortage 

22 upon patients and those risks associated with 

23 the violation involved before taking such action 

24 or issuing such letter on the grounds that there 

25 was imminent risk of serious adverse health 

mstockstill on DSK4VPTVN1PROD with BILLS

269 

•S 2516 PCS

1 consequences or death to humans, and a sum2 mary of the determinations. 

3 ‘‘(H) A summary of the communications 

4 made and actions taken under subsection (d) in 

5 each calendar year. 

6 ‘‘(I) Any other information the Secretary 

7 deems appropriate to better prevent and miti8 gate drug shortages. 

9 ‘‘(2) TREND ANALYSIS.—The Secretary is au10 thorized to retain a third party to conduct a study, 

11 if the Secretary believes such a study would help 

12 clarify the causes, trends, or solutions related to 

13 drug shortages. 

14 ‘‘(3) ANNUAL SUMMARY.—Not later than 18 

15 months after the date of enactment of the Food and 

16 Drug Administration Safety and Innovation Act, and 

17 annually thereafter, the Secretary shall submit to 

18 the Committee on Health, Education, Labor, and 

19 Pensions of the Senate and the Committee on En20 ergy and Commerce of the House of Representatives 

21 a report summarizing, with respect to the 1-year pe22 riod preceding such report, the information de23 scribed in paragraph (1). Such report shall not in24 clude any information that is exempt from disclosure 

25 under subsection (a) of section 552 of title 5, United 

mstockstill on DSK4VPTVN1PROD with BILLS

270 

•S 2516 PCS

1 States Code, by reason of subsection (b)(4) of such 

2 section. 

3 ‘‘(f) DEFINITIONS.—For purposes of this section— 

4 ‘‘(1) the term ‘drug’— 

5 ‘‘(A) means a drug (as defined in section 

6 201(g)) that is intended for human use; and 

7 ‘‘(B) does not include biological products 

8 (as defined in section 351 of the Public Health 

9 Service Act), unless otherwise provided by the 

10 Secretary in the regulations promulgated under 

11 subsection (h); 

12 ‘‘(2) the term ‘drug shortage’ or ‘shortage’, 

13 with respect to a drug, means a period of time when 

14 the demand or projected demand for the drug within 

15 the United States exceeds the supply of the drug; 

16 and 

17 ‘‘(3) the term ‘meaningful disruption’— 

18 ‘‘(A) means a change in production that is 

19 reasonably likely to lead to a reduction in the 

20 supply of a drug by a manufacturer that is 

21 more than negligible and impacts the ability of 

22 the manufacturer to fill orders or meet expected 

23 demand for its product; and 

24 ‘‘(B) does not include interruptions in 

25 manufacturing due to matters such as routine 

mstockstill on DSK4VPTVN1PROD with BILLS

271 

•S 2516 PCS

1 maintenance or insignificant changes in manu2 facturing so long as the manufacturer expects 

3 to resume operations in a short period of time. 

4 ‘‘(g) DISTRIBUTION.—To the maximum extent prac5 ticable, the Secretary may distribute information on drug 

6 shortages and on the permanent discontinuation of the 

7 drugs described in this section to appropriate provider and 

8 patient organizations, except that any such distribution 

9 shall not include any information that is exempt from dis10 closure under section 552 of title 5, United States Code, 

11 by reason of subsection (b)(4) of such section. 

12 ‘‘(h) REGULATIONS.— 

13 ‘‘(1) IN GENERAL.—Not later than 18 months 

14 after the date of enactment of the Food and Drug 

15 Administration Safety and Innovation Act, the Sec16 retary shall adopt a final regulation implementing 

17 this section. 

18 ‘‘(2) INCLUSION OF BIOLOGICAL PRODUCTS.— 

19 ‘‘(A) IN GENERAL.—The Secretary may by 

20 regulation apply this section to biological prod21 ucts (as defined in section 351 of the Public 

22 Health Service Act) if the Secretary determines 

23 such inclusion would benefit the public health. 

mstockstill on DSK4VPTVN1PROD with BILLS

272 

•S 2516 PCS

1 ‘‘(B) RULE FOR VACCINES.—If the Sec2 retary applies this section to vaccines pursuant 

3 to subparagraph (A), the Secretary shall— 

4 ‘‘(i) consider whether the notification 

5 requirement under subsection (a) may be 

6 satisfied by submitting a notification to the 

7 Centers for Disease Control and Preven8 tion under the vaccine shortage notification 

9 program of such Centers; and 

10 ‘‘(ii) explain the determination made 

11 by the Secretary under clause (i) in the 

12 regulation. 

13 ‘‘(3) PROCEDURE.—In promulgating a regula14 tion implementing this section, the Secretary shall— 

15 ‘‘(A) issue a notice of proposed rulemaking 

16 that includes the proposed regulation; 

17 ‘‘(B) provide a period of not less than 60 

18 days for comments on the proposed regulation; 

19 and 

20 ‘‘(C) publish the final regulation not less 

21 than 30 days before the regulation’s effective 

22 date. 

23 ‘‘(4) RESTRICTIONS.—Notwithstanding any 

24 other provision of Federal law, in implementing this 

mstockstill on DSK4VPTVN1PROD with BILLS

273 

•S 2516 PCS

1 section, the Secretary shall only promulgate regula2 tions as described in paragraph (3).’’. 

3 (b) EFFECT OF NOTIFICATION.—The submission of 

4 a notification to the Secretary of Health and Human Serv5 ices (referred to in this section as the ‘‘Secretary’’) for 

6 purposes of complying with the requirement in section 

7 506C(a) of the Federal Food, Drug, and Cosmetic Act (as 

8 amended by subsection (a)) shall not be construed— 

9 (1) as an admission that any product that is 

10 the subject of such notification violates any provision 

11 of the Federal Food, Drug, and Cosmetic Act (21 

12 U.S.C. 301 et seq.); or 

13 (2) as evidence of an intention to promote or 

14 market the product for an indication or use for 

15 which the product has not been approved by the Sec16 retary. 

17 (c) INTERNAL REVIEW.—Not later than 2 years after 

18 the date of enactment of this Act, the Secretary shall— 

19 (1) analyze and review the regulations promul20 gated under the Federal Food, Drug, and Cosmetic 

21 Act (21 U.S.C. 301 et seq.), the guidances or poli22 cies issued under such Act related to drugs intended 

23 for human use, and the practices of the Food and 

24 Drug Administration regarding enforcing such Act 

25 related to manufacturing of such drugs, to identify 

mstockstill on DSK4VPTVN1PROD with BILLS

274 

•S 2516 PCS

1 any such regulations, guidances, policies, or prac2 tices that cause, exacerbate, prevent, or mitigate 

3 drug shortages (as defined in section 506C of the 

4 Federal Food, Drug, and Cosmetic Act (as amended 

5 by subsection (a)); and 

6 (2) determine how regulations, guidances, poli7 cies, or practices identified under paragraph (1) 

8 should be modified, streamlined, expanded, or dis9 continued in order to reduce or prevent such drug 

10 shortages, taking into consideration the effect of any 

11 changes on the public health. 

12 (d) STUDY ON MARKET FACTORS CONTRIBUTING TO

13 DRUG SHORTAGES AND STOCKPILING.— 

14 (1) IN GENERAL.—Not later than 1 year after 

15 the date of enactment of this Act, the Comptroller 

16 General of the United States, in consultation with 

17 the Secretary, the Department of Health and 

18 Human Services Office of the Inspector General, the 

19 Attorney General, and Chairman of the Federal 

20 Trade Commission, shall publish a report reviewing 

21 any findings that drug shortages (as so defined) 

22 have led market participants to stockpile affected 

23 drugs or sell them at significantly increased prices, 

24 the impact of such activities on Federal revenue, and 

mstockstill on DSK4VPTVN1PROD with BILLS

275 

•S 2516 PCS

1 any economic factors that have exacerbated or cre2 ated a market for such actions. 

3 (2) CONTENT.—The report under paragraph 

4 (1) shall include— 

5 (A) an analysis of the incidence of any of 

6 the activities described in paragraph (1) and 

7 the effect of such activities on the public health; 

8 (B) an evaluation of whether in such cases 

9 there is a correlation between drugs in shortage 

10 and— 

11 (i) the number of manufacturers pro12 ducing such drugs; 

13 (ii) the pricing structure, including 

14 Federal reimbursements, for such drugs 

15 before such drugs were in shortage, and to 

16 the extent possible, revenue received by 

17 each such manufacturer of such drugs; 

18 (iii) pricing structure and revenue, to 

19 the extent possible, for the same drugs 

20 when sold under the conditions described 

21 in paragraph (1); and 

22 (iv) the impact of contracting prac23 tices by market participants (including 

24 manufacturers, distributors, group pur25 chasing organizations, and providers) on 

mstockstill on DSK4VPTVN1PROD with BILLS

276 

•S 2516 PCS

1 competition, access to drugs, and pricing 

2 of drugs; 

3 (C) whether the activities described in 

4 paragraph (1) are consistent with applicable 

5 law; and 

6 (D) recommendations to Congress on what, 

7 if any, additional reporting or enforcement ac8 tions are necessary. 

9 (3) TRADE SECRET AND CONFIDENTIAL INFOR10 MATION.—Nothing in this subsection alters or 

11 amends section 1905 of title 18, United States Code, 

12 or section 552(b)(4) of title 5, United States Code. 

13 (e) GUIDANCE REGARDING REPACKAGING.—Not 

14 later than 1 year after the date of enactment of this Act, 

15 the Secretary shall issue guidance that clarifies the policy 

16 of the Food and Drug Administration regarding hospital 

17 pharmacies repackaging and safely transferring repack18 aged drugs among hospitals within a common health sys19 tem during a drug shortage, as identified by the Secretary. 

mstockstill on DSK4VPTVN1PROD with BILLS

277 

•S 2516 PCS

1 TITLE XI—OTHER PROVISIONS 

2 Subtitle A—Reauthorizations 

3 SEC. 1101. REAUTHORIZATION OF PROVISION RELATING TO 

4 EXCLUSIVITY OF CERTAIN DRUGS CON5 TAINING SINGLE ENANTIOMERS. 

6 Section 505(u)(4) (21 U.S.C. 355(u)(4)) is amended 

7 by striking ‘‘2012’’ and inserting ‘‘2017’’. 

8 SEC. 1102. REAUTHORIZATION OF THE CRITICAL PATH 

9 PUBLIC-PRIVATE PARTNERSHIPS. 

10 Section 566(f) (21 U.S.C. 360bbb–5(f)) is amended 

11 by striking ‘‘2012’’ and inserting ‘‘2017’’. 

12 Subtitle B—Medical Gas Product 

13 Regulation 

14 SEC. 1111. REGULATION OF MEDICAL GAS PRODUCTS. 

15 (a) REGULATION.—Chapter V (21 U.S.C. 351 et 

16 seq.) is amended by adding at the end the following: 

17 ‘‘Subchapter G—Medical Gas Products 

18 ‘‘SEC. 575. DEFINITIONS. 

19 ‘‘In this subchapter: 

20 ‘‘(1) The term ‘designated medical gas product’ 

21 means any of the following: 

22 ‘‘(A) Oxygen, that meets the standards set 

23 forth in an official compendium. 

24 ‘‘(B) Nitrogen, that meets the standards 

25 set forth in an official compendium. 

mstockstill on DSK4VPTVN1PROD with BILLS

278 

•S 2516 PCS

1 ‘‘(C) Nitrous oxide, that meets the stand2 ards set forth in an official compendium. 

3 ‘‘(D) Carbon dioxide, that meets the stand4 ards set forth in an official compendium. 

5 ‘‘(E) Helium, that meets the standards set 

6 forth in an official compendium. 

7 ‘‘(F) Carbon monoxide, that meets the 

8 standards set forth in an official compendium. 

9 ‘‘(G) Medical air, that meets the standards 

10 set forth in an official compendium. 

11 ‘‘(H) Any other medical gas product 

12 deemed appropriate by the Secretary, unless 

13 any period of exclusivity under section 

14 505(c)(3)(E)(ii) or 505(j)(5)(F)(ii), or the ex15 tension of any such period under section 505A, 

16 applicable to such medical gas product has not 

17 expired. 

18 ‘‘(2) The term ‘medical gas product’ means a 

19 drug that— 

20 ‘‘(A) is manufactured or stored in a lique21 fied, nonliquefied, or cryogenic state; and 

22 ‘‘(B) is administered as a gas. 

23 ‘‘SEC. 576. REGULATION OF MEDICAL GAS PRODUCTS. 

24 ‘‘(a) CERTIFICATION OF DESIGNATED MEDICAL GAS

25 PRODUCTS.— 

mstockstill on DSK4VPTVN1PROD with BILLS

279 

•S 2516 PCS

1 ‘‘(1) SUBMISSION.— 

2 ‘‘(A) IN GENERAL.—Beginning on the date 

3 of enactment of this section, any person may 

4 file with the Secretary a request for a certifi5 cation of a designated medical gas product. 

6 ‘‘(B) CONTENT.—A request under sub7 paragraph (A) shall contain— 

8 ‘‘(i) a description of the medical gas 

9 product; 

10 ‘‘(ii) the name and address of the 

11 sponsor; 

12 ‘‘(iii) the name and address of the fa13 cility or facilities where the gas product is 

14 or will be manufactured; and 

15 ‘‘(iv) any other information deemed 

16 appropriate by the Secretary to determine 

17 whether the medical gas product is a des18 ignated medical gas product. 

19 ‘‘(2) GRANT OF CERTIFICATION.—A certifi20 cation described under paragraph (1)(A) shall be de21 termined to have been granted unless, not later than 

22 60 days after the filing of a request under para23 graph (1), the Secretary finds that— 

mstockstill on DSK4VPTVN1PROD with BILLS

280 

•S 2516 PCS

1 ‘‘(A) the medical gas product subject to 

2 the certification is not a designated medical gas 

3 product; 

4 ‘‘(B) the request does not contain the in5 formation required under paragraph (1) or oth6 erwise lacks sufficient information to permit the 

7 Secretary to determine that the gas product is 

8 a designated medical gas product; or 

9 ‘‘(C) granting the request would be con10 trary to public health. 

11 ‘‘(3) EFFECT OF CERTIFICATION.— 

12 ‘‘(A) IN GENERAL.— 

13 ‘‘(i) APPROVED USES.—A designated 

14 medical gas product for which a certifi15 cation is granted under paragraph (2) is 

16 deemed, alone or in combination with an17 other designated gas product or products 

18 as medically appropriate, to have in effect 

19 an approved application under section 505 

20 or 512, subject to all applicable post21 approval requirements, for the following in22 dications for use: 

23 ‘‘(I) Oxygen for the treatment or 

24 prevention of hypoxemia or hypoxia. 

mstockstill on DSK4VPTVN1PROD with BILLS

281 

•S 2516 PCS

1 ‘‘(II) Nitrogen for use in hypoxic 

2 challenge testing. 

3 ‘‘(III) Nitrous oxide for analge4 sia. 

5 ‘‘(IV) Carbon dioxide for use in 

6 extracorporeal membrane oxygenation 

7 therapy or respiratory stimulation. 

8 ‘‘(V) Helium for the treatment of 

9 upper airway obstruction or increased 

10 airway resistance. 

11 ‘‘(VI) Medical air to reduce the 

12 risk of hyperoxia. 

13 ‘‘(VII) Carbon monoxide for use 

14 in lung diffusion testing. 

15 ‘‘(VIII) Any other indication for 

16 use for a designated medical gas prod17 uct or combination of designated med18 ical gas products deemed appropriate 

19 by the Secretary, unless any period of 

20 exclusivity under clause (iii) or (iv) of 

21 section 505(c)(3)(E), under clause 

22 (iii) or (iv) of section 505(j)(5)(F), or 

23 under section 527, or the extension of 

24 any such period under section 505A, 

25 applicable to such indication for use 

mstockstill on DSK4VPTVN1PROD with BILLS

282 

•S 2516 PCS

1 for such gas product or combination 

2 of products has not expired. 

3 ‘‘(ii) LABELING.—The requirements 

4 established in sections 503(b)(4) and 

5 502(f) shall be deemed to have been met 

6 for a designated medical gas product if the 

7 labeling on final use containers of such gas 

8 product bears the information required by 

9 section 503(b)(4) and a warning statement 

10 concerning the use of the gas product, as 

11 determined by the Secretary by regulation, 

12 as well as appropriate directions and warn13 ings concerning storage and handling. 

14 ‘‘(B) INAPPLICABILITY OF EXCLUSIVITY

15 PROVISIONS.— 

16 ‘‘(i) EFFECT ON INELIGIBILITY.—No 

17 designated medical gas product deemed 

18 under paragraph (3)(A)(i) to have in effect 

19 an approved application shall be eligible for 

20 any periods of exclusivity under sections 

21 505(c), 505(j), or 527, or the extension of 

22 any such period under section 505A, on 

23 the basis of such deemed approval. 

24 ‘‘(ii) EFFECT ON CERTIFICATION.— 

25 No period of exclusivity under sections 

mstockstill on DSK4VPTVN1PROD with BILLS

283 

•S 2516 PCS

1 505(c), 505(j), or section 527, or the ex2 tension of any such period under section 

3 505A, with respect to an application for a 

4 drug shall prohibit, limit, or otherwise af5 fect the submission, grant, or effect of a 

6 certification under this section, except as 

7 provided in paragraph (3)(A)(i)(VIII). 

8 ‘‘(4) WITHDRAWAL, SUSPENSION, OR REVOCA9 TION OF APPROVAL.— 

10 ‘‘(A) IN GENERAL.—Nothing in this sub11 chapter limits the authority of the Secretary to 

12 withdraw or suspend approval of a drug, includ13 ing a designated medical gas product deemed 

14 under this section to have in effect an approved 

15 application, under section 505 or section 512. 

16 ‘‘(B) REVOCATION.—The Secretary may 

17 revoke the grant of a certification under this 

18 section if the Secretary determines that the re19 quest for certification contains any material 

20 omission or falsification. 

21 ‘‘(b) PRESCRIPTION REQUIREMENT.— 

22 ‘‘(1) IN GENERAL.—A designated medical gas 

23 product shall be subject to section 503(b)(1) unless 

24 the Secretary exercises the authority provided in sec25 tion 503(b)(3) to remove such gas product from the 

mstockstill on DSK4VPTVN1PROD with BILLS

284 

•S 2516 PCS

1 requirements of section 503(b)(1) or the use in ques2 tion is authorized pursuant to another provision of 

3 this Act relating to use of medical products in emer4 gencies. 

5 ‘‘(2) EXCEPTION FOR OXYGEN.— 

6 ‘‘(A) IN GENERAL.—Notwithstanding para7 graph (1), oxygen may be provided without a 

8 prescription for the following uses: 

9 ‘‘(i) The use in the event of depres10 surization or other environmental oxygen 

11 deficiency. 

12 ‘‘(ii) The use in the event of oxygen 

13 deficiency or use in emergency resuscita14 tion, when administered by properly 

15 trained personnel. 

16 ‘‘(B) LABELING.—For oxygen provided 

17 pursuant to subparagraph (A), the require18 ments established in section 503(b)(4) shall be 

19 deemed to have been met if the labeling of the 

20 oxygen bears a warning that the medical gas 

21 product can be used for emergency use only and 

22 for all other medical applications a prescription 

23 is required. 

24 ‘‘(c) INAPPLICABILITY OF DRUGS FEES TO DES25 IGNATED MEDICAL GAS PRODUCTS.—A designated medmstockstill on DSK4VPTVN1PROD with BILLS

285 

•S 2516 PCS

1 ical gas product deemed under this section to have in ef2 fect an approved application shall not be assessed fees 

3 under section 736(a) on the basis of such deemed ap4 proval.’’. 

5 SEC. 1112. REGULATIONS. 

6 (a) REVIEW OF REGULATIONS.—Not later than 18 

7 months after the date of enactment of this Act, the Sec8 retary of Health and Human Services (referred to in this 

9 section as the ‘‘Secretary’’) shall, after obtaining input 

10 from medical gas product manufacturers, and any other 

11 interested members of the public, submit a report to the 

12 Committee on Health, Education, Labor, and Pensions of 

13 the Senate and the Committee on Energy and Commerce 

14 of the House of Representatives regarding any changes to 

15 the Federal drug regulations in title 21, Code of Federal 

16 Regulations that the Secretary determines to be necessary. 

17 (b) AMENDED REGULATIONS.—If the Secretary de18 termines that changes to the Federal drug regulations in 

19 title 21, Code of Federal Regulations are necessary under 

20 subsection (a), the Secretary shall issue final regulations 

21 implementing such changes not later than 4 years after 

22 the date of enactment of this Act. 

23 SEC. 1113. APPLICABILITY. 

24 Nothing in this subtitle or the amendments made by 

25 this subtitle shall apply to— 

mstockstill on DSK4VPTVN1PROD with BILLS

286 

•S 2516 PCS

1 (1) a drug that is covered by an application 

2 under section 505 or 512 of the Federal Food, 

3 Drug, and Cosmetic Act (21 U.S.C. 355, 360b) ap4 proved prior to May 1, 2012; or 

5 (2) any of the gases listed in subparagraphs (A) 

6 through (G) of section 575(1) of such Act (as added 

7 by section 1111), or any mixture of any such gases, 

8 for an indication that— 

9 (A) is not included in, or is different from, 

10 those specified in subclauses (I) through (VII) 

11 of section 576(a)(3)(i) of such Act (as added by 

12 section 1111); and 

13 (B) is approved on or after May 1, 2012, 

14 pursuant to an application submitted under sec15 tion 505 or 512 of such Act. 

16 Subtitle C—Miscellaneous 

17 Provisions 

18 SEC. 1121. ADVISORY COMMITTEE CONFLICTS OF INTER19 EST. 

20 Section 712 (21 U.S.C. 379d–1) is amended— 

21 (1) in subsection (b)— 

22 (A) by striking paragraph (2); and 

23 (B) in paragraph (1)— 

24 (i) by redesignating subparagraph (B) 

25 as paragraph (2) and moving such paramstockstill on DSK4VPTVN1PROD with BILLS

287 

•S 2516 PCS

1 graph, as so redesignated, 2 ems to the 

2 left; 

3 (ii) in subparagraph (A), by redesig4 nating clauses (i) through (iii) as subpara5 graphs (A) through (C), respectively, and 

6 moving such subparagraphs, as so redesig7 nated, 2 ems to the left; 

8 (iii) in subparagraph (A), as so redes9 ignated, by inserting ‘‘, including strategies 

10 to increase the number of special Govern11 ment employees across medical and sci12 entific specialties in areas where the Sec13 retary would benefit from specific sci14 entific, medical, or technical expertise nec15 essary for the performance of its regu16 latory responsibilities’’ before the semicolon 

17 at the end; 

18 (iv) by striking ‘‘(1) RECRUITMENT.— 

19 ’’ and inserting ‘‘(1) RECRUITMENT IN

20 GENERAL.—The Secretary shall—’’; 

21 (v) by striking ‘‘(A) IN GENERAL.— 

22 The Secretary shall—’’; 

23 (vi) by redesignating clauses (i) 

24 through (iii) of paragraph (2) (as so redes25 ignated) as subparagraphs (A) through 

mstockstill on DSK4VPTVN1PROD with BILLS

288 

•S 2516 PCS

1 (C), respectively, and moving such sub2 paragraphs, as so redesignated, 2 ems to 

3 the left; 

4 (vii) in paragraph (2) (as so redesig5 nated), in the matter before subparagraph 

6 (A) (as so redesignated), by striking ‘‘sub7 paragraph (A)’’ and inserting ‘‘paragraph 

8 (1)’’; and 

9 (viii) by adding at the end the fol10 lowing: 

11 ‘‘(3) RECRUITMENT THROUGH REFERRALS.—In 

12 carrying out paragraph (1), the Secretary shall, in 

13 order to further the goal of including in advisory 

14 committees the most qualified and specialized ex15 perts in the specific diseases to be considered by 

16 such advisory committees, at least every 180 days, 

17 request referrals from a variety of stakeholders, in18 cluding the Institute of Medicine, the National Insti19 tutes of Health, product developers, patient groups, 

20 disease advocacy organizations, professional soci21 eties, medical societies, including the American 

22 Academy of Medical Colleges, and other govern23 mental organizations.’’; 

24 (2) by amending subsection (c)(2)(C) to read as 

25 follows: 

mstockstill on DSK4VPTVN1PROD with BILLS

289 

•S 2516 PCS

1 ‘‘(C) CONSIDERATION BY SECRETARY.— 

2 The Secretary shall ensure that each determina3 tion made under subparagraph (B) considers 

4 the type, nature, and magnitude of the financial 

5 interests at issue and the public health interest 

6 in having the expertise of the member with re7 spect to the particular matter before the advi8 sory committee.’’; 

9 (3) in subsection (e), by inserting ‘‘, and shall 

10 make publicly available,’’ after ‘‘House of Represent11 atives’’; and 

12 (4) by adding at the end the following: 

13 ‘‘(g) GUIDANCE ON REPORTED FINANCIAL INTEREST

14 OR INVOLVEMENT.—The Secretary shall issue guidance 

15 that describes how the Secretary reviews the financial in16 terests and involvement of advisory committee members 

17 that are reported under subsection (c)(1) but that the Sec18 retary determines not to meet the definition of a disquali19 fying interest under section 208 of title 18, United States 

20 Code for the purposes of participating in a particular mat21 ter.’’. 

22 SEC. 1122. GUIDANCE DOCUMENT REGARDING PRODUCT 

23 PROMOTION USING THE INTERNET. 

24 Not later than 2 years after the date of enactment 

25 this Act, the Secretary of Health and Human Services 

mstockstill on DSK4VPTVN1PROD with BILLS

290 

•S 2516 PCS

1 shall issue guidance that describes Food and Drug Admin2 istration policy regarding the promotion, using the Inter3 net (including social media), of medical products that are 

4 regulated by such Administration. 

5 SEC. 1123. ELECTRONIC SUBMISSION OF APPLICATIONS. 

6 Subchapter D of chapter VII (21 U.S.C. 379k et 

7 seq.) is amended by inserting after section 745 the fol8 lowing: 

9 ‘‘SEC. 745A. ELECTRONIC FORMAT FOR SUBMISSIONS. 

10 ‘‘(a) DRUGS AND BIOLOGICS.— 

11 ‘‘(1) IN GENERAL.—Beginning no earlier than 

12 24 months after the issuance of a final guidance 

13 issued after public notice and opportunity for com14 ment, submissions under subsection (b), (i), or (j) of 

15 section 505 of this Act or subsection (a) or (k) of 

16 section 351 of the Public Health Service Act shall 

17 be submitted in such electronic format as specified 

18 by the Secretary in such guidance. 

19 ‘‘(2) GUIDANCE CONTENTS.—In the guidance 

20 under paragraph (1), the Secretary may— 

21 ‘‘(A) provide a timetable for establishment 

22 by the Secretary of further standards for elec23 tronic submission as required by such para24 graph; and 

mstockstill on DSK4VPTVN1PROD with BILLS

291 

•S 2516 PCS

1 ‘‘(B) set forth criteria for waivers of and 

2 exemptions from the requirements of this sub3 section. 

4 ‘‘(3) EXCEPTION.—This subsection shall not 

5 apply to submissions described in section 561. 

6 ‘‘(b) DEVICES.— 

7 ‘‘(1) IN GENERAL.—Beginning after the 

8 issuance of final guidance implementing this para9 graph, pre-submissions and submissions for devices 

10 under section 510(k), 513(f)(2)(A), 515(c), 515(d), 

11 515(f), 520(g), 520(m), or 564 of this Act or section 

12 351 of the Public Health Service Act, and any sup13 plements to such pre-submissions or submissions, 

14 shall include an electronic copy of such pre-submis15 sions or submissions. 

16 ‘‘(2) GUIDANCE CONTENTS.—In the guidance 

17 under paragraph (1), the Secretary may— 

18 ‘‘(A) provide standards for the electronic 

19 copy required under such paragraph; and 

20 ‘‘(B) set forth criteria for waivers of and 

21 exemptions from the requirements of this sub22 section.’’. 

23 SEC. 1124. COMBATING PRESCRIPTION DRUG ABUSE. 

24 (a) IN GENERAL.—To combat the significant rise in 

25 prescription drug abuse and the consequences of such 

mstockstill on DSK4VPTVN1PROD with BILLS

292 

•S 2516 PCS

1 abuse, the Secretary of Health and Human Services (re2 ferred to in this section as the ‘‘Secretary’’), acting 

3 through the Commissioner of Food and Drugs (referred 

4 to in this section as the ‘‘Commissioner’’) and in coordina5 tion with other Federal agencies, as appropriate, shall re6 view current Federal initiatives and identify gaps and op7 portunities with respect to ensuring the safe use of pre8 scription drugs with the potential for abuse. 

9 (b) REPORT.—Not later than 1 year after the date 

10 of enactment of this Act, the Secretary shall issue a report 

11 to Congress on the findings of the review under subsection 

12 (a). Such report shall include recommendations on— 

13 (1) how best to leverage and build upon existing 

14 Federal and federally funded data sources, such as 

15 prescription drug monitoring program data and the 

16 sentinel initiative of the Food and Drug Administra17 tion under section 505(k)(3) of the Federal Food, 

18 Drug, and Cosmetic Act (21 U.S.C. 351(k)(3)), as 

19 it relates to collection of information relevant to ad20 verse events, patient safety, and patient outcomes, to 

21 create a centralized data clearinghouse and early 

22 warning tool; 

23 (2) how best to develop and disseminate widely 

24 best practices models and suggested standard re25 quirements to States for achieving greater interopermstockstill on DSK4VPTVN1PROD with BILLS

293 

•S 2516 PCS

1 ability and effectiveness of prescription drug moni2 toring programs, especially with respect to producing 

3 standardized data on adverse events, patient safety, 

4 and patient outcomes; and 

5 (3) how best to develop provider and patient 

6 education tools and a strategy to widely disseminate 

7 such tools and assess the efficacy of such tools. 

8 (c) GUIDANCE ON TAMPER-DETERRENT PROD9 UCTS.—Not later than 6 months after the date of enact10 ment of this Act, the Secretary, acting through the Com11 missioner, shall promulgate guidance on the development 

12 of tamper-deterrent drug products. 

13 SEC. 1125. TANNING BED LABELING. 

14 Not later than 18 months after the date of enactment 

15 of this Act, the Secretary of Health and Human Services 

16 shall determine whether to amend the warning label re17 quirements for sunlamp products to include specific re18 quirements to more clearly and effectively convey the risks 

19 that such products pose for the development of irreversible 

20 damage to the eyes and skin, including skin cancer. 

21 SEC. 1126. OPTIMIZING GLOBAL CLINICAL TRIALS. 

22 Subchapter E of chapter V (21 U.S.C. 360bbb et 

23 seq.), as amended by section 903, is further amended by 

24 adding at the end the following: 

mstockstill on DSK4VPTVN1PROD with BILLS

294 

•S 2516 PCS

1 ‘‘SEC. 569A. OPTIMIZING GLOBAL CLINICAL TRIALS. 

2 ‘‘(a) IN GENERAL.—The Secretary shall— 

3 ‘‘(1) work with other regulatory authorities of 

4 similar standing, medical research companies, and 

5 international organizations to foster and encourage 

6 uniform, scientifically-driven clinical trial standards 

7 with respect to medical products around the world; 

8 and 

9 ‘‘(2) enhance the commitment to provide con10 sistent parallel scientific advice to manufacturers 

11 seeking simultaneous global development of new 

12 medical products in order to— 

13 ‘‘(A) enhance medical product develop14 ment; 

15 ‘‘(B) facilitate the use of foreign data; and 

16 ‘‘(C) minimize the need to conduct duplica17 tive clinical studies, preclinical studies, or non18 clinical studies. 

19 ‘‘(b) MEDICAL PRODUCT.—In this section, the term 

20 ‘medical product’ means a drug, as defined in subsection 

21 (g) of section 201, a device, as defined in subsection (h) 

22 of such section, or a biological product, as defined in sec23 tion 351(i) of the Public Health Service Act. 

24 ‘‘(c) SAVINGS CLAUSE.—Nothing in this section shall 

25 alter the criteria for evaluating the safety or effectiveness 

26 of a medical product under this Act.’’. 

mstockstill on DSK4VPTVN1PROD with BILLS

295 

•S 2516 PCS

1 SEC. 1127. ADVANCING REGULATORY SCIENCE TO PRO2 MOTE PUBLIC HEALTH INNOVATION. 

3 (a) IN GENERAL.—Not later than 1 year after the 

4 date of enactment of this Act, the Secretary of Health and 

5 Human Services (referred to in this section as the ‘‘Sec6 retary’’) shall develop a strategy and implementation plan 

7 for advancing regulatory science for medical products in 

8 order to promote the public health and advance innovation 

9 in regulatory decisionmaking. 

10 (b) REQUIREMENTS.—The strategy and implementa11 tion plan developed under subsection (a) shall be con12 sistent with the user fee performance goals in the Pre13 scription Drug User Fee Agreement commitment letter, 

14 the Generic Drug User Fee Agreement commitment letter, 

15 and the Biosimilar User Fee Agreement commitment let16 ter transmitted by the Secretary to Congress on January 

17 13, 2012, and the Medical Device User Fee Agreement 

18 commitment letter transmitted by the Secretary to Con19 gress on April 20, 2012, and shall— 

20 (1) identify a clear vision of the fundamental 

21 role of efficient, consistent, and predictable, science22 based decisions throughout regulatory decision23 making of the Food and Drug Administration with 

24 respect to medical products; 

25 (2) identify the regulatory science priorities of 

26 the Food and Drug Administration directly related 

mstockstill on DSK4VPTVN1PROD with BILLS

296 

•S 2516 PCS

1 to fulfilling the mission of the agency with respect 

2 to decisionmaking concerning medical products and 

3 allocation of resources towards such regulatory 

4 science priorities; 

5 (3) identify regulatory and scientific gaps that 

6 impede the timely development and review of, and 

7 regulatory certainty with respect to, the approval, li8 censure, or clearance of medical products, including 

9 with respect to companion products and new tech10 nologies, and facilitating the timely introduction and 

11 adoption of new technologies and methodologies in a 

12 safe and effective manner; 

13 (4) identify clear, measurable metrics by which 

14 progress on the priorities identified under paragraph 

15 (2) and gaps identified under paragraph (3) will be 

16 measured by the Food and Drug Administration, in17 cluding metrics specific to the integration and adop18 tion of advances in regulatory science described in 

19 paragraph (5) and improving medical product deci20 sionmaking, in a predictable and science-based man21 ner; and 

22 (5) set forth how the Food and Drug Adminis23 tration will ensure that advances in regulatory 

24 science for medical products are adopted, as appro25 priate, on an ongoing basis and in an manner intemstockstill on DSK4VPTVN1PROD with BILLS

297 

•S 2516 PCS

1 grated across centers, divisions, and branches of the 

2 Food and Drug Administration, including by senior 

3 managers and reviewers, including through the— 

4 (A) development, updating, and consistent 

5 application of guidance documents that support 

6 medical product decisionmaking; and 

7 (B) the adoption of the tools, methods, and 

8 processes under section 566 of the Federal 

9 Food, Drug, and Cosmetic Act (21 U.S.C. 

10 360bbb–5). 

11 (c) ANNUAL PERFORMANCE REPORTS.—As part of 

12 the annual performance reports submitted to Congress 

13 under sections 736B(a) (as amended by section 104), 

14 738A(a) (as amended by section 204), 744C(a) (as added 

15 by section 303), and 744I(a) (as added by section 403) 

16 of the Federal Food, Drug, and Cosmetic Act for each 

17 of fiscal years 2013 through 2017, the Secretary shall an18 nually report on the progress made with respect to— 

19 (1) advancing the regulatory science priorities 

20 identified under paragraph (2) of subsection (b) and 

21 resolving the gaps identified under paragraph (3) of 

22 such subsection, including reporting on specific 

23 metrics identified under paragraph (4) of such sub24 section; 

mstockstill on DSK4VPTVN1PROD with BILLS

298 

•S 2516 PCS

1 (2) the integration and adoption of advances in 

2 regulatory science as set forth in paragraph (5) of 

3 such subsection; and 

4 (3) the progress made in advancing the regu5 latory science goals outlined in the Prescription 

6 Drug User Fee Agreement commitment letter, the 

7 Generic Drug User Fee Agreement commitment let8 ter, and the Biosimilar User Fee Agreement commit9 ment letter transmitted by the Secretary to Congress 

10 on January 13, 2012, and the Medical Device User 

11 Fee Agreement transmitted by the Secretary to Con12 gress on April 20, 2012. 

13 (d) INDEPENDENT ASSESSMENT.—Not later than 

14 January 1, 2016, the Comptroller General of the United 

15 States shall submit to Congress a report— 

16 (1) detailing the progress made by the Food 

17 and Drug Administration in meeting the priorities 

18 and addressing the gaps identified in subsection (b), 

19 including any outstanding gaps; and 

20 (2) containing recommendations, as appro21 priate, on how regulatory science initiatives for med22 ical products can be strengthened and improved to 

23 promote the public health and advance innovation in 

24 regulatory decisionmaking. 

mstockstill on DSK4VPTVN1PROD with BILLS

299 

•S 2516 PCS

1 (e) MEDICAL PRODUCT.—In this section, the term 

2 ‘‘medical product’’ means a drug, as defined in subsection 

3 (g) of section 201 of the Federal Food, Drug, and Cos4 metic Act (21 U.S.C. 321), a device, as defined in sub5 section (h) of such section, or a biological product, as de6 fined in section 351(i) of the Public Health Service Act. 

7 SEC. 1128. INFORMATION TECHNOLOGY. 

8 (a) HHS REPORT.—Not later than 1 year after the 

9 date of enactment of this Act, the Secretary of Health and 

10 Human Services shall— 

11 (1) report to Congress on— 

12 (A) the milestones and a completion date 

13 for developing and implementing a comprehen14 sive information technology strategic plan to 

15 align the information technology systems mod16 ernization projects with the strategic goals of 

17 the Food and Drug Administration, including 

18 results-oriented goals, strategies, milestones, 

19 performance measures; 

20 (B) efforts to finalize and approve a com21 prehensive inventory of the information tech22 nology systems of the Food and Drug Adminis23 tration that includes information describing 

24 each system, such as costs, system function or 

25 purpose, and status information, and incormstockstill on DSK4VPTVN1PROD with BILLS

300 

•S 2516 PCS

1 porate use of the system portfolio into the in2 formation investment management process of 

3 the Food and Drug Administration; 

4 (C) the ways in which the Food and Drug 

5 Administration uses the plan described in sub6 paragraph (A) to guide and coordinate the 

7 modernization projects and activities of the 

8 Food and Drug Administration, including the 

9 interdependencies among projects and activities; 

10 and 

11 (D) the extent to which the Food and 

12 Drug Administration has fulfilled or is imple13 menting recommendations of the Government 

14 Accountability Office with respect to the Food 

15 and Drug Administration and information tech16 nology; and 

17 (2) develop— 

18 (A) a documented enterprise architecture 

19 program management plan that includes the 

20 tasks, activities, and timeframes associated with 

21 developing and using the architecture and ad22 dresses how the enterprise architecture program 

23 management will be performed in coordination 

24 with other management disciplines, such as or25 ganizational strategic planning, capital planning 

mstockstill on DSK4VPTVN1PROD with BILLS

301 

•S 2516 PCS

1 and investment control, and performance man2 agement; and 

3 (B) a skills inventory, needs assessment, 

4 gap analysis, and initiatives to address skills 

5 gaps as part of a strategic approach to informa6 tion technology human capital planning. 

7 (b) GAO REPORT.—Not later than January 1, 2016, 

8 the Comptroller General of the United States shall issue 

9 a report regarding the strategic plan described in sub10 section (a)(1)(A) and related actions carried out by the 

11 Food and Drug Administration. Such report shall assess 

12 the progress the Food and Drug Administration has made 

13 on— 

14 (1) the development and implementation of a 

15 comprehensive information technology strategic plan, 

16 including the results-oriented goals, strategies, mile17 stones, and performance measures identified in sub18 section (a)(1)(A); 

19 (2) the effectiveness of the comprehensive infor20 mation technology strategic plan described in sub21 section (a)(1)(A), including the results-oriented 

22 goals and performance measures; and 

23 (3) the extent to which the Food and Drug Ad24 ministration has fulfilled recommendations of the 

mstockstill on DSK4VPTVN1PROD with BILLS

302 

•S 2516 PCS

1 Government Accountability Office with respect to 

2 such agency and information technology. 

3 SEC. 1129. REPORTING REQUIREMENTS. 

4 Subchapter A of chapter VII (21 U.S.C. 371 et seq.), 

5 as amended by section 208, is further amended by adding 

6 at the end the following: 

7 ‘‘SEC. 715. REPORTING REQUIREMENTS. 

8 ‘‘(a) NEW DRUGS.—Beginning with fiscal year 2013 

9 and ending with fiscal year 2017, not later than 120 days 

10 after the end of each fiscal year for which fees are col11 lected under part 2 of subchapter C, the Secretary shall 

12 prepare and submit to the Committee on Health Edu13 cation, Labor, and Pensions of the Senate and the Com14 mittee on Energy and Commerce of the House of Rep15 resentatives a report concerning, for all applications for 

16 approval of a new drug under section 505(b) of this Act 

17 or a new biological product under section 351(a) of the 

18 Public Health Service Act filed in the previous fiscal 

19 year— 

20 ‘‘(1) the number of such applications that met 

21 the goals identified for purposes of part 2 of sub22 chapter C in the letters from the Secretary of 

23 Health and Human Services to the Chairman of the 

24 Committee on Health, Education, Labor, and Pen25 sions of the Senate and the Chairman of the Commstockstill on DSK4VPTVN1PROD with BILLS

303 

•S 2516 PCS

1 mittee on Energy and Commerce of the House of 

2 Representatives, as set forth in the Congressional 

3 Record; 

4 ‘‘(2) the percentage of such applications that 

5 were approved; 

6 ‘‘(3) the percentage of such applications that 

7 were issued complete response letters; 

8 ‘‘(4) the percentage of such applications that 

9 were subject to a refuse-to-file action; 

10 ‘‘(5) the percentage of such applications that 

11 were withdrawn; and 

12 ‘‘(6) the average total time to decision by the 

13 Secretary for all applications for approval of a new 

14 drug under section 505(b) of this Act or a new bio15 logical product under section 351(a) of the Public 

16 Health Service Act filed in the previous fiscal year, 

17 including the number of calendar days spent during 

18 the review by the Food and Drug Administration 

19 and the number of calendar days spent by the spon20 sor responding to a complete response letter or rel21 evant legal, scientific, or medical questions raised by 

22 the Secretary.’’. 

23 ‘‘(b) GENERIC DRUGS.—Beginning with fiscal year 

24 2013 and ending after fiscal year 2017, not later than 

25 120 days after the end of each fiscal year for which fees 

mstockstill on DSK4VPTVN1PROD with BILLS

304 

•S 2516 PCS

1 are collected under part 7 of subchapter C, the Secretary 

2 shall prepare and submit to the Committee on Health 

3 Education, Labor, and Pensions of the Senate and the 

4 Committee on Energy and Commerce of the House of 

5 Representatives a report concerning, for all applications 

6 for approval of a generic drug under section 505(j), 

7 amendments to such applications, and prior approval sup8 plements with respect to such applications filed in the pre9 vious fiscal year— 

10 ‘‘(1) the number of such applications that met 

11 the goals identified for purposes of part 7 of sub12 chapter C, in the letters from the Secretary of 

13 Health and Human Services to the Chairman of the 

14 Committee on Health, Education, Labor, and Pen15 sions of the Senate and the Chairman of the Com16 mittee on Energy and Commerce of the House of 

17 Representatives, as set forth in the Congressional 

18 Record; 

19 ‘‘(2) the average total time to decision by the 

20 Secretary for applications for approval of a generic 

21 drug under section 505(j), amendments to such ap22 plications, and prior approval supplements with re23 spect to such applications filed in the previous fiscal 

24 year, including the number of calendar days spent 

25 during the review by the Food and Drug Adminismstockstill on DSK4VPTVN1PROD with BILLS

305 

•S 2516 PCS

1 tration and the number of calendar days spent by 

2 the sponsor responding to a complete response letter 

3 or relevant legal, scientific, or medical questions 

4 raised by the Secretary; 

5 ‘‘(3) the total number of applications under sec6 tion 505(j), amendments to such applications, and 

7 prior approval supplements with respect to such ap8 plications that were pending with the Secretary for 

9 more than 10 months on the date of enactment of 

10 the Food and Drug Administration Safety and Inno11 vation Act; and 

12 ‘‘(4) the number of applications described in 

13 paragraph (3) on which the Food and Drug Admin14 istration took final regulatory action in the previous 

15 fiscal year. 

16 ‘‘(c) BIOSIMILAR BIOLOGICAL PRODUCTS.— 

17 ‘‘(1) IN GENERAL.—Beginning with fiscal year 

18 2014, not later than 120 days after the end of each 

19 fiscal year for which fees are collected under part 8 

20 of subchapter C, the Secretary shall prepare and 

21 submit to the Committee on Health Education, 

22 Labor, and Pensions of the Senate and the Com23 mittee on Energy and Commerce of the House of 

24 Representatives a report concerning— 

mstockstill on DSK4VPTVN1PROD with BILLS

306 

•S 2516 PCS

1 ‘‘(A) the number of applications for ap2 proval filed under section 351(k) of the Public 

3 Health Service Act; and 

4 ‘‘(B) the percentage of applications de5 scribed in subparagraph (A) that were approved 

6 by the Secretary. 

7 ‘‘(2) ADDITIONAL INFORMATION.—As part of 

8 the performance report described in paragraph (1), 

9 the Secretary shall include an explanation of how the 

10 Food and Drug Administration is managing the bio11 logical product review program to ensure that the 

12 user fees collected under part 2 are not used to re13 view an application under section 351(k) of the Pub14 lic Health Service Act.’’. 

15 SEC. 1130. STRATEGIC INTEGRATED MANAGEMENT PLAN. 

16 (a) STRATEGIC INTEGRATED MANAGEMENT PLAN.— 

17 Not later than 1 year after the date of enactment of this 

18 Act, the Secretary of Health and Human Services (re19 ferred to in this section as the ‘‘Secretary’’) shall submit 

20 to Congress a strategic integrated management plan for 

21 the Center for Drug Evaluation and Research, the Center 

22 for Biologics Evaluation and Research, and the Center for 

23 Devices and Radiological Health. Such strategic manage24 ment plan shall— 

mstockstill on DSK4VPTVN1PROD with BILLS

307 

•S 2516 PCS

1 (1) identify strategic institutional goals and pri2 orities for the Center for Drug Evaluation and Re3 search, the Center for Biologics Evaluation and Re4 search, and the Center for Devices and Radiological 

5 Health; 

6 (2) describe the actions the Secretary will take 

7 to recruit, retain, train, and continue to develop the 

8 workforce at the Center for Drug Evaluation and 

9 Research, the Center for Biologics Evaluation and 

10 Research, and the Center for Devices and Radio11 logical Health to fulfill the public health mission of 

12 the Food and Drug Administration; and 

13 (3) identify results-oriented, outcome-based 

14 measures that the Secretary will use to measure the 

15 progress of achieving the strategic goals and prior16 ities identified under paragraph (1) and the effec17 tiveness of the actions identified under paragraph 

18 (2), including metrics to ensure that managers and 

19 reviewers of the Center for Drug Evaluation and Re20 search, the Center for Biologics Evaluation and Re21 search, and the Center for Devices and Radiological 

22 Health are familiar with and appropriately and con23 sistently apply the requirements under the Federal 

24 Food, Drug, and Cosmetic Act (21 U.S.C. 301 et 

25 seq.), including new requirements under parts 2, 3, 

mstockstill on DSK4VPTVN1PROD with BILLS

308 

•S 2516 PCS

1 7, and 8 of subchapter C of title VII of the Federal 

2 Food, Drug, and Cosmetic Act (21 U.S.C. 379f et 

3 seq.). 

4 (b) REPORT.—Not later than January 1, 2016, the 

5 Comptroller General of the United States shall issue a re6 port regarding the strategic management plan described 

7 in subsection (a) and related actions carried out by the 

8 Food and Drug Administration. Such report shall— 

9 (1) assess the effectiveness of the actions de10 scribed in subsection (a)(2) in recruiting, retaining, 

11 training, and developing the workforce at the Center 

12 for Drug Evaluation and Research, the Center for 

13 Biologics Evaluation and Research, and the Center 

14 for Devices and Radiological Health in fulfilling the 

15 public health mission of the Food and Drug Admin16 istration; 

17 (2) assess the effectiveness of the measures 

18 identified under subsection (a)(3) in gauging 

19 progress against the strategic goals and priorities 

20 identified under subsection (a)(1); 

21 (3) assess the extent to which the Center for 

22 Drug Evaluation and Research, the Center for Bio23 logics Evaluation and Research, and the Center for 

24 Devices and Radiological Health are using the iden25 tified results-oriented set of performance measures 

mstockstill on DSK4VPTVN1PROD with BILLS

309 

•S 2516 PCS

1 in tracking their workload by strategic goals and the 

2 effectiveness of such measures; 

3 (4) assess the extent to which performance in4 formation is collected, analyzed, and acted on by 

5 managers; and 

6 (5) make recommendations, as appropriate, re7 garding how the strategic management plan and re8 lated actions of the Center for Drug Evaluation and 

9 Research, the Center for Biologics Evaluation and 

10 Research, and the Center for Devices and Radio11 logical Health could be improved to fulfill the public 

12 health mission of the Food and Drug Administration 

13 in as efficient and effective manner as possible. 

14 SEC. 1131. DRUG DEVELOPMENT AND BIOEQUIVALENCE 

15 TESTING. 

16 (a) IN GENERAL.—Section 505–1 (21 U.S.C. 355– 

17 1) is amended by adding at the end the following: 

18 ‘‘(k) DRUG DEVELOPMENT AND BIOEQUIVALENCE

19 TESTING.— 

20 ‘‘(1) IN GENERAL.—Notwithstanding any other 

21 provision of law, if a drug is a covered drug, no ele22 ments to ensure safe use shall prohibit, or be con23 strued or applied to prohibit, supply of such drug to 

24 any eligible drug developer for the purpose of devel25 oping, or conducting bioequivalence testing necessary 

mstockstill on DSK4VPTVN1PROD with BILLS

310 

•S 2516 PCS

1 to support, an application under subsection (b)(2) or 

2 (j) of section 505 of this Act or section 351(k) of 

3 the Public Health Service Act, if the Secretary has 

4 issued a written notice described in paragraph (2), 

5 and the eligible drug developer has agreed to comply 

6 with the terms of the notice. 

7 ‘‘(2) WRITTEN NOTICE.—For purposes of this 

8 subsection, the Secretary shall issue a written notice 

9 to an eligible drug developer and the holder of an 

10 application for a covered drug authorizing the supply 

11 of a drug to such eligible drug developer for pur12 poses of bioequivalence testing if— 

13 ‘‘(A) the eligible drug developer has agreed 

14 to comply with any conditions the Secretary 

15 considers necessary; and 

16 ‘‘(B) the eligible drug developer has sub17 mitted and the Secretary has approved a pro18 tocol for bioequivalence testing that includes 

19 protections that the Secretary finds will provide 

20 assurance of safety comparable to the assurance 

21 of safety provided by the elements to ensure 

22 safe use in the risk evaluation and mitigation 

23 strategy for the covered drug. 

24 ‘‘(3) ADDITIONAL REQUIRED ELEMENT.—The 

25 Secretary shall require as an element of each risk 

mstockstill on DSK4VPTVN1PROD with BILLS

311 

•S 2516 PCS

1 evaluation and mitigation strategy approved by the 

2 Secretary that the holder of an application for a cov3 ered drug shall not restrict the resale of the covered 

4 drug to an eligible drug developer that receives a 

5 written notice from the Secretary under paragraph 

6 (2). 

7 ‘‘(4) PENALTIES.—For purposes of subsection 

8 (f)(8) and sections 301, 303(f)(4), 502(y), and 

9 505(p), it shall be a violation of the risk evaluation 

10 and mitigation strategy for the holder of the applica11 tion for a covered drug to restrict the sale of the 

12 drug to an eligible drug developer. The Secretary 

13 shall provide written notice to the Committee on 

14 Health, Education, Labor, and Pensions of the Sen15 ate and the Committee on Energy and Commerce of 

16 the House of Representatives of any penalty as17 sessed under this subsection within 7 days of such 

18 assessment. 

19 ‘‘(5) LIABILITY.—The holder of an application 

20 for a covered drug shall not be liable for any claim 

21 arising out of the eligible drug developer’s provision 

22 or testing of a drug obtained under this subsection, 

23 including a claim arising out of failure of the eligible 

24 drug developer to follow adequate safeguards to en25 sure safe use of the drug. 

mstockstill on DSK4VPTVN1PROD with BILLS

312 

•S 2516 PCS

1 ‘‘(6) DEFINITIONS.— 

2 ‘‘(A) COVERED DRUG.—Notwithstanding 

3 subsection (b)(2), for purposes of this sub4 section, the term ‘covered drug’ means a drug 

5 subject to a risk evaluation and mitigation 

6 strategy with elements to ensure safe use under 

7 subsection (f), or that is deemed under section 

8 909(b) of the Food and Drug Administration 

9 Amendments Act of 2007 to be a drug, includ10 ing a biological product licensed under section 

11 351(a) of the Public Health Service Act, subject 

12 to a risk evaluation and mitigation strategy 

13 with elements to ensure safe use. 

14 ‘‘(B) ELIGIBLE DRUG DEVELOPER.—For 

15 purposes of this subsection, the term ‘eligible 

16 drug developer’ means a sponsor seeking to de17 velop an application for submission under sub18 section (b)(2) or (j) of section 505 of this Act 

19 or section 351(k) of the Public Health Service 

20 Act.’’. 

21 (b) TECHNICAL AND CONFORMING AMENDMENT.— 

22 Section 505–1(c)(2) (21 U.S.C. 355–1(c)(2)) is amended 

23 by striking ‘‘(e) and (f)’’ and inserting ‘‘(e), (f), and 

24 (k)(3)’’. 

mstockstill on DSK4VPTVN1PROD with BILLS

mstockstill on DSK4VPTVN1PROD with BILLS

Calendar No. 389 

112TH CONGRESS 

2D SESSION S. 2516 

A BILL 

To amend the Federal Food, Drug, and Cosmetic 

biosimilars, and for other purposes. tablish user-fee programs for generic drugs and for prescription drugs and medical devices, to esAct to revise and extend the user-fee programs 

MAY 7, 2012 

Read twice and placed on the calendar 

mstockstill on DSK4VPTVN1PROD with BILLS